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SUMMARY
Historical aspects and general concepts regarding the onco- 
developmental proteins are reviewed together with a review of 
the specific proteins studied.
Radioimmunoassays for hPL, hCG and AFP are described together 
with studies of the assay parameters. The methods were 
shown to be suitable for use in this thesis.
General concepts of enzyme-immunoassays are described. A 
previously described ELISA for SP^ was investigated and further 
sensitized for use in monitoring patients with tumours producing
Enzyme immunoassays for PAPP-A and CPAP were developed and 
validated for use in monitoring pregnant patients and patients 
with tumours producing PAPP-A. Problems specific to the assay 
of PAPP-A and SP^ are described.
Certain factors influencing ELISA are considered - the choice 
of a suitable solid phase, the leakage of antibody from the 
solid phase and the reduction of NSB by use of protein or deter­
gent. \
Plastic microtitre plates were shown to be suitable as a solid 
phase although antibody leakage was confirmed. NSB was 
reduced to acceptable levels.
An antigen excess effect was noted during time course experi­
ments on various antigens. A possible explanation is provided 
and the importance of time course studies in, assay devlopment 
is emphasized.
Studies into the effects of molecular heterogeneity of SP^ on 
ELISA were performed.
Methods of automated data reduction were developed after 
investigating the kinetics of various stages of the assays.
The time courses were shown to obey previously described mathe­
matical relationships and computer programs were developed 
to provide curve fitting for automating assays.
Having established assay conditions, the application of the 
measurement of these proteins to pregnancy and oncology were 
studied.
Reference ranges of hPL, SP^ and PAPP-A were established for 
the third trimester of pregnancy. Investigations into the 
concentrations of these proteins in patients producing a light 
for dates baby, patients with a poor weight profile during 
pregnancy, patients with pregnancy induced hypertension and 
pregnant diabetic patients were performed.
HPL was shown to be a useful predictor of intra uterine growth 
retardation and conversely could be used for reassurance in 
patients v/ith poor'weight profiles who produce normal weight 
babies.
Previous reports of: elevated PAPP-A concentrations in patients 
with hypertension were not confirmed. A possible relationship 
between SP^ and carbohydrate metabolism in pregnancy v/as shown.
In the field of oncology, other than, established markers such 
as AFP and HCG, only GPAP was shown to be of possible use in 
patients v/ith seminoma or ovarian carcinoma. The percentage 
of patients with positive results v/as low however and any use 
v/ould be in a monitoring situation only.
The importance of test assessment is discussed and possible 
development of markers in the field of oncology are alluded to.
CHAPTER 1
THE ONCODEVELOPMENTAL PROTEINS
1 .1 Historical- Aspects
The human foeto-placental unit produces a wide variety of proteins 
In addition, many of these have now .been found to have analogues 
produced by neoplastic cells. Thus the term "onco-developmental" 
(encompassing placental, foetal and oncological) proteins was 
coined to describe this group.
The exclusive foetal, placental or neoplastic production is now 
open to question however (Searle et al 1978, Duberg et al 1982, 
Rosen 1982).
Although many of these proteins have only been recognized in 
the last 25 years, one pregnancy protein (human chorionic gona­
dotrophin) has-been known for many years (Zondek and Ascheim 1927)
Several years later, in 193** an increase in serum alkaline 
phosphatase in normal pregnancy was recognized (Coryn 193*0 which 
was later shown to be of placental origin (Messer 19&7)•
Some 30 years after Ascheim's original work, the first recorded 
mention of a foetal protein - cC foeto protein is found (Berg- 
strand and Czar 1957)•
This was followed a year later by Thornes who demonstrated, using 
a gel diffusion technique, that pregnancy serum contained a group 
of proteins which were not present in serum from a non pregnant 
population (Thornes 1938). Using starch gel electrophoresis, 
Smithies (1959) was able to show that in the cC^ region there 
was a distinct band from about 10# of sera from pregnant women.
He referred to this band as the Pregnancy Zone. Subsequently, 
Afonzo and Farnham (1962) and Cooper (1963) were able to demon­
strate that this "Pregnancy Zone” protein identified by Smithies 
was present in over 80# of pregnant subjects.
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The isolation in'19^2 of human placental lactogen (Josimovich 
and Maclaren 1962) opened the way to the application of cir­
culating concentrations of placental proteins to the monitoring 
of placental function*
Similarly the discovery of the Regan isoenzyme of alkaline phos­
phatase (Fishman et al 1968) opened the way to the biochemical 
monitoring of neoplastic processes, widening the search for 
other markers.
In 1970, Tatarinov and Masyukevich (1970), and independently 
in 19711 Bohn described the first of the "new placental proteins", 
Pregnancy Specific p  ^  Glycoprotein (Schwangerschafts - protein
1» SPl)* V
Since this time considerable interest has been generated in the 
pregnancy proteins. Thus in 1980 Bohn reported that 10 proteins 
were known (1980 a). Two years later it was twice that number 
(Klopper 1982)•
With the increasing number of onco developmental proteins, some 
form of classification became necessary such as the one shown 
in Table 11 (after Horne and Nisbet 1979)• However this type 
of classification is not entirely satisfactory. Thus SP^ has 
been shown to be produced by fibroblasts in vitro (Rosen 1982) 
and epithelial cells cultured from human amniotic fluid 
(Heikinheimo et al 1980). Similarly production of pregnancy 
associated plasma protein- A (PAPP-A) by non trophoblastic 
cells:in vivo has been shown.(Duberg et al 1982).
Such classifications as exist must not be regarded as rigid 
but require updating as knowledge increases.
2
1.2 The Placental Proteins
1.2.1 General Concepts
It is known that placental cells contain a wide range of 
proteins and small peptides. Some are produced by this organ, 
whilst others appear simply as a consequence of the placenta 
containing a large volume of maternal blood and thus reflectJ 
the general elevation of these proteins in pregnancy.
As stated before, many placental proteins are not truly specific 
to the placenta. Nonetheless measurement of these may be 
relevant to studies on this organ in that:-
i) They reflect aspects of the function of an organ which is 
the only lifeline to the foetus.
ii) Their measurement is widely used as a clinical index of 
the adequacy of this function.
iii) The placenta has many features in common with a wide 
range of tumours of non-placental origin.
1.2.2 The Site of Production of Placental Proteins 
Until recently, identification of the production site of 
placental proteins was by immunohistochemical localization. 
However, demonstration of the presence of a protein in a tissue 
does not distinguish synthesis from storage.. Also, immuno- 
histochemistry is fraught with problems of non-specificity -
a problem even more obvious when applied to the placenta 
(Gau and Chard 1976)•
Nevertheless, the syncytiotrophoblast appears to be the 
principal site of production in late pregnancy. It is
possible that in early pregnancy the cytotrophoblast may
fe ta l  c a p i l la r /
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Fig 1i Diagramatic representation of the Syncytiotrophoblast 
and foetal capillary showing a thick area specialized for 
protein synthesis and a thin area (Vasculo-syncytial membrane) 
specialized for transfer.
also contribute - a theory that would be compatible with the 
fact that the cytotrophoblast is abundant and active at this 
time and has a somewhat nebulous interface with the syncytium.
McWilliams and Boime (1980) have confirmed the exclusive synthesis 
of hPL by the syncytiotrophoblast, using an isotopically labelled 
gene probe, to detect specific mRNA. The exact site of: protein 
synthesis has been the subject of a number of studies. Burgos and Rod­
riguez (1966) observed that there are "thick” areas of syncytio­
trophoblast which are rich in endoplasmic reticulum and micro­
villi; and thin areas without microvilli which appear to be 
specialized for nutrient and waste material transport (Fig 1 i).
1.3 Production of Oncodevelopmental Proteins by the Normal Adult
It is well recognized that normal adults produce the so called 
foetal proteins eCfoeto protein (AFP) and carcinoembryonic 
antigen (CEA) in small amounts. A considerable body of evidence 
now exists to show that the so called "specific” placental 
proteins are in fact produced by normal non pregnant adults.
Allusion to SP^ production by fibroblasts in vitro (Rosen 1982) 
has already been made. Similarly, hCG has been isolated from 
normal testes (Braunstein et al 1975) and more recently these 
observations have been extended by the demonstration of other 
"placental" proteins in seminal plasma (Rantaetal 1981, Bischof
et al 1983).
The source of these proteins is unknown; they cannot be attributed 
to the testes or the sperm as levels are identical in vasectomized 
and non vasectomized subjects. Again, the functional signif­
icance is unknown.
if

1 .k Control Mechanisms for the production of placental proteins
Few mechanisms have been identified which control the production 
of placental proteins. Mechanisms have been proposed for the 
control of hPL release by maternal carbohydrate and lipids, 
but the evidence is subject to alternative explanations (Pavlou 
et al 1972).
Chard however has proposed a hypothesis which accounts for all 
the known facts about placental protein synthesis (Chard 1982a)•
He suggests that the potential for placental protein production 
is a direct function of the.’total mass of the trophoblast, that 
the rate of release (and secondarily of synthesis) is a function 
of the concentration in the maternal blood of the intervillous 
space surrounding the syncytiotrophoblast and that this in turn 
depends on the rate of blood flow in the intervillous space.
(Fig 1 ii). The key implication is that the rate of placental 
protein production will be closely related to uteroplacental 
blood flow.
It may also explain why non-placental areas of the trophoblast 
ie chorion produce only very small quantities of placental 
proteins as a direct result of their not being in contact with 
a large fast flowing pool of blood.
1.5 Production of Oncodevelopmental Proteins by Tumours
It is now certain that a small proportion of adult non tropho­
blastic tumours secrete placental proteins including hCG 
(Vaitukatis 1977), hPL (Rosen et al 1975) .and SP1 (Grud- 
zinskas et al 1980 a) • Since it is clear that “placental11 
proteins can appear in normal tissues, these fihdings are- • •
5

rather less surprising - but do not of themselves explain the 
relatively high levels found in the circulation of some patients 
with tumours*
The discovery of products such as AFP, CEA and ectopically 
produced hormonal products in patients with various malignancies 
led to the development of the repression - derepression theory 
In essence the theory states that the abberent gene expression 
of tumour cells is not random, but represents a reversion of 
the cell progeny to a more primitive, less differentiated state, 
ie that genes "switched off" in the differentiated cell remain 
"switched on" in the more primitive form. With increased 
assay sensitivity, it appears that developmental genes may be 
"turned on" slightly in the normal adult.
Chard however proposes an extension of this hypothesis concerning 
synthesis in the placenta to explain the observations. There 
may be numerous cells in adult tissue capable of synthesising 
"placental specific" proteins but these are either not secreted 
or are only secreted in very small quantities because they are 
not in contact with the bloodstream. In the case of a tumour 
with invasion of blood vessels, cells of this type may establish 
direct contact with blood and thus form a "mini placenta" (Fig 
1 iii). This contrasts markedly with the older repression - 
depression theories of ectopic protein production, and does 
not entirely explain the observed’ facts eg in trophoblastic 
tumours such as hydatidiform mole there is a striking diss?- 
ociation between the production of different placental proteins, 
this being related to the degree of malignancy (Lee et al 1981).
a v present, no one xneory n/cs a±± tne Known observations, out 
they provide useful models for further investigation.
1.6 Review of the Proteins studied
1.6.1 Human Chorionic Gonadotrophin (hCG)
The placenta is a source of various peptides which play an active 
role in the maintenance of pregnancy.
This concept followed the demonstration in blood and urine of 
pregnant women of a gonadotrophin (Ascheim and Zondek 1927), now 
known to be human chorionic gonadotrophin (hCG)•
HCG is a glycoprotein with a molecular weight of about 39000 
(Morgan et al 1975) and a carbohydrate content of about 30$.
The molecule consists of two dissimilar non covalently linked 
subunits designated0C and p  • The oC subunit is common to 
human luteinizing hormone (LH), follicle stimulating hormone 
(FSH) and thyroid stimulating hormone (TSH) and consists of 
89 to 92 amino acid residues in identical sequences, although 
the carbohydrate moieties may be somewhat different (Morgan
et al 1975).
The p subunit confers immunological identity upon the molecule 
and in contrast to the OC subunit there are distinctive yet 
similar amino acid sequences. Whilst there are similarities 
between the P subunit of hCG and those of FSH and TSH, extensive 
similarity exists between P hCG and P LH. Of the first 115 
amino acid residues, 80^ are identical, but hCG has an 
additional distinctive COOH terminal 30 amino acid residues 
(Birken and Canfield 1977)•
The difference in ft subunits has proved useful in raising 
an antiserum that does not recognize LH. Either purified
7
P subunit (Vaitukaitis et al 1971) or a conjugated peptide 
(synthetic or natural) from the unique COOH terminal section 
(Louvet et al 197*0 can be used as an immunogen*
HCG has a strong luteotropic function in the human female and 
plays an important role in maintaining the function of the corpus 
luteum during the early stage of pregnancy via stimulation of 
adenyl cyclase activity.
A variety of uses for hCG in laboratory investigation of disease 
have been documented. The detection of hCG appears to be a 
specific indicator for the presence of viable trophoblast. 
hCG can be detected in the maternal serum as early as 6 days 
sifter fertilization ie before implantation; and production of 
hCG by the blastocyst has been suggested (Saxena et al 197*0 • 
Maximal serum hCG concentrations are found between 8 and 10 weeks 
after the last menstrual period, after which concentrations 
decrease b y 90% and remain so throughout the remainder of 
pregnancy. Thus hCG estimation in maternal urine and serum 
has been widely used as a pregnancy test and in the prognosis 
of pregnancies with first trimester bleeding (Van Leusden 1976).
HCG has proved of little use in monitoring foeto-placental function 
however.,-;'
HCG estimation is also a sensitive marker in gestational tropho­
blastic disease and is used both in diagnosis and monitoring 
of patients with the disease (Lee et al 1982)•
Measurement of hCG is also used in diagnosis and prognosis of 
disease in patients with a variety of gonadal and non gonadal 
tumours such as tumours of the stomach, liver, lung, kidney, 
pancreas, ovary and testes (Vaitukaitis et al 1976, Lange et 
al 1976) .
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Human Placental”Lactogen (hPL) was independently identified by 
Ito & Higashi (1 9 6 1 ) and Josimovich 8c Maclaren (1 9 6 2 ). The 
latter group alluded to an immunological relationship between 
hPL and growth hormone and later, sequencing studies showed a 
considerable degree of homology (8 5^) between the amino acid 
sequences of human growth hormone and hPL (Sherwood et al 1 9 .71)*'
HPL has a molecular weight of about 22,000 but unlike many other 
trophoblast protein products contains no carbohydrate (Li et 
al 1973)•
Using a fluorescent antibody technique, hPL has been localized 
in the cytoplasm of the syncytiotrophoblast (Sciarra et al 19&3)• 
HPL is detectable in maternal serum as early as 5 weeks-after 
conception; the concentration rising steadily until about 3 6  
weeks of gestation after which a plateau or slight decrease 
occurs*
A number of biological activities have been proposed for hPL 
including lactogenesis, growth promotion, effects on carbo­
hydrate and lipid metabolism, stimulation of the corpus luteum, 
erythropoiesis,inhibition of fibrinolysis and immunosuppresion 
(Chard 1 9 8 2  b)* Gaede et al (1978) however argue against 
a vital function in'pregnancy as clinically normal pregnancies 
with 110 detectable hPL have been recorded* It has thus been 
suggested that although various activities can be shown in 
experimental systems, the placental proteins are merely waste 
products of the general activities of the placenta as as indep­
endent organism (Gordon and Chard 1 9 7 9 )0 '
9
The problem of defining a biological role for hPL is reflected 
by equal difficulty in defining the physiological control 
mechanisms. There is little evidence of control mechanisms 
of the type which apply to endocrine products of the normal 
adult eg no releasing or inhibiting factors have been identified. 
The hypothesis given previously for placental protein production 
(I.Jf) suggests that the potential for hPL synthesis is a function 
of the total mass of trophoblast.
The half life of hPL in the maternal circulation as estimated 
by its rate of disappearance after delivery of the placenta is 
1 0 - 2 0  rain (Pavlou et al 1972), and it appears that there is 
no circadian rhythm in maternal serum concentrations. However, 
there are random fluctuations over a 2k hour period which are 
greater than those attributable to assay imprecisioni Thus the 
- diagnostic significance of hPL levels is enhanced if serial results 
are available.
HPL concentrations in maternal serum have been used in the 
investigation of a wide variety of pathological conditions.
The results are frequently contradictory having been reviewed 
recently by Chard (1982 b). However it should be appreciated 
that negative information is also valuable and irrespective 
of the clinical condition, a value in the upper end of the 
normal range indicates a relatively small risk to the foetus.
hPL levels are widely used therefore as a measure of placental 
function and this has posed a number of groups to question 
whether placental function testing is worthwhile (Gordon et 
al 1978, Grudzinskas et al 1981). There is still good 
reason for continuing hPL measurements but further refinement 
in the application of hPL values is required.
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1.6.3 Carcino Placental Alkaline Phosphatase (CPAP)
The occurrence of a placental alkaline phosphatase (heat-stable 
alkaline phosphatase) was recognized relatively early (Coryn 
193*0 • However despite a large volume of literature on the 
application of placental alkaline phosphatase concentrations 
in the prediction of foetal problems, controversy still remains 
and the assay is little used for this purpose (Stigbrand et
al 1982).
However the demonstration of the presence of placental alkaline 
phosphatase as an oncofoetal or carcinoplacental antigen (Regan 
isoenzyme) by Fishman et al (1968) and the later description 
of several other tumour related forms (Nakayama 1970V Warnock 
1989) have led to the use of this enzyme in the field of tumour 
markers.
The placenta is known to produce a variety of allotypic alkaline 
phosphatases and it is now obvious that many tumours produce 
isoenzymes that share early and late placental alkaline phos­
phatases (Fishman & Singer 1978). These alkaline phosphatase 
isoenzymes in tumours are named after the patients in whom they 
were identified. Table 1 II shows the characteristics of 
these isoenzymes and their developmental counterparts.
Elevated levels of "placental11 alkaline phosphatase have been 
reported in a variety of malignancies, the highest incidence 
being for germ cell tumours of the testes, ovary ; 
although elevations have also been reported in tumours of the 
pancreas, lung, breast, colon, kidney, stomach, bladder and 
lymphatic system (Stigbrand et al 1982). One seemingly hope­
ful application is as a marker for seminoma where alternative 
markers such as hCG and AFP are seldom of use.
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1.6.V Pregnancy Specific j£^ Glycoprotein (SP^)
The identification of PS ^  (SP^) by two groups (Tatarinov
1970 and Bohn 1972) stimulated research into the "new" placental 
proteins•
SP^ is a glycoprotein, the carbohydrate content of which is 
about 28$. Early estimates of the molecular weight suggested 
values of 90,000-120,000 (Bohn 1972) but it later became app­
arent that SP^ was a heterogeneous molecule consisting of a 
number of molecular forms with varying molecular weights 
(Teisner et al 1978)- The exact situation remains unclear 
and will be discussed later.
Immunoreactive SP^ with a molecular weight of 65OOO has been 
detected in pregnancy urine and it is possible that urinary 
SP^ may be a fragment of circulating SP^ (Bohn and Kraus 1977)*
No definite physiological role for SP^ has been determined. 
Affinity of various steroids to SP^ has been reported (Bohn 
197*+) • It has also been suggested that SP^ may be involved 
in iron metabolism during pregnancy (Lin et al 197*0. Other 
groups have observed an immunosuppressive effect in vitro 
(Bohn etal 1976) and it has also been suggested that SP^ may 
exert an effect on carbohydrate metabolism (Singh et al 1979■» 
Pledger et al 1982). More recently, it has been suggested 
that the endometrium might be the target organ for any 
hormonal action this protein possesses (Ahmed & Klopper 1983 a)*
Several reports exist suggesting that SP^ is also present in 
the circulation of normal males and non pregnant females 
(Searle et al 1978, Engvall and Yonemoto 1979)•
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SP^ has been used as a ’’pregnancy test” (Ahmed & Klopper 1983 b) 
and in the prognosis of patients with threatened abortion and 
ectopic pregnancy (Ho & Jones 1980). In late pregnancy the 
data is extensive although specific groups of clinical abnor­
malities are sparse. Associations between SP^ and IUGR 
(Gordon et al 1977a), SP^ and fetal distress, SP^ and maternal 
hypertension or diabetes mellitus (Grudzinskas et al 1979) 
have been investigated. As no common baseline was taken in 
various studies, it is difficult to form an overall impression 
of the usefulness of this test in the assessment of foetal 
wellbeing however.
Several attempts to utilize SP^ as a tumour marker have also 
been made, in tumours with trophoblastic elements (Horne et 
al 1977) and in non trophoblastic tumours (Grudzinskas et al 
1980 a). The presence of SP^ in normal sera detracts from 
the use of this protein in any diagnostic mode but there is 
still the possibility of use in a monitoring situation, where 
other markers are of little use. With the discovery of the 
molecular heterogeneity of SP^ and the recognition of the 
components in differing assay systems, doubt has been expressed 
over previous work in a clinical context. The possibility 
of assaying SP^ cC separately from SP^ f> may offer wider 
clinical application for this protein.* .
1.6.5 Pregnancy Associated Plasma Protein A (PAPP-A)
PAPP-A is a glycoprotein with a molecular weight of about 
7501000 (Lin et al 197*0 but is distinct from other high 
molecular weight glycoproteins. The origin of PAPP-A 
remains in doubt - it is detectable in non pregnant subjects, 
in endometrium and seminal plasma (Duberg et al 1982,
15
Bischof et al 1982 a, Bischof et al 1983)• The sudden
increase in PAPP-A levels in pregnancy suggests that the 
production and/or metabolism of this protein is hormone 
dependent and that early in pregnancy some event triggers 
production. In contrast to many pregnancy proteins, PAPP-A 
concentrations continue to rise to term, suggesting that 
PAPP-A production is not related to placental mass, or that 
a source other than the placenta is responsible.
As with many other pregnancy proteins, no definitive actions 
are known for PAPP-A although a variety of interesting hypo­
theses have been made. In vitro, pure PAPP-A inhibits the 
activity of the complement system although this may be linked 
to the fact that PAPP-A binds heparin (Toop & Klopper 1983)•
If the observed in-vitro inhibition of complement activity 
has any physiological importance, it implies that PAPP-A 
acts as an immunosuppressor. Taking all the known facts 
into account, Bischof proposes that the protein is carried 
by the maternal blood stream until it reaches the intervillous 
space, where it binds to the surface of the syncytiotrophoblast. 
Tightly bound to the microvilli, PAPP-A would exert its immuno­
suppressive effects by inhibiting complement activity and by 
reducing the transformation rate of lymphocytes into lympho­
blasts. These effects would lead to an increased tolerance 
of the foetal allograft by the mother through the local impair­
ment of the maternal immune defences such as cell lysis, immuno- 
adherence, macrophage recruitment and phagocytosis.
The applications of PAPP-A measurement in pregnancy apart from 
one aspect seem at present unpromising. PAPP-A seems of little
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due to the failure to remove hypertensive patients from the 
IUGR population (Bischof et al 1980)* Similarly it seems of 
little use in monitoring diabetic pregnancies (Lin et al 1977)•
One area where considerable interest has been generated is in 
pre-eclampsia and antepartum haemorrhage. Indeed it has been 
suggested that PAPP-A levels are elevated in advance of premature 
labour, antepartum haemorrhage and hypertension (Klopper et al 
1980, Hughes et al 1980). If these findings are correct, 
then measurement of PAPP-A will play a central role in monitoring 
”at risk” pregnancies.
1.6.6 Alpha Foeto Protein (AFP)
Whilst tfr'e proteins discussed so far are products of the maternal 
component, AFP in contrast is produced by the foetal component 
and can be detected as early as 29 days after conception, being 
produced by both the yolk sac and the foetal liver.
AFP is a glycoprotein composed of a single polypeptide chain 
with a molecular weight of 69,000 but may exhibit heterogeneity 
(Alpert and Perencevich 1975)• It resembles albumin in its 
amino acid composition but differs in being a glycoprotein 
containing about carbohydrate. It is likely that there was 
a common ancestor for AFP and albumin.
The major use of AFP in pregnancy has been in screening programmes 
to detect foetal neural tube defects (UK collaborative study on 
AFP in relation to NTD (1979)). More recently interest has been 
generated in applying AFP measurements in the prediction of 
foetal growth retardation (Wald et al 1980, Brock et al 1982).
In the field of tumour monitoring, much use has been made of 
AFP in following patients with hepatoma. Equally in conjunction
15
of ovary and tested Pederson et al 19 7 8 ) „ However, not 
all patients with teratoma are AFP or hCG positive, and patients 
with seminoma are seldom marker positive. Therefore, there 
is a need for other markers in these conditions.
16
CHAPTER 2
DESCRIPTION OF THE RADIOIMMUNOASSAYS EMPLOYED
2.1 Introduction
The assay of proteins in body fluids has been a subject of invest­
igation for many years. Whilst chemical methods allowed quantit­
ation of the major protein fractions and enzymes, specific protein 
assay was largely dependent upon the evolution of immunological' 
techniques.
Whilst ”in vivo” assays (bio-assays) were available for some 
proteins with hormonal activity, the majority of proteins could 
not be assayed until suitable in vitro techniques became available.
The antigen-antibody reaction common to all immunoassays was 
first described in 1897 (Kraus) and formed the basis of a variety 
of immunoassays (Chow 19^7i Ouchterlony 19^8, Oudin 19^9, Feinberg 
1957, Mancini 1965)• Extension of immunoassay with the application 
of electrophoretic techniques (Graber 19531 Laurell 1966) led 
to a wider usage. None of these techniques however were well 
suited to rapid, precise and sensitive assays of large numbers 
of patient specimens.
2.2 Radio-labelled Assays
The introduction of radioimmunoassay (RIA) (lalow & Berson i960) 
therefore had an explosive impact upon endocrinology and specific 
protein assay. These methods now represent a common analytical 
approach to the measurement of a vast range of biological substances., 
often present in minute amounts.
The distinguishing concept of conventional RIA (Saturation Assay) 
is that by allowing the substance to be measured (P) to react 
with a specific receptor (Q) of limited capacity, substance P
17
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Fig 2 i The Saturation (Radioimmuno) Assay 
P is the substance to be measured, and P* its radioactively 
labelled analogue. Q is the binding material.
by saturating Q is partitioned into two moieties, such that the 
ratio of the two varies as a function of the total amount of P 
present. An unknown amount of P may thus be quantitated by 
comparing its distribution With distributions yielded by stand­
ard amounts of P. Identification of the two components relies 
on addition of radioactive material (usually) identical to P. 
Following physical separation of the bound (PQ) and residual 
free P moieties, the partition of radioactivity between them 
is observed (Fig 2i). Suitable receptors are often antibodies 
and this type of RIA obeys the general antigen-antibody concept. 
Because of the limited amount of Q an alternative name for 
this assay type is the Competitive Assay.
However radioimmunoassays have problems associated with them.
Disadvantages such as the use of radioactive tracers with short 
shelf life, the legal implications of the use of radioactivity 
and the expensive counting equipment often required led to the 
development of alternative labels for these assay systems, such 
as enzymes.
2.3 The Choice of Analytical Methods
The objectives of the work described in this thesis were the 
investigation of foeto-placental function and the diagnosis/ 
monitoring of patients with cancer. A number of assays connected 
with this work were already available. Where existing radio­
immunoassays were available, their reaction conditions were 
re-established before use for this thesis.
2 . Radioimmunoassay of human Placental Lactogen (hPL)
2.4.1 Introduction and Principle
The radioimmunoassay of hPL used in this study was that routinely 
in use in the department. The method based on that of Letchworth
(197  ^ a)i had undergone extensive investigation prior to the 
commencement of this study in an attempt to ensure a precise 
and robust assay and also to standardize the assay in terms 
of the. International Reference Preparation (IRP 73/5^5) that 
was now available (Cotes and Das Gaines 1978),. this trend 
being encouraged by National Quality Assurance Schemes•
Certain aspects of the routine assay were confirmed personally
before use as detailed below.
' 125 .hPL labelled with I and an antibody raised against hPL are
incubated with standards, quality control material or patient's
sera. After equilibrium is reached, free and bound antibody
are separated by selective precipitation using propan-2-ol.
The precipitate is centrifuged, the supernatant discarded and,.
the radioactivity associated with the pellet counted on a
^  counter.
2.^.2 Method of Iodination
A solid phase lactoperoxidase method was used (Karonen et al
1975) • ■■
7*33 pg hPL (iodination grade), 10 pi pH 7-^, 0.5 mol/1 phos­
phate buffer, 10 pi working solution solid phase lactoperoxidase
'125
and 10 pi (1 mCi) I were mixed gently in a small test tube 
and 5 pi of hydrogen peroxide (10 pi of 30 vol H^O^ diluted 
in 100 ml water)• After vortexing and incubating for 15 
minutes at room temperature, a further 5 pi of hydrogen peroxide 
was added, vortexed and incubated for a further 15 minutes.
200 pi of 0.05 Mol/1 phosphate buffer containing 2.5 g/1 BSA 
were then added.
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Table 2 I
123 "
Incorporation of I assessed by paper electrophoresis of 
hPL iodination mixture
Strip Section (cm) Counts
1
2
3
if
3
6
7
8
J m
10
11
12
13
1if
15
16
17
18
19
20 
21
285^5
i f¥ f2 l6
Sk9kS3
125^97
117232
16669**
110783
61705
-256Z9. 
11530 
19275 
321 **39 
**78531
1629**
6**7**
3570
3369
1609
787
973
1026
hPL
Total counts
Free Iodine 
Total Counts
V .  Total counts = 1927763 + 868l8*f = 27959**7
% incorporation = Counts in hPL 1n
Total counts x
= 1927763 __
2795947
1927763
868i8if
=  69^
0 Counts /  lOsec
5
4
3
2
1
3 010 . 20 
Fraction number
Fig 2 ii A Typical hPL Iodination Profile
Peak (a) represents labelled hPL and peak (b) is unreacted iodine.
e. a. iu yui cui^uuko uj. uic xuuiuatiuu uiiAtux e wei'e a p p n e u  to
a filter paper Strip ( Whatman 3 MM) marked in 1 era sections
for electrophoresis to assess incorporation, the remaining
iodination mixture being transferred to a 60 cm x 1 cm column
of Sephadex G150, previously equilibrated with 0.05 Mol/1
phosphate buffer containing 2.5 g/1 BSA. Fractions of
approximately 1 ml volume were collected.
125Two or three fractions of I hPL containing the highest counts 
were pooled. For use, a 50 pi aliquot of this pool was diluted
in a suitable volume of assay diluent to give a count of about
12 000 counts/20 secs/50 pi. The volume of assay diluent required 
was usually about 3 ml* Bo and maximal binding were assessed 
for this material.
2.*f.3 Assessment of a Typical hPL Iodination
(i) Electrophoresis of iodination mixture
Paper electrophoresis of the mixture was performed on a 10 pi 
aliquot of the iodination mixture. After drying the paper 
strip, it was cut into 1 cm sections and the radioactivity 
present in each section counted. Table 2 1 shows the results 
obtained.
(ii) Gel filtration of iodination mixture and assessment 
of label dilution
Figure 2 ii shows the profile of- counts obtained from the fractions 
collected from the Sephadex G150 column.
Fractions 16 and 17 were pooled, diluted to 3 ml in assay 
diluent and a 50 pi aliquot of the diluted label counted.
12,300 counts were accumulated in 20 seconds. This dilution 
of label was then used for assay.
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Table 2 II
Assessment of hPL Label Characteristics
Tube No, Description Counts Mean % of Total
1
2
3
k
5
6
7
B
Total
Counts
Bo
Bmax
NSB
12257
12200
9792
9730
11397
11200
720
633
12229
9761
11299
677
80#
926
5.5*
Duplicate tubes* were prepared for the following:- 
Total counts 
Bo
Bmax (antibody concentration 10 x that routinely used)
NSB (no antibody)
Following the normal assay protocol, the bound radioactivity 
in each tube was counted and percentage Bo, Bmax and NSB were 
calculated (Table 211)•
Method of Assay 
50 pi of standard, quality control sera or test sera were
mixed with 300 pi assay diluent (barbitone buffer pH 8.6)
. - / 125 '
containing 250 mg human albumin and 50 p i  of diluted I
hPL. 100 pi of anti hPL (diluted 1/250 in .assay diluent)
was then added, the tube contents mixed on a vortex mixer
and incubated at room temperature for 30 minutes. Total
125count tubes (50 pi I hPL only) and NSB tubes ( no antibody) 
were also prepared.
After incubation,1 ml of propan-2-ol was added to all tubes 
except "total counts", mixed and stood for 5 minutes. The 
tubes were then centrifuged for 10 minutes at 1100 g, the 
supernatant aspirated and the bound fraction counted on a 
Y counter. Calculation of test results was performed by 
comparison of counts in the test samples with counts in the 
standards using a suitable curve fitting procedure ( Chapter 5)
2mb.5 Investigation of Factors Affecting the Assay of hPL
i) Optimal Antiserum Dilution
Various dilutions of antiserum were prepared in assay 
diluent• Standard materials were processed according
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antiserum dilutions. A plot of % B/Bo against 
concentration (logarithmic scale) was made.
ii) Optimal Precipitant Volume
Replicate tubes were prepared containing 50 j i l  of either
0 standard or 6.8 mU/l standard. 300 jul of assay diluent
’ 125- '
and 50 ul of I hPL were added to each tube, followed
by either 100 pi of diluted antiserum or 100 jul of diluent 
(for NSB estimation). Following incubation for 30 
minutes at room temperature, precipitation was carried 
out using varying volumes of propan-2-ol. Duplicate 
binding and NSB tubes were used for each volume of 
precipitant considered. After centrifuging and aspir­
ating the supernatant, the bound radioactivity was 
counted. A plot of % (counts/total counts) after NSB 
correction against precipitant volume was made.
iii) Comparison of hPL standards in horse serum and male serum 
Standard materials were prepared in Wellcome Horse Serum 
No. 3 to cover the range 0-11.3' miu/1. Equivalent concen­
trations were also prepared in a pool of human (male) 
serum. Both sets of standards were assayed according to 
the protocol given•
-2.4.6 Characteristics of hPL Radioimmunoassay
i) Recovery was calculated by adding known amounts of standard
material to horse serum. After assay, the hPL concentration 
found was expressed as a percentage of the theoretical 
concentration.
ii) Within batch precision
Two pools of pregnancy serum were assayed 10 times in duplicate
in a single assay.
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iii) Overall-pre c i si on
Two quality control materials were included in each assay 
performed (215 assays in total)•
2.^.7 Results and Discussion
Figure 2 iii shows the curves with varying antiserum dilutions.
A dilution of 1/250 was chosen for the assay.
From the precipitation studies (Fig 2 iv) it can be seen that at 
volumes of isopropanol of less than 1 ml incomplete precipitation 
of the bound fraction was achieved, shown by the increasing 
percentage counts precipitated. At isopropanol volumes greater 
than 1.3 ml however, the corrected counts precipitated decrease 
due to an increase in the NSB component, ie free label is being 
precipitated in addition to bound label. The optimum isopro­
panol volume was thus defined as 1 ml.
No difference was observed between the standard curves prepared 
in male serum and horse serum (Fig 2 v) • Thus measurement of ' 
hPL in human specimens by comparison with standards in horse 
serum is acceptable.
Recovery over the range of hPL concentrations commonly encountered 
in the 3rd trimester of pregnancy varied between 89# and 108#.
Within batch precision at mean hPL concentrations of 3*9 mU/l 
and 6.0 mU/l was shown to be 6.9/6 and 6.0# CV respectively 
whilst the CV for overall precision varied between 12# at a 
concentration of 2.7 mU/l and 8 .9# at a concentration of 
6 A  mU/l.
The assay therefore provides a suitable means of measuring hPL 
concentrations in the range commonly encountered in the third 
trimester of pregnancy.
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2.5 Radioimmunoassay of human Chorionic Gonadotrophin (hCG)
2.5*1 Introduction and Principle
The radioimmunoassay of hCG was carried out using a kit manufactured 
by NMS Pharmaceuticals Ltd, Newport Beach, California (Kit Code 
NMS 1023) and supplied through RIA (UK) Ltd, Washington, Tyne 
and Wear.
: 125A fixed amount of labelled antigen (I hCG) competes with the
sample, standard or control for a fixed number of binding sites
in a specific antiserum (rabbit anti fb hCG)• After this
incubation, the bound antigen is precipitated using a second
■ 125antibody (goat anti-rabbit gamma globulin). The I bound 
to anti P hCG is precipitated and counted. The leit is stand­
ardized against the 2nd International Reference Preparation (WHO) , 
Holly Hill, England.
Before use in this study, certain characteristics of the kit 
were verified.
2*5*2 Method of Assay
Duplicate tubes were prepared containing 100 pi of standard or
test serum. 100 pi of anti hCG was then added and the tubes
*125 -incubated at room temperature for JO min. 100 pi of I hCG 
was then added to each tube. All tubes were then incubated 
overnight at room temperature, after which 200 pi of second 
antibody were added and the tubes incubated for JO mins at 
room temperature. Immediately prior to centrifugation 2.0 ml 
of cold phosphate buffered saline was added. The tubes were 
then centrifuged at k°C (3000 rpm) for 15 minutes. The super­
natant was aspirated and the bound fraction counted.
2k
xjn.vtisxxKcm.pii ox n e tn o a  o n a r a c t e n s t i c s
i) Assessment of Cross Reaction with other Peptide Hormones
Standards for follicle stimulating hormone (FSH 81/L), 
luteinizing hormone (LH 81/L) and thyroid stimulating 
hormone (TSH 68/38) were obtained from the National 
Institute for Biological Standards, and Control, Holly 
Hill, London*
Each standard was reconstituted according to the protocols 
supplied and further dilutions of this solution were made 
in PBS to give standard ranges:-
FSH 0 - 4 0 0  mU/L
LH 0 - 5 0 0  mU/L
TSH 0 -  75 mU/L
The diluted standards were then assayed following the 
routine assay protocol supplied by the manufacturers 
of the kit. A plot of percentage B/Bo was made.
ii) Limit of Detection
This parameter was assessed by assaying 10 duplicate 
Bo's in 1 assay as described previously (Pledger et al 
1981). :
iii) Precision ^
Within batch and overall precision were calculated using 
quality control materials supplied in the kit, and a 
pool of pregnancy serum for overall precision.
iv) Normal Range
The normal range for hCG in a non pregnant population 
was assessed by assaying 2? male sera and 26 female 
sera drawn from laboratory staff.
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2.5.** Results and Discussion
Fig 2 vr shows the results of the cross reaction studies.
There was no significant cross reaction with any of the 
peptide hormones considered over the working range of the 
'assay. .
The limit of detection was assessed as 2.06 miu/ml which is 
in agreement with the manufacturer’s quoted value of 2.0 miu/ml.
Most normal sera had hCG concentrations less than the limit 
of detection of the assay, and no sera had hCG concentrations 
greater than 5 miu/ml. The normal range was therefore defined 
as 0-5 miu/ml which is in accordance with the kit manufacturer’s 
estimate.
The limit of detection is acceptable within this context and
the assay is also precise (CV varying between 9 and 7-05&
at mean concentrations of 7.6 miu/ml and 60.5 miu/ml) •
2.6 Radioimmunoassay of Alpha Foeto Protein
2.6.1 Introduction and Principle
The assay used was that routinely in use in this department.
' ; 125 ■
AFP labelled with I and unlabelled AFP (standards, tests) 
together with an antibody raised against AFP are incubated in 
barbitone buffer containing 11.2$ polyethylene glycol, overnight 
at room temperature.
The following day, the tubes are centrifuged, the supernatant 
discarded and the bound radioactivity counted.
The assay was standardized against IRP 7^/227 obtained from 
NIBSC.
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2.6.2 Method of Assay
Duplicate tubes were prepared containing 100 pi antibody, 100 pi 
labelled AFP, 50 pi standard, serum or quality control, 600jul 
PEG. The tubes were incubated at room temperature overnight 
and the following day were centrifuged at 2000 g for 20 minutes, 
the supernatant aspirated and the bound radioactivity counted.
2.6.3 Assay Characteristics and Discussion
Within batch and overall precision were estimated using horse 
serum spiked with foetal cord serum. Within batch precision 
was 7•9# at a concentration of ^5»3 u/ml and overall precision 
was 9# at a concentration of 50»0 u/ml.
The limit of detection assessed by assaying 10 duplicate
Bo*s in 1 assay was calculated as 1.8 u/ml.
The assay provides a suitable method for the determination of
AFP in patients with neoplastic disease.
The method is acceptably sensitive and precise.
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CHAPTER 3
DESCRIPTION OF ENZYME LINKED IMMUNOSORBENT ASSAYS EMPLOYED
s
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Fig 3 i The Sandwich ELISA
3*1 Introduction
The disadvantages of radioactive labels led chemists and immuno­
logists to investigate alternative non-isotopic labels. These 
labels included enzymes (Van Weemen and Schurrs 1 9 7 1 ) erythro­
cytes (Adler and Liu 1971)» bacteriophages (Haimovich et al 
1970), fluorescent groups (Aalberse 1973) and stable free 
radicals (Leute et al 1972)• Of these labels only enzymes 
gained rapidly in popularity. Whether this was due to an 
existing knowledge of enzyme kinetics, or the easily remembered 
acronym (ELISA) Enzyme Linked ImmunoSorbent-Assay coined by 
Engvall and Perlmann is debatable. (1972)
Enzyme immunoassays may be classified into two main types viz 
homogeneous (exemplified by EMIT assays) and heterogeneous 
(generally known as ELISA), the distinction being made on the 
absence or presence of washing stages.
Terminology still poses a problem, various acronyms having 
been used (Van Weemen and Schurrs 1971* Pinon and Dropsy 1977, 
Saunders et al 1977* Yorde et al 1976)•
The enzyme immunoassays considered in this study will be classi­
fied as ELISA, as this acronym encompasses the essential concepts 
(Fig 3 i) .
3.2 Choice of Analytical Technique
Where it was necessary to establish assays for placental proteins 
which had not previously been assayed on a regular basis in 
these laboratories, ELISA systems were devised. Because ELISA 
has not been so widely used as RIA, factors influencing perform­
ance have not always been clearly defined. Thus an investi­
gation of some of these factors was also undertaken.
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SOLID PHASE
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Wash several times to remove 
non-specifically bound Antibody-enzyme
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Colour Development
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Acid Stop
n!/
Read Absorbances
Fig 3 ii Flow Sheet for Sandwich ELISA for antigen assay
3*3*1 The Options Available
A variety of assay types have been described with analogues 
in conventional radiolabelled assays. These have been well 
reviewed by a number of authors (Wisdom 1976, O'Sullivan et al 
1979) and no further description will be given here.
Sandwich ELISA offers sensitive, specific assays with ease 
of separation, avoiding problems sometimes seen with interfering 
factors in competitive ELISA. Only sandwich assays were utilized 
in this study and this assay type will be considered in more detail.,
3*2.2 Sandwich ELISA for antigen
This procedure requires the antigen to have at least 2 binding 
sites. Antigen is reacted with excess solid phase antibody 
and after incubation followed by washing, the bound antigen 
is reacted with excess labelled antibody. After further washing, 
the bound label is assayed, thus providing a direct measure of the 
amount of antigen present (Maiolini and Masseyeff 1975)- Two 
assumptions are made in this type of assay:-
a) that an enzyme marker may be attached to an antibody with 
retention of both immunological and enzymic activity.
b) that an antibody may be linked to a solid phase carrier 
surface. ~\
In practice, both of these assumptions hold true. The assay 
concept is shown schematically in Fig 3 ii»
3.3.3 Immobilization of Antibodies
ELISA is distinguished from other types of enzyme immunoassay 
by the immobilization of antibody, allowing rapid, simple sep­
aration of free antigen and antibody enzyme from the immobilized 
(bound) fraction. .
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Table 3 I
Criteria for Enzyme Labels
1) Availability of purified low-cost homogeneous enzyme 
preparations.
2) High specific activity.
3) Presence of residues through which the enzyme can be 
cross-linked to other molecules with minimal loss of 
both enzyme and antibody activity.
*f) Stable enzyme conjugates.
5) Enzyme absent from biological fluids.
6) Assay method should be cheap, simple, sensitive, precise 
and not affected by factors present in biological fluids.
7) Enzyme, substrate, co-factors etc should not pose a potential 
health hazard.
A wide variety of solid phases have been used - PVC (Macdonald 
et al 1979), polystyrene (Pledger and Belfield 1983)i micro­
crystalline cellulose (Maiolini and Masseyeff 1975) * nylon 
(Hendry and Herrmann 1980) and activated paper discs (Lehtonen 
and Viljanen 1980).
Most proteins adsorb to plastic surfaces probably as a result 
of hydrophobic interaction between non-polar protein substructures 
and the non-polar protein matrix. However, as the antibody 
is only physically adsorbed, loss of protein during washes 
and incubations is possible (Lehtonen and Viljanen 1980). 
Furthermore, adsorbed proteins may undergo denaturation with 
loss of immunological activity. Further investigation of these 
factors is warranted.
3.3 .^  Choice of Enzyme Label
The enzyme label forms an integral part of ELISA and the choice 
of enzyme must therefore be made carefully. Ideal enzyme 
properties are listed in Table 3 I* Few if any enzymes possess 
all these properties and the choice of label is thus to a 
large'-.extent dictated by the nature of the assay ie homogeneous 
or heterogeneous.
Assay sensitivity is also partially dependent on the enzyme 
label. Thus whilst lysozyme has been used as a label to detect 
a number of drugs in urine at the mg/1 range (Rubenstein et 
al 1972) it would not be a suitable label for assays requiring 
high sensitivity, due to its low specific activity.
The most widely used enzymes have been horse-radish peroxidase 
(HRP), ^ galactosidase and alkaline phosphatase.
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3*3-5 Preparation of Enzyme Labels
A wide variety of chemical methods for preparing antibody- 
enzyme conjugates have been proposed. Most depend on activa­
tion of residues on the antibody/enzyme, or cross linking using 
a heterobifunctional reagent. The general principles are 
similar and are shown by reference to two reactions (Figs 
3 iii and 3 iv)• Each method has points to commend it, but 
when preparing conjugates of HRP, the most widely used procedure 
has been that of Avrameas (1969a) - the two step glutaraldehyde 
procedure. Although the yield is low, the technique is easily 
performed and provides a stable conjugate with reasonably standard 
properties from batch to batch.
Following conjugation, separation of the reaction components 
is effected by techniques such as gel filtration.
Most conjugation procedures give rise to high molecular weight 
complexes containing several enzyme molecules bound to several 
antibody molecules. In a solid phase assay only one of the 
antibody molecules in such a complex-will be available to react 
with an antigen. Thus although the complex may exhibit high 
specific activity this cannot be realized in practice. The 
differing nature of these complexes compared with natural anti­
body does not seem to present problems in ELISA, as results 
are always obtained by comparing the unknown sample with a 
standard, which will react identically in a given system.
3*3*6 Detection of Enzyme Labelled Antibody
Detection systems used are largely dictated by the choice of 
enzyme. Many enzymes may be detected by simple colorimetric 
procedures and this may have been a reason for the initial 
rise in ELISA.
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Table 3 II
Advantages and Disadvantages of Enzyme Labels 
Advantages
1) Sensitive assays result from the enzyme amplification effect
2) Reagents are relatively cheap and can have a long shelf life
3) A variety of enzymes can be used as labels. Thus:-
a) multiple simultaneous assays are theoretically possible
b) labels may be prepared using a wide variety of con­
jugation techniques
c) a number of systems for detecting enzyme activity 
may be used
k) t Equipment can be inexpensive and is widely available.
5) No radiation hazards occur during labelling or disposal
of waste.
Disadvantages
1) Measurement of enzyme activity can be more complex than 
measurement of the activity of some types of radioisotopes.
2) Enzyme activity may be affected by plasma constituents.
3) Solid phase problems•
k) More stages involved than in RIA.
5) Interference by serum components.
Other techniques such as fluorescence (Kato et al 1975)* 
turbidity measurement (Rubenstein et al 1972) and scintil­
lation counting (Van der Waart and Schuurs 1975) have been used.
More novel ideas have included the use of electrode detectors 
utilizing a thermistor (Mattiasson et al 1978) and recently 
the advent of luminescence assays (Velan and Halmann 1978) 
offers the prospect of increased sensitivity. However these 
methods have their own problems in terms of interfering factors 
(Tsuji et al 1978).
The particular type of apparatus used is often dictated by the 
nature of the solid phase. Thus whilst it is possible to 
aspirate solutions from the wells of a microtitre plate for 
individual readings in a spectrophotometer, it is easier and 
quicker to use a microtitre plate Reader, allowing the entire 
plate to be read in about 60 seconds.
3 .3 .7 Problems Associated with ELISA
Hosking (1982) has described ELISA as a "paragon of virtue". 
However, problems do exist. Whilst the use of enzyme labels 
avoided some of the problems associated with radioactive labels, 
certain disadvantages were also recognized (Table 3 II)•
Leaching'of immobilized antibody has been alluded to and non­
specific adsorption may occur.
Whilst washing stages avoid many of the problems of interfering 
factors, difficulties have been experienced with sera containing 
high concentrations of rheumatoid factor (Maiolini and Masseyeff) 
1975) and also with the complement system (Belfield and Macdonald 
1979).
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It is hoped that the investigations carried out for this thesis 
will place the assays on a more theoretical basis. This will 
improve the design and optimization of assays and could lead 
to an improved laboratory service.
3.*f Enzyme Linked ImmunoSorbent Assay of Pregnancy Specific 
Glycoprotein (SP^)
3.^.1 Introduction and Principle
The assay of this protein was based on the method described 
by Macdonald et al (1979) following validation and extension 
of the assay parameters.
Antibodies to SP^ are bound to the wells of plastic microtitre 
plates. After removing Unbound antibody by washing, antigen 
is added. After incubation the antigen is removed, and anti­
body linked to horseradish peroxidase is then incubated in the 
wells. Following removal of excess antibody enzyme, chromogen 
is added and colour allowed to develop. The reaction is term­
inated by addition of acid. The resulting colours are read 
in a spectrophotometer, the absorbances compared with those 
for the standards and calculation of the unknown concentrations 
made.
3*^*2 Materials and Methods 
Materials as defined in Appendix I.
Method of Assay Microtitre plates were coated with antiserum 
to SPn (diluted 1/1200 in pH 9*6 carbonate/bicarbonate buffer), 
overnight at +^°C. Prior to use, the plates were emptied and 
washed three times with wash buffer, following which the plates 
were shaken dry. 100 p i  of standards or test sera (diluted
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1/1000 in diluting solution) were pipetted in duplicate into 
wells of the microtitre plate and incubated for 30 minutes.
The well contents were then aspirated, the plate washed 3 times 
and dried. 100 jil of antibody-peroxidase conjugate diluted 
1/1000 in PBS/25^ chicken serum with 100 j*l of molar sodium 
citrate per 10 ml of solution, was pipetted into the wells. 
Incubation was carried out for 30 minutes followed by a 
further washing cycle. After drying the plate, 100jil 
of chromogen were added and colour development allowed to 
proceed for 30 minutes, at the end of which time, the reaction 
was stopped by addition of 100 jil of A mol /I sulphuric acid.
3*^*3 Investigation of Factors affecting the assay
Investigation of the effect of varying contact time of antigen 
with antibody, of antibody enzyme with antigen, the effect of 
the antiserum dilution used for coating and the effect of 
antibody-enzyme dilution were assessed as described by Macdonald 
(1979).
Recovery was assessed by spiking a pool of male serum with 
known volumes of SP^ standard.
Precision Within batch precision was assessed by replicate 
assay of 2 serum pools on a single microtitre plate. Overall 
precision was assessed at two concentrations by assaying serum 
pools on each plate.
Parallelism of Assay Parallelism was checked using a pool
1-1 1of pregnancy serum. Initial dilutions (neat, — , ~ ) were 
made in pooled male serum. A further dilution of 1/1000 was 
made in diluting solution. Replicate assays of each dilution 
were performed.
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Table 3 III
Recovery of SP^ added to male serum
Theoretical Measured
Concentration Concentration $ Recovery
mg/1  MgA_________   .
60 58.6 97*5
90 94 10^.5
120 126 105
Mean Recovery 100$
Table 3 IV
Precision of SP^ Assay
a) Within Batch
Lo Hi
Mean
Concentration (mg/1) 104 198
Std. Deviation 7.2 15.6
CV %
’ 7.0 7.9
n 20 20
b) Overall
Lo Hi
Mean
Concentration (mg/l) 107 200
Std. Deviation 13.1 32.7
CV % 12.2 16.3
n . 60 64
Table 3 V
Parallelism of SP^ Assay
Dilution
SP^ Concentration (mg/l) after correction 
for dilution factor (Mean — SD)
Neat 330 + 41
■1
2 322 + 42
1
? !  ■ -
301 + 11
■1
5
326 + 13
From Fig 3 v, 3 vi it can be seen that increased incubation 
times lead to increased colour development and that at no 
point is equilibrium reached. Adequate assay sensitivity 
for the range of SP^ concentrations seen in pregnancy are 
achieved using incubation times of 30 minutes.
Optimal antibody dilution for coating the plate (Fig 3 vii) ^  
was found to be 1/1200 and adequate assay sensitivity with-these 
. factors set was' achieved with Ab-E dilutions of 1/1000 (Fig 3 
viii)v These findings are'in agreement with Macdonald*s results 
(1979) except that he used a different Ab-E preparation• Varying 
Ab-E concentration was however found to affect non specific bind­
ing. This is discussed further in chapter *f.
Recovery varied between 97*5$ snb. 105^ (Table 3 III) so the 
method is accurate. It is also acceptably precise (Table 3 IV), 
CV*s being in the range associated with many immunoassays. 
Parallelism was exhibited over the range of dilutions considered 
(Table 3 V). This finding is not at variance with the discovery 
of the heterogeneity of SP^ (Towler etal 1978, Anthony etal 
1980a, Ahmed et al 1982a) as there is no change in the 
relative concentrations of the two components.
The assay provides' an accurate, precise method of quantitating 
SP^ in suitably diluted pregnancy serum. Further sensitization 
would be desirable before its use in detecting SP^ in patients 
with neoplasia however (Pledger et al 1981).
3»5 Development of ELISA with Improved Sensitivity for the 
Assay of SP^
3.5.1 Introduction
The assay was based on the principles described for the assay
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provide increased sensitivity as described. Whilst the ELISA 
described previously is suitable for assaying SP^ concentrations 
commonly found^In late pregnancy, increased assay;sensitivity 
is desirable for assay of SP^ in patients with neoplastic disease.
3*5 • 2 Method for Removal of endogenous SP^ from male serum
• 2 .5 g of cyanogen bromide activated-sepharose was swollen and
—3washed for 2*f hours in 100 ml of 10 mol/l hydrochloric acid 
with 3 changes of wash. 10 ml of sepharose were prepared and 
to this was coupled 5 nig anti SP^/ml of sepharose (protein 
content of antiserum — 25 g/l) as follows.
2 ml of anti SP^ were equilibrated with k ml carbonate/bicarb­
onate buffer pH 9*6 containing 0 .5 mol/l sodium chloride (to 
prevent protein-protein interaction). This was added to the 
sepharose gel also equilibrated' at pH 9*6 in the same buffer, 
and mixed for 2 hours at room temperature. The gel volume 
of 0.2 mol/l Tris buffer pH 8.0 was then added and mixed with 
the gel at room temperature to block any remaining active 
sites on the gel. Following centrifugation, the supernatant 
was discarded and the gel complex washed alternately with 
acetate buffer (0.1 mol/l, pH A.O) and borate buffer (0.1 mol/l 
pH 8.5) each with addition of 1 molar sodium chloride, centri­
fuged and the supernatant discarded.
Efficiency of Antigen Stripping Initially a study using 
radioactively labelled SP^ (kindly donated by Professor K Bag- 
shawe, Department of Medical Oncology, Charing Cross Hospital) 
was performed to investigate the efficiency of antigen stripping. 
The experiment was performed either with or without changes 
of the sepharose-antiserura gel, mixed with a pool of male 
serum spiked with labelled SP^. Counting of the remaining
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Table 3 VI
Efficiency of Antigen Removal by Sepharose-Anti SP^ Solid Phase
a) With changes of solid phase (change performed at noted 
..times)
Time Counts/20 secs % SP^ Removed
0 min 12,500 -
60 " 3,060 75
90 " 1,800 88
120 ** 1,800 88
16 hrs 960 92
b) No change of solid phase
Time Counts/20 secs % SP^ Removed
0 min 12,500 -
60 " 3,075 75
90 " 3,200 75
120 " . 3,100 75 
16 hrs 3,100 75
stages to assess" the efficiency of removal (Table 3-VI)'* From 
the findings of this experiment, the pool of male serum to be 
used for preparation of standards was mixed with sepharose- 
antiserum gel for 18 hours at room tempera’ture with 3 changes 
of gel.
3 .5 .3  Sensitized SP^ Assay Method
Anti SP^ diluted 1/1200 in coating buffer pH 9*6 (100 jil) was 
pipetted into the wells of microtitre plates and incubated 
overnight at 4°C. Following washing 3 times with wash buffer 
and drying, 100 p i  of standards, test sera or quality control 
material was pipetted into the wells in duplicate and incubated 
at room temperature for 75 minutes, after which the well contents 
were aspirated and the plates washed and dried again. Ab-E 
diluted 1/500 in PBS/chicken serum was then added to the wells 
and incubated for 75 minutes. Following a further washing 
cycle, chromogen was added (100 p i ) to each well and colour 
development allowed to proceed for 30 minutes. The reaction was 
stopped by addition of 100 jil of 4 mol/l sulphuric acid to each 
well, and the developed colour read on a Multiskan^late reader.
3.5»4 Investigation of Factors Affecting the Assay
The effects of increasing incubation times of antigen with anti­
body and of antigen with antibody enzyme at 3 concentrations 
of SP^ were investigated over a prolonged time course in a 
similar manner to that described previously (Macdonald 1979)•
The optimal dilution of Ab-E was also investigated as described 
previously.
The Effect of the Protein Matrix As SP^ in this sensitized 
assay was to be assayed in undiluted sera as opposed to highly
used to prepare'standards was investigated.
Standards of varying concentration were prepared in 3 different 
matrices. BehringwerkeSP^ standard was diluted in either 
PBS/citrate containing 1# BSA, chicken serum or a pool of male 
serum stripped of endogenous SP^. A number of sera from male 
and non pregnant female laboratory staff were also used in 
these studies.
The standards in PBS/citrate and chicken serum were investigated 
initially. These standard solutions were assayed according 
to the routine assay protocol and a graph of absorbance (cor­
rected for blank value) against concentration was made. The 
sera from laboratory staff were also assayed and also a series 
of chicken sera containing no SP^ were assayed.
In a second experiment, standards prepared in chicken serum 
and SP^—free male serum were compared. Replicate male serum 
blanks were also utilized.
3*5-5 Assessment of Assay Sensitivity
Sensitivity was assessed by assaying a series of blanks according 
to the routine protocol. On 1 plate Ab-E at a dilution of 
1/1000 was used, on the second plate Ab-E at a dilution of 
1/500 was used. Assay sensitivity was calculated using the 
formula: -
Sensitivity = 0D blank + 2 SD
the SD being calculated from the formula
Id2
2N-1
where D = difference between duplicate blank ODs 
N = Number of duplicates
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It had been shown previously that increasing contact time of 
antigen with antibody and antibody enzyme with antigen led to 
increased colour development (3*4.4) • Figs 3 ix, 3 x show 
that it is possible to extend these incubation times consider­
ably and thus increase assay sensitivity. However maximal 
increase in colour is seen over the first 80 minutes at each 
incubation stage and there is little point in extending incuba­
tions beyond this. Fig 3 xi shows that decreased dilutions 
of Ab-E leads to a more sensitive assay, although NSB increases. 
A suitable compromise is thus 1/500 dilution.
The assay sensitivity using Ab-E at a dilution of 1/1000 was
4.3 p s / l and using Ab-E at a dilution of 1/500 was 3 ^ ig/1.
In' practice however, an arbitrary decision must be made in 
a similar way to that for RIA.
Over a number of assays, the mean practical sensitivity was 
6.13 p-g/1 + 0.80 (SD) • In view of the findings of Anthony's 
group (1980 a) who found values up to 6 ug/1 in the normal 
population, this practical limit of detection is suitable.
The effect of the protein matrix upon the standard curve is 
shown in Figs 3 xii, 3 xiii. As undiluted test sera were 
to be assayed, it is apparent that SP^ standards must be 
prepared in a male serum protein matrix or results will not 
be comparable. Further evidence for this fact is obtained 
from the fact that a number of normal sera (34$) showed 
detectable levels of SP^ when compared against a standard 
curve prepared in PBS/citrate. Comparing against a 
standard curve prepared in male serum, only 14$ of normal 
.sera were positive. This is close to the number found by 
Searle (1978) using an assay of comparable sensitivity.
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Table 3 VII
Recovery of SP^ using Radial Immunodiffusion Assay 
Expected Found
Concentration Concentration Recovery
(mg/l) (mg/1) $
90 86 98
191 168 88
197 168 85
Mean 90$
Table 3 VIII
Comparison of SP^ Concentrations obtained by ELISA with 
Concentrations obtained by RID
0 .8 3 (p< 0 .001) 
0.32 
66.2 
0.03 
9.0
Correlation coefft 
Gradient 
Y Axis Intercept 
Std Error of Gradient 
Std Error of Intercept
3*6.1 Materials and Methods
Standards and test sera (5 >il) were pipetted into the wells 
of the RID plate. After incubation at room temperature for 2 
days to allow maximum immunodiffusion, the diameters of the 
precipitin rings were measured. A standard curve was con- 
structed using a plot of (diameter) against antigen concen­
tration.
Recovery was assessed by addition of known volumes of standard 
SP^ j material to known volumes of pooled male serum. Within 
batch precision was assessed by replicate analyses of a pool 
of pregnancy serum on 1 RID plate.
3.6.2 Results and Discussion
Table 3 VII shows the results of the recovery experiments. 
V/ithin batch precision was A.O% at a concentration of l6 h mg/l. 
Table 3 VIII shows the comparison of results obtained by RID 
compared to those obtained by ELISA. Results obtained by 
ELISA were significantly higher when tested by the paired 
t test. However, a significant degree of correlation exists 
between the results obtained.
The finding of a lower recovery using RID may partially account 
for this and the problem may be further complicated by the 
molecular heterogeneity of SP^ (Teisner et al 1978).
Whilst the precision is improved using RID, this is offset by 
the longer turn-round time to obtain results, the decreased 
working range, and the unsuitability of RID to cope with large 
numbers of specimens. ELISA therefore remains the method of 
choice.
ko
Plasma Protein A (PAPP-A)
3-7-1 Introduction and Principle
This assay was based on an assay in use for the measurement of 
SP^ (Macdonald et al 1979)* Antibodies to PAPP-A are bound 
to the wells of plastic microtitre plates. After removing 
unbound antibody, antigen is added. Following incubation, 
the antigen is removed and antibody linked to horseradish 
peroxidase is then incubated in the wells. Following removal 
of excess antibody-enzyme, chromogen is added and colour allowed 
to develop. The reaction is terminated by addition of acid.
The resulting colours are read in a spectrophotometer, the 
absorbances compared with those for the standards and calculation 
of the unknown concentrations made.
3*7*2 Materials
PAPP-A Laboratory Standard - Sera from 50 patients in the 3rd 
trimester (28-^0 weeks gestation) of a normal pregnancy were 
pooled to give a pool of 250 ml volume. This pool was aliquoted 
and stored at -20°C until use. A nominal value of 1000 arbit­
rary units/litre (AU/L) was assigned to this pool until calib­
ration against IRP 78/610 was made. Dilutions of this standard 
pool were made in PBS/citrate to give a range of standards 
from 0-20 AU/L.
Anti-PAPPA- Peroxidase was prepared by a two step glutaraldehyde 
conjugation method (Avrameas and Ternynck 197*0 as described 
(3-7*3)• After purification on a Sephacryl S200 column the 
conjugate was stored at -20°C. For use a 1/20 dilution was 
made in PBS/chicken serum. .
All other materials are as described in Appendix I.
xne Hetnoa 01 Avrameas and Ternynctc lor Antibody 
Enzyme Conjugation
10 mg of horseradish peroxidase (HRP) were dissolved in 200 jil 
of 0 .1 mol/l phosphate buffer (pH 7**0 containing 1.2556 
(v/v) glutaraldehyde and mixed for 2k hours at room temp­
erature. The solution was then dialyzed at -k°C for 2k 
hours against 0 .9% saline.
The total protein content of the PAPP-A antiserum was shown to 
be 15 g/1 by the Lowry method for protein assay. 0*3 ml 
(^5 mg) of antiserum were equilibriated in 0 .6 ml of carbonate/ 
bicarbonate buffer pH 9*6 added to the HRP solution, and reacted 
for 2k hours at k°C with continual mixing.
0.1 ml of a 0 .2  mol/l solution of lysine was then added and mixed 
for 2 hours at k°C, to : inactivate residual aldehyde.
Dialysis was then performed against PBS for 2k hours.
Separation of Ab-E from unreacted components was investigated 
using Ultragel ACA 3k and Sephacryl S200.
3»7»k Methods of Separation of Conjugate from Unreacted 
Components
i) Separation using Ultragel - A column measuring k3 cm x
2.2 cm (total volume 171 ml) was packed with Ultragel
ACA J k . The void volume assessed by Dextran Blue was
56.0 ml. The column was equilibrated' using a set of
protein standards purchased from Pharmacia.
Kav values for these standards were estimated using the
formula: - .
Ve - Vo
K = rrr n— where Ve = elution volume
Vt - V° Vo = void volume
Vt = total volume
k2
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3) Ovalbumin 11 kj> 000
k) Albumin M 6? 000
5) Aldolase "  158 000
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Table 3 IX
Molecular weight estimates of Ab-E conjugate and individual 
components using Ultragel ACA and Sephacryl S200 columns
a) Ultragel column
Peak Number Elution Volume K Molecular
(ml) av Weight
II Anti PAPP-A-HRP 100 0.37 260,000
III Free HRP 127 0 .6 2 110,000
b) Sephacryl S200 column
(i) Conjugate Mixture
Peak Number Elution Volume 
(ml)
Kav MolecularWeight
I (Anti PAPP-A-HRP) Void — 160,000
II (Free Anti PAPP-A) 19.0 0 .08 1*t0,000
III (Free HRP) 22.9 0.27 71,000
(ii) Free Components
Component Elution Volume K Molecular
(ml) av Weight
(**5 mg) Anti PAPP-A 20.2 0 .1*t 120,000
10 mg HRP 22.5 0.25 76,000
xxic ouuju&ctut: iuxalux t? wcis appnea t,o tne column ana
eluted with PBS, collecting 1 ml fractions. Protein
elution was monitored at 280 nm and K values calculated.av
A plot of K&v against log molecular weight for the 
standards was made and used to calculate molecular 
weights for the conjugate mixture proteins.
ii) Separation using Sephacryl S200 - A column measuring
60 cm x 0.9 cm was packed with Sephacryl S200 (total 
volume 38 .2 ml, void volume 17*3 ml). The column was 
calibrated with protein standards as before.
Ab-E conjugate, unconjugated anti PAPP-A, and HRP 
were applied in separate chromatographic runs to the 
column, the elution volumes noted, and molecular weights 
j estimated.
3*7»5 Results
Figures 3 xiv and 3 xv show the calibration line for the Ultra­
gel column and the elution profile of Ab-E conjugate on this 
column. Figures 3 xvi and 3 xvii show the same details for 
the Sephacryl S200 column. Table 3 IX shows the molecular 
weight estimates on the different columns. Initial use of 
the Ultragel column proved unsatisfactory in its inability to 
separate the conjugate from unreacted antiserum and further, 
the estimated molecular weight for HRP using this column was 
not in accordance with other workers estimates (Morita et al 
1980).
Using the Sephacryl column improved resolution of the components 
was obtained. Molecular weight of the antibody was. in agree­
ment with general estimates, although that for HRP was still 
higher than most estimates. This finding may be due to the
• ^3
MW estimates by 'gel filtration unreliable.
It is not possible to assign an exact molecular weight to the 
Ab-E conjugate as it eluted in the void volume. Avrameas and 
Ternynck (197*0 felt that the molecular weight of the conjugate 
was not in excess of 200,000 indicating that it consisted of 
one molecule of HRP linked to 1 molecule of antibody and that 
the main objective of the two stage procedure had been attained. 
The major disadvantage of this procedure is its low yield, about 
2$ of the HRP being conjugated to antibody (Nakane and Kawaoi 
197*0• Nevertheless experience with the Avrameas technique 
in this laboratory has shown it to be reproducible in terms of 
the optimal dilutions of Ab-E required for assay purposes.
Further Anti PAPP-A-HRP conjugates were separated on Sephacryl 
S200 for use in PAPP-A assay.
3.7.6 Method of Assay
100 j i l  of antihuman PAPP-A previously diluted 1/1200 in carbonate/ 
bicarbonate buffer pH 9-6 was pipetted into each well of a 
microtitre plate excluding the outer rows because of previously 
reported "edge” effects (Burt et al 1979)•
The plates were left overnight at +if°C. No special methods 
were used to enhance antibody binding.
Before use, the plates were emptied by inversion, washed three 
times with wash buffer and shaken dry.
100^11 of standard materials or 100 jil of test serum diluted 
1/100 in PBS/citrate were added in duplicate to the wells at 
timed intervals. Incubation at room temperature was allowed 
to proceed for 120 minutes after which the solutions were
v> v jv w  if  v  w  m  ^ v » *  v  jb  a m  v  w  n M U ii \> >  \A  ^ i l l  C  C  U iL l i t C O  W JL U i l  W A O i i  U  U  X X  6 X ' c U lQ
shaken dry.
100 ^ il of antibody enzyme conjugate (diluted 1/20 in PBS contain­
ing 23% chicken serum) was then added to each well and incubated 
for 120 minutes at room temperature. The solutions were then 
aspirated and the plate washed and dried as before.
100 jtl of chromogen was then added to each well. After k3 
minutes of colour development in the dark at room temperature 
the reaction was stopped by addition of 100 jtil of k mol/l sulphuric 
acid to each well.
The developed colours were read on either an Abbott ABA 100 
bichromatic analyzer (Abbott Laboratories Ltd, Basingstoke,
Hants) or latterly on a Titertek Multiskan (Flow Laboratories).
To enable comparison of results from these 2 instruments readings . 
were converted to absorbance values for a 1 cm path length (A 1 cm).
The Abbott ABA analyzer was used only during initial development 
stages of this assay. All further work was performed on the 
Multiskan plate reader giving absorbance values directly.
Calibration curves of absorbance against concentration were plot­
ted oh semilogarithmic graph paper. Alternatively a suitable 
curve fitting procedure may be utilized to allow automation
(Chapter 5) •
3«7*7 Investigation of Factors Affecting the Assay
i Time course of Antibody Antigen Reaction.
100 ^ il of standard material containing 1, 2 and 20 AU/L 
were pipetted in duplicate into wells coated with anti­
serum as in the routine assay protocol. Preliminary 
investigation had shown that incubation times of less 
than 80 mins did not give adequate sensitivity. In
‘ ^
an attempt to increase sensitivity the reaction time
course was investigated between 80 and 150 minutes.
The plates were then processed as in the routine 
. assay.
ii Time course of antibody-enzyrae antigen reaction.
100 jil standard material containing 1,2 and 20 AU/L 
were pipetted into the wells of microtitre plates 
previously coated with antibody and allowed to incubate 
for 120 minutes. The sera were then aspirated and the 
plate washed. Diluted Ab-E solution was added to each 
well and incubated at room temperature for times varying 
between 80 and 150 minutes. After this incubation the 
plate was processed according to the routine assay proto-
J' ' . col.' ■.
iii Variation of incubation time for colour development. 
Antigen at concentration of 10, 100, 500 and 1000 AU/L 
v;as applied to microtitre plates, followed by Ab-E 
according to the routine assay protocol. Chromogen 
was then added (100 jil/well) and incubated for times 
varying between 10 and 80 minutes.
iv Effect of antiserum dilution used to coat plates. 
Antiserum at dilutions varying from 1/500 to 1/2000
in carbonate/bicarbonate buffer was dispensed into the 
wells of 5 microtitre plates and incubated overnight 
at +4°C.
After washing, standards were added to each well prev­
iously coated with antibody and processed according to 
the routine assay schedule.
' , k6 T ;
colour development.
100 jil of standards were added to wells of a microtitre 
plate previously coated with anti-PAPP-A at a dilution 
of 1/1200. After incubating, washing and drying in 
the normal way, 100 jil Ab-E at dilutions ranging from 
1/20 to 1/60 was added to each well and incubated for 
120 minutes. Further steps were according to the 
routine protocol.
3*7*8 The Effect of haemolysis on the assay of PAPP-A
Blood samples were collected from patients undergoing routine 
antenatal biochemical monitoring# 5 nil blood specimens were 
collected into lithium heparin containers and mixed well.
On arrival in the laboratory, the specimen was divided into four
1 ml parts and treated as follows:
part (1) immediate separation of plasma from cells (fresh
plasma);
part (2) incubation of specimen at room temperature for 2k h 
before separation of plasma (incubated plasma); 
part (3) addition of 0 .5 ml deionised water, mixed by inversion 
separation of plasma (haemolysed); 
part (4) addition of 0 .5 ml isotonic saline, mixed by inversion
separation of plasma (non-haemolysed).
Blood samples from male laboratory staff were also collected 
into heparin and treated as in (3) and (k ) above.
All separated plasma specimens were immediately stored at -20°C 
until assay. PAPP-A and SP^ concentrations were assessed by 
enzyme-linked immunoassay described earlier and hPL by RIA.
batch for each dnalyte. Comparison of results was made by use
of the paired t test*
3*7*9 Assay Characteristics
i The standard pool of pregnancy serum prepared in this
laboratory was calibrated against International Ref­
erence material 78/610 reconstituted according to the 
schedule supplied. Dilutions of the reconstituted 
material were made in PBS/citrate to give a range of 
standards from 0 - 2*0 IU/L.
ii Precision Studies - Within plate precision was calculated
for three QC pools prepared by diluting a third trimester
pool of pregnancy serum in chicken serum. Past exper­
ience in this laboratory has shown that chicken serum 
provides a suitable protein matrix without interfering 
factors that may be present in human serum.
Precision was calculated for each pool by running 10 
duplicates of each pool on one microtitre plate.
Overall precision was estimated for three QC pools over 
43 batches of PAPP-A analyses on separate microtitre 
plates.
iii Recovery Studies - Dilutions of the standard pool were 
made in chicken serum to give concentrations of 9 *0 ,
22.3, ^5 and 90 IU/L. Aliquots of a male serum pool 
were spiked with the above material and recoveries 
estimated. The male pool used showed no evidence of 
containing PAPP-A.
iv Limit of Detection - The sensitivity was assessed by 
running 20 duplicates of OAU/L standards (blanks) on
■ •  kS ■
uiiv luxi/i c yjLd.l.c • uciivDX uxvj. was cieimeQ as
that concentration in an undiluted specimen which 
correspond to an OD of the zero standard in the stand­
ard curve + 2 standard deviations (SD) where:
SD J D2 
t* 2N — 1
D = Difference m  duplicate 
blanks
N = Number of duplicates
v Specificity of Antiserum - Possible cross reactions with
three other placental proteins were investigated at
comcentrations which may be present in pregnancy. These
proteins were human placental lactogen (10 MU/L), human 
chorionic gonadotrophin (44,000 IU/L) and pregnancy 
< specific glycoprotein (705 mg/l) prepared as follows.
7*3 P-B iodination grade hPL (obtained from NIBSC) was 
dissolved in 7*2 ml of diluting solution and used neat 
in cross reaction studies. The hPL concentration was 
thus 10 times that routinely encountered in the PAPP-A 
assay using diluted serum.
1 vial of hCG (Calbiochem) was dissolved in 0.5 ml 
of diluting fluid and used neat in these studies.
SP^ extracted from placentae was diluted 1/100 in 
diluting solution to give a concentration of 7050 jig/ 1  ■ 
This is 20 times greater than that routinely encountered 
in the PAPP-A assay after dilution of the test serum.
3*7*10 PAPP-A Levels in Non Pregnant Subjects
PAPP-A levels were measured in serum from laboratory staff
(29 males and 31 non pregnant females)•
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Fig 3 xviii Time course of PAPP-A with immobilized 
anti PAPP-A at 3 concentrations of antigen
0 3
02
0 1
80 90 100 110 120 130 140 150
time (mins)
Fig 3 xix Time course of antibody-peroxidase with 
bound PAPP-A at 3 antigen concentrations
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Fig 3 xx Time course of chromogen reaction for 
PAPP-A assay at 4 concentrations of antigen*
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Fig 3 xxii The effect of varying antibody-enzyme
concentration on the standard curve for PAPP-A assay.-
Antibody enzyme was diluted (o o) 1/20, (e a) 1/30,
or (©— ®) 1/30 in PBS containing 25$ chicken serum and 
—210 mole/l citrate.
Figs 3 xviii - xx show the effect of increasing contact time 
of antigen with antibody, antibody enzyme with antigen and 
chromogen with antibody enzyme respectively. Over the time 
course considered, equilibrium was not achieved at any stage 
of the assay.
Adequate assay sensitivity was achieved by allowing contact of 
antigen with antibody for 120 minutes and antibody enzyme with 
antigen for 120 minutes. With these parameters set, a suitable 
colour development time was found to be minutes, thus allowing 
the assay to be completed within the working day.
Fig 3 xxi shows the effect of varying antibody dilutions used 
to coat the microtitre plates. The best sensitivity was achieved 
using an antibody dilution of 1/1250.
The influence of antibody-enzyme dilutions upon final colour 
development is shown in Fig 3 xxii. A 1/20 dilution was found 
necessary to achieve adequate sensitivity within the time courses 
previously set.
Fig 3 xxiii shows the curves obtained for standards prepared from 
the laboratory serum standard pool and International Reference 
Preparation 78/610. Parallelism was exhibited from 1 - 20 AU/L 
this being the range routinely used for analysis. It is thus 
valid to assign values to the laboratory standard pool based 
on IRP 78/610. From these curves, a regression line was plotted - 
IRP 78/610 has an assigned value of 100 IU/L (Bohn et al 1980b ) 
and based on this value, the undiluted laboratory pool is equiva­
lent to 90 IU/L (Fig 3 xxi v) .
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Fig 3 xxiii Standardisation of laboratory standard 
for PAPP-A fa-:— ▼ ) against International Reference 
Preparation 78/610 (O— O) .
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Table 3 X
Precision of PAPP-A Assay
A) Within batch
I (IU/L) II (IU/L) III (IU/L)
Mean 1 3 . 2 1 6 . 7 35-8
SD •1.19 1.19 ■1.^9
CY% 9 7-1 V . 2
n 1 0 1 0 1 0
Betv/een batch (overall)
I (IU/L) II (IU/L) III (IU/L)
Mean .2 2 . 1 2 9 . 6 ■ 70.5
SD 2.30 • 2 . 6 2 7 . 6 2
CY% 1 0 . 2 8.9 1 0 . .8
n 38 ' 45 •
xaoxe j? a x
PAPP-A concentrations (in terms of IRP 78/610)
Fresh Incubated
plasma plasma Haemolysed Non-haemolysed
Mean concentration (IU/L) >2.3 48.5 49.6 33.0
Standard deviation 31.3 30.5 33.5 24.2
Number of samples 13 13 31 31
Paired t
> > 0 .0 5
= 2.03 Paired t = 
p C O .01
4.3
Table 3 XII
hPL concentrations (in terms of IRP 73/545^
.
Fresh
plasma
Incubated
plasma Haemolysed Non-haemolysed
Mean concentration (mU/1) 7.6 ; 7.8 4.21 4.15
Standard deviation 2.1 2.1 2.7 2.5
Number of samples 13 13 30 30
; Paired t
p > o.i :
= 1.71 Paired t = 
p> 0.1
0.76
Table 3 XIII
SP^ concentrations (in terms of Behringwerke SP^ standard)
• ~\
Fresh 
. plasma
Incubated
plasma Haemolysed Non-haemolysed
Mean concentration (mg/l) 454 423 144 140
Standard deviation 303 ' 262 116 109
Number of samples 13 13 28 28
Paired t 
0.03'
= 1 .8 Paired t =
p’) 0.1
1.1
Table 3 XIV
Absorbances obtained in ELISA for PAPP-A content of 
male plasma
Haemolysed Non-haemolysed
Mean absorbance 0.144 0.078
Standard deviation 3 8 . 6 8.9
Number of samples 12 12
paired t = 3*6; p^O.01
No evidence of cross reaction of the antiserum with the three 
other pregnancy proteins tested was observed, all the protein 
solutions having ODs less than the zero PAPP-A standard.
From Fig 3 xxv it can be seen that recovery varied between 120$ 
and 102$. Over the range 200 to 1000 AU/L of undiluted serum, 
recovery did not vary significantly from 100$.
The assay sensitivity was shown to be 7-6 IU/L in an undiluted 
specimen 0.076 IU/L per well after 1/100 dilution of test mat­
erial.
Comparison of assay sensitivity is difficult until a universally 
acceptable reference preparation is available. Thus Sinosich 
reported an assay sensitivity of 2 .9 pg/ 1  (of pure protein)
(1982) Bischof reported 32.5 ng/ml (1981 a), or by Laurell rocket 
technique 10 u/ml (1979b) • It is not possible at present to 
relate our sensitivity in terms of IRP 78/610 to the above 
findings•
In a further immuno«-enzymatic assay (Bersinger 1983) an equiva­
lent sensitivity was however achieved.
Table 3 X shows that the assay precision is satisfactory over 
the range of concentrations considered.
Results obtained in the haemolysis studies are shown in Tables 
3 XI - 3 XIV. Only in the case of PAPP-A was a significant 
difference in concentration between haemolysed and non haemolysed 
specimens observed (t = A . 3 pCO.001).
A slight increase in PAPP-A concentration in the incubated 
specimens was observed but this difference was not significant 
(t - 2.03 p<0.05).
Table 3 XIV shows the effect of haemolysis on the male blood 
specimens. Since the concentrations of PAPP-A found in the
5 1
it was necessary to compare absorbances obtained in ELISA rather 
than concentrations. The absorbances with haemolysed male 
plasma were significantly greater than for unhaemolysed speci- 
mens (t = 3*6; P < 0 ;P1).
Toop and Klopper (19^3) and Sutcliffe (19S2) have previously 
alluded to the conditions under which specimens for pregnancy 
associated proteins are collected. The apparent PAPP-A con­
centration in deliberately haemolysed specimens was signifi­
cantly higher than in non haemolysed specimens.
Since the unhaemolysed male specimens showed no evidence of 
containing PAPP-A, the apparent increase in PAPP-A concen­
tration is probably due to a red cell component binding the 
PAPP-A antibody non-specifically•
It appears for the proteins under consideration here, that this 
effect is specific to PAPP-A. It is unlikely that this finding 
is due to the method of assay (ELISA), since no significant 
difference could be shown for SP^ concentrations in the same 
haemolysed and non-haemolysed pregnancy specimen pairs using 
a similar ELISA technique.
Similarly, no difference was observed for hPL using radioimmuno­
assay. The suggestion that anti-PAPP-A binds a component 
present in red blood cells would account both for the small 
increase in concentration found in plasma unseparated for 2*f h 
and the considerable elevation in concentration upon haemolysis.
Of the normal sera from laboratory staff (male and non pregnant 
female) , 28% of -the male sera and 32% of female sera showed 
PAPP-A concentrations above the limit of detection. This is
5 2
perhaps not surprising with the discovery of PAPP-A production 
by the endometrium (Bischof et al 1982a) and the PAPP-A content 
of seminal plasma (Bischof et al 1983)•
Previously published assays for this protein have been either 
radioimmunoassays  ^ or Laurell "rocket” techniques V 
measurement of PAPP-A by ELISA allows results to be obtained 
within one working day which is of advantage in the clinical 
context envisaged.
The advantage of this assay may lie in possible improvement in 
sensitivity by prolonging incubation times* The assay may 
then find use in the investigation of PAPP-A production in 
neoplasia and in early pregnancy.
3*8 Carcino Placental Alkaline Phosphatase (CPAP)
3*8.1 Introduction
This enzyme was measured by an immunoenzymatic assay developed 
in this department (Mabon et al 198*0 •
Principle - CPAP is specifically extracted from serum using an 
immobilized antibody raised against placental alkaline phospha­
tase. The antibody bound CPAP is then detected using intrinsic 
hydrolytic activity to release the yellow chromophore p-nitro- 
phenol from p-nitrophenyl phosphate.
3.8.2 Alkaline Phosphatase Preparations and Antisera
Placental alkaline phosphatase was obtained commercially (Miles . 
Laboratories). This preparation was assayed at 37°C in accord­
ance with the recommendations of the Committee on Enzymes of 
the Scandinavian Society for* Clinical Chemistry (197*0 and 
used to standardize the assay. Bone, liver and intestinal 
preparations were made using a butanol extraction procedure 
(Pledger et all982).
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Antiserum to CPAP - New Zealand rabbits were injected with 
500 jig of placental alkaline phosphatase (Miles Laboratories) 
in Freund’s Complete Adjuvant and boosted at monthly intervals 
with 20 jig. Animals were bled about 2 weeks after booster 
dose.
3*8*3 Method of Assay
Antiserum was diluted 1 in 1000 in carbonate-bicarbonate buffer 
and 200 jil dispensed into each of the wells of a microtitre 
plate (Nunc Certified Grade I). After refrigeration over­
night at *f°C the antiserum was removed and the wells washed 
with TBS. Standards and test sera were diluted, where 
necessary, to lie within the range 0 to 8 u/ 1  and incubated 
at room temperature (18-20°C) overnight in covered microtitre 
plates. The volume of standards and of serum used in each 
was 200 p i and estimations were performed in triplicate. 
Following incubation the sera were removed, the wells washed 
and 200 pi of chromogen dispensed into each well.
One hour was allowed for colour development at room temperature 
after which the absorbance of the chromophore at A05 nm was 
measured using a Titertek Multiskan plate reader interfaced 
to a Commodore PET *f0l6 micro-computer.
3*8.*f Investigation of factors affecting the assay
Dilution of antiserum - A range of dilutions ranging from 1 in 
10 to 1 in 100 000 was used to coat the wells of the microtitre 
plates. Pooled sera from pregnant women was used as a con­
venient source of antigen and the same volume was added to each 
well and assayed according to the procedure described above.
Specificity of antiserum - Bone, liver and intestinal alkaline 
phosphatases were diluted in TBS containing albumin and assayed.
5**
Time of reaction - Pooled pregnancy sera diluted to three dif- 
ferent activities was incubated with immobilised antibody for 
times ranging from two to 2k h. In each case colour develop­
ment was allowed for 6 0  min.
Time of colour reaction - Standard sera were processed as usual 
but extra measurements of the optical density of the chromophore 
were made within and beyond the normal time allowed for colour 
development.
Concentration of albumin in the diluent - T h e  concentration of 
albumin necessary to prevent non-specific adsorption onto the 
wells of the microtitre plate was determined by studying cali- 
' bration curves from assays using TBS containing 10, 50 1 70 
and 100 g/1 human albumin respectively.
Detection limit - Forty-two replicate blank determinations were 
carried out and the precision of the blank determined.
Precision - Replicate measurements were made at two CPAP levels 
of activity and both within-batch and overall precision calcul­
ated.
3 .8 . 5  Comparison with a chemical inhibition method
Because the primary concern was to develop a sensitive assay 
to be used in the investigation of cancer, direct comparisons 
•with the less sensitive* chemical inhibition method using samples 
from patients with cancer was not possible. Instead, 30 sera 
from pregnant women were assayed for placental alkaline phos­
phatase after suitable dilution, by the immunoenzymatic
assay described above.
Normal Range - Sera from 27 male and 29 female apparently 
healthy laboratory workers were obtained and assayed for CPAP.
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Table 3 XV
Cross reactivity of three alkaline phosphatases with anti-CPAP
Measured activity in 
immunoenzymatic assay 
Alkaline phosphatase Activity (u/l)____ system (u/l)
Bone 550 1.6
Liver 630 0.6
Gut 550 3.3
3.8.6 Results and discussion
Dilution of antiserum - Maximum colour development occurred at 
a dilution of 1 in 1000 and this dilution was therefore used 
routinely, being similar to that used in other similar systems 
(Macdonald et al 1979* Pledger et al 1982).
Specificity of antiserum - The commercial preparation of pla­
cental alkaline phosphatase was not further purified before it 
was used to immunize the rabbits as antibodies raised to contam­
inants would not bind alkaline phosphatase, which is eventually 
detected by its intrinsic enzyme activity; thus only CPAP 
should be detected unless all isoenzymes have a common structure 
recognized by the antiserum. In their method for CPAP^Haije 
et al first heated their specimens to 65°C for 10 min to destroy 
any intestinal alkaline phosphatase which cross-reacted with 
their antiserum. We chose not to pre-heat samples because 
the extent of the cross-reactivity which we found (Table 3 XV) 
was insufficient to cause interference within the range of alk­
aline phosphatase activation encountered in normal subjects 
or at significantly elevated activities.
Concentration of albumin in the diluent - Increasing the albumin 
added to TBS from 10 to 50 g/1 reduced non-specific adsorption 
slightly but between 50 and 100 g/ 1  no additional reduction 
occurred. Routinely 75 g/1 was used.
Detection limit - The detection limit was calculated as twice 
the standard deviation of the blank value absorbance, which was 
referred to the standard curve and a detection limit of 0 .1 2 u/l 
found* This is quite adequate representing about 5% of the 
normal range (as defined below)•
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Table 3 XVI
Standard Coefficient of 
 ______ _______ Number Mean deviation variation (%)
Within-batch precision Sample 1 11 1.02 0.07 6 .6
Sample 2 10 3.06 0.17 5-6
Overall precision Sample 1 21 1.05 0.16 15.5
during one month Sample 2 22 3*59 0 .5 0 1^.8
100
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<D 40
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Fig 3 xxvi Cumulative Frequency Curve of
CPAP concentrations in a normal population
coefficient of variation of 10# obtained by H a i j e  e t  al (1979)i 
at the upper limit of their normal range. (NB These workers also 
used triplicate measurements)•
Comparison with a chemical inhibition method - Mean activity 
of the 30 samples was 102 u/l with a standard deviation of 
66 u/l, when measured by a chemical inhibition method. After 
allowance for dilution the mean activity by immunoenzymatic 
assay was 99 u/l with a standard deviation of 60 u/l. The 
paired t test revealed no significant difference between the 
results obtained by the two methods.
Normal range - A positively skewed distribition was obtained 
for male and female subjects. As there was no apparent sex 
difference the results were pooled, a cummulative frequency 
curve constructed and a median value of 0 .5 u/l and a 97*5th 
centile value of 2.0 u/l obtained (Fig 3 xxvi)«Haije et al 
(1979) also failed to detect any significant sex difference 
but the upper limit of their normal range was lower than that 
which we obtained. Comparisons with results obtained by other 
workers (Kellen et al 1976, Millan and Stigbrand 1981) are dif­
ficult because of extensive methodological differences.
The assay provides a sensitive specific method for the estima­
tion of carcino-placental alkaline phosphatase in patients with 
neoplastic disease.
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CHAPTER if
THE ASSESSMENT OF CRITICAL FACTORS WHICH INFLUENCE THE 
PERFORMANCE OF ELISA
During the last two decades many of the physico-chemical factors 
which influence radio-immunoassay have been thoroughly invest­
igated and the design of new radioimmunoassays is based on 
established scientific principles. Radioimmunoassay suffers 
several disadvantages inherent in the use of radioisotopes - 
short shelf life, health hazard, etc. These disadvantages do 
not apply to enzyme labels and for this reason the new methods 
employed in this thesis were based on enzyme immunoassay.
Several versions of ELISA exist, but the one used here, which 
is best suited to the assay of proteins and peptides is a two 
site assay and is not strictly comparable with RIA. Several 
factors were found which influenced the performance of ELISA 
in a manner not encountered in RIA.
4.2 Characterization of Microtitre Plates used in ELISA
4.2.1 Investigation of Optical Uniformity of Microtitre Plates
Three types of microtitre plate were investigated:-
a) Cooke Flexible Microtitre Plates (M29A) obtained from 
Dynatech Laboratories, Billingshurst, Sussex.
b) Immulon Micro Elisa Plates (M129A) obtained from Dynatech 
Laboratories, Billingshurst, Sussex.
c) Nunc Micro Elisa Plates (Grade I certified) obtained from 
Gibco Europe, Paisley, Scotland.
Absorbance values for the empty wells were read using a Multi- 
skan Plate Reader (Flow Laboratories, Irvine, Scotland) and 
normal distribution statistics calculated.
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Table k I
The Optical Uniformity of 3 Types of Microtitre Plates for use in ELISA
Nunc Immuno 
I
Cooke Flexible 
M29A
Dynatech 
Microelisa M129A
Mean OD .0053 .0076 .0023
Std Deviation .0015 .00^3 .0022
n 96 96 96
99# Confidence + .00^5 + .0129 Hh .0066
Limits (3SD)
Table 4 II
Ad Readings for Standard Curves and Backgrounds for Three Different Types of 
Microtitre Plate.
(Readings corrected for 0 standard)
SP. Concentration Nunc Certificated Cooke Flexible Immulon Rigid
(ng/l) I M29A M129A
31.25 0.067 0.009 0 .06
62.5 0.269 0.151 0.039
125 0.466 0.277 0.060
250 0.773 0.567 0.256
500 1.043 0.911 0.445
1000 1.252 0.918 0.507
Replicate blanks 0.118 0.150 0.159
.102 .168 .135
.113 .151 .138
.103 .134 .150
.088 .156- .139
.098 .152 .140
.101 .1 5 6 . .143
.103 .157 .138
;113 .152 .154
.112 .149 .151
.119 .158 .151
.097 .150 .143
.099 .201 .122
.104 .142 .142
.101 .134 .129
. 104 .163 .141
.115 .158 .135
.109 .160 .134
.105 .153 .141
• 093 .160 .142
- .174 .129
- .179 .193
— .172
Mean Background 0.105 0.158 0.143
n 20 23 22
Std Deviation 0.008 0.015 0.014
CV % 7-9 9.5 9.8
+>
<H
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H
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Table k III
SP^ Assay Precision on Various Microtitre Plates
a) Low Pool
Nunc Certified 
I
M129A Immulon 
Rigid
M29A PVC 
Flexible
Mean Concentration 113.2 130.5 109.3
Standard Deviation 9.00 13.5 21.8
n 11 12 12
CV % 8 .0 10.V 20.0
b) High Pool
Nunc Certified 
I
M129A Immulon 
Rigid
M29A PVC 
Flexible
Mean Concentration 210.7 207.7 19^.5
Standard Deviation . 21.8 18.2 b5
n <\k 1*f 13
CV % 'lO.b 8.8 23.0
4.2.2 Investigation of Assay Sensitivity and Non Specific
Binding using Various Microtitre Plates
Microtitre plates (as detailed in 4.2.1) were coated overnight 
at 4°C with antibody diluted 1/1200 in coating buffer (Appendix I)• 
Before use the plates were emptied and washed three times with 
wash buffer. 100 pi of standard SP^ solutions and a series 
of zero standards were pipetted into the wells and incubated 
for 30 minutes at the end of which, the well contents were asp­
irated and a further washing cycle performed. Antibody enzyme 
conjugate (100 pi) diluted 1/1000 in PBS containing 25# chicken 
serum and 0 .1$ citrate was then added to each well and incubated 
for 30 minutes followed by a further aspiration/washing cycle.
100 pi of chromogen was then added to each well and after colour 
development for 30 minutes, the reaction was terminated by the 
addition of 100 pi sulphuric acid. The developed colours were 
read on an Abbott ABA 100 bichromatic analyzer and the Absorbance 
Difference (Ad) obtained.
Assay precision was assessed by assaying two pools of pregnancy 
serum in replicate on each type of plate.
4.2.3 Results and Discussion
Figs 4 i - iii show the optical densities of empty wells for 
the three types of plate considered. The Nunc plates showed least 
variation and the 99^ confidence limits were within the range quoted 
by the manufacturer .(Table 4 I). Table 4 II and Figure 4 iv show 
the standard curves and background readings obtained for each 
type of plate. As the variances between the backgrounds for 
each plate were not equal, comparison was made by means of the 
Wilcoxon U statistic. Nunc plates gave significantly lower 
backgrounds than either Immulon plates or Flexible plates 
(p^0.01). Furthermore the standard curve obtained with the
  ^ _____________   J -  W  M  W  V .1.  V S« v v c i o  n v ^ l U C V C U *
Precision of the assays is shown in Table 4 III • Nunc plates 
and Immulon Plates gave comparable precision whilst precision 
using the Flexible plates was decreased.
These initial studies suggest that either Nunc or Dynatech 
Immulon Microtitre Plates would provide a suitable basis for 
ELISA.//
4.3 Antibody Binding Characteristics of Plastic Microtitre 
Plates, Polystyrene Beads and Nylon Beads
4.3.1 Method
Anti-TSH was coupled to cellulose, the unbound antibodies eluted
and the antibody complex iodinated using a Chloramine T method.
After iodination, the complex was washed extensively with 10~^ mol/1
HC1, pH 3*0. Iodinated anti TSH was eluted from the column using 
_2
10 mol/l HC1 pH 2.0, followed by 0.1 mol/l sodium bicarbonate pH 10. 
The pH 2’and pH 10 fractions were pooled and-further purified on 
Sepharose 6B, collecting the-iodinated antiserum peak.
Iodinated anti-TSH was diluted 1/10 with coating buffer.
Individual wells cut from the three types of microtitre 
plates listed in 4.2.1 were coated using 100 pi of diluted 
antibody overnight, at +4°C.
Polystyrene (6.4, 4.8, 3*2 mm diameter) and nylon beads (6.4,
3 -2 mm diameter) were coated by immersion in the diluted anti­
body overnight at +4°C. The following day the antibody solu­
tion was aspirated from the wells and beads and both were 
washed 3 times with wash-buffer, the wells dried by shaking 
and the beads by blotting on absorbent paper.
Individual wells and beads were then counted on a Y counter 
for 75 seconds.
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Table k IV
The Binding of Iodinated Anti~TSH to Polystyrene Beads
Bead Diameter 3 -2 mm ^ .8 mm 6 .k  mm
Number of Beads 12 11 12
Mean % binding 0 .88 1.36 2.36
Std Deviation 0.07 ■0'.2k "0,33
Coefft. of Variation 8.28 17.75 13.9^
Following additional 
^8 hr incubation 
Mean % binding 
= 2 .6
Table k V
The Binding of Iodinated Anti-TSH to Nylon Beads
Bead Diameter 3-2 mm 6 .if mm
Mean % Binding 0.^3 1.01
SD 0.09 0.28
CV 21# 27#
n ' ' ' 12 12
Table b VI
The Binding of Iodinated Anti TSH to Microtitre Plates
Nunc Intmuno I Dynatech Microelisa Cooke Flexible
Humber of Y/ells 12 12 12
Mean % binding 17-2. 19.^ 23.2
Variance *2.7 15.2 0.3
Standard Deviation 1.6 3.9 0.5
Standard Error 0.5 1.1 0.2
Coefft of Variation 9.6 20.1 2.3
antibody once more and incubated for a further 48 hours, fol­
lowed by washing and counting as before.
The total counts for the microtitre plates experiment were 
assessed by counting duplicate 100 jil aliquots of the diluted 
antiserum and taking the mean value•
For the beads, total counts were assessed by counting duplicate 
100 pi aliquots of the diluted antiserum and multiplying the 
counts by a factor to allow for the total volume in which the 
beads were suspended.
4.3*2 Results ,
Tables 4 IV - .4 VI show the mean % labelled antibody bound to 
the various solid phases. Comparison of the differences were 
made by the t test. The mean binding on Dynatech Micro Elisa 
plates was significantly lower than binding to the Cooke Flex­
ible Plates (t = 3*5 p^O.01). Binding to Nunc microtitre 
plates was not significantly lower than binding to Dynatech 
plates ( t = 2.1 p> 0.05) • There was a significantly lower 
binding to Nunc plates compared with the Cooke Flexible plates 
(t = 11.4 p < 0 .01).
4.3*3 Discussion
For all 3 microtitre plates investigated, the capacity to bind 
antibody is far in excess of the capacity of the polystyrene 
or nylon beads.
' -
The low binding observed for nylon beads is perhaps not surpri­
sing in view of the inert nature of nylon. Nonetheless, nylon 
rings have been used in ELISA systems without prior chemical 
activation (Lehtonen and Viljanen 1980). Hendry however (I98O) 
found it necessary to carry out chemical activation of nylon
higher amount of protein could be bound using this technique 
and the binding was stable, a further stage of reagent pre­
paration is encountered.
The improved binding capacity of polystyrene microtitre plates
compared with polystyrene beads was unexpected. The surface
2areas of a polished 4.8 mm bead (72 mm ) and a microtitre 
plate well (60 mm ) are comparable. However the beads used 
were matt finished and thus the practical surface area is far 
in excess of the calculated area.
The answer may lie in different structural forms of polystyrene 
used in manufacture. It has been pointed out (Ratcliffe 
1974) that there is considerable variation In suitability of 
polystyrene tubes from different sources and indeed between 
different batches of tubes from the same source.
A further possibility is that the leakage of bound antibody 
from the plates and beads during washing varies.. Proteins 
are bound to plastic polymer surfaces by weak physical forces 
(van Oss and Singer 1966) and the stability of this binding 
is uncertain. Thus the amount of antibody apparently bound 
might also vary.
It was noted in 4.2.2 that there was a gradation 1 of NSB (back­
ground) values according to the type of plate used. It is 
interesting that those plates exhibiting the highest NSB (Cooke PVC 
plates) are those exhibiting the maximal binding capacity. Con­
versely plates with lower binding capacity (Nune Immuno I) had 
the lowest NSB-and'also showed the steepest standard curve.
Extending this concept further, the most sensitive assays might 
be expected with polystyrene beads. However other problems
further in 4.4.2.
4.4 ELISA using Polystyrene Beads as a Solid Phase
4.4.1 Materials and Method
Polystyrene beads as detailed in 4.3-1* Other ELISA reagents 
as detailed in Appendix I.
Method - Antiserum to SP^ was diluted 1/1200 in coating buffer 
and the beads (3*2, 4.8, 6.4 mm diameter) coated overnight 
at +4°C by immersion in the diluted antiserum.
Before use, the beads were removed from the coating mixture, 
blotted on absorbent paper and washed three times in wash 
buffer with gentle stirring. The beads were then dried and 
placed into individual test tubes.
300 pi of standard SP^ solutions were added in triplicate at 
timed intervals, the tubes covered and incubated for 30 minutes 
with gentle agitation at room temperature. After incubation, 
the standard solutions were aspirated, and each bead washed 
3 times in its tube with wash buffer, using a vortex mixer 
to ensure adequate washing.
After drying the bead, 300 pi of antibody enzyme diluted 1/1000 
in PBS/25^ chicken serum were added to each tube and incubated 
for 30 minutes with gentle agitation at room temperature.
The tube contents were then aspirated and the beads washed 
as before. 300 pi of chromogen were then added to each tube 
and colour allowed to develop for 30 minutes after which the 
reaction was stopped by addition of 300 pi of 4 mol/l sulphuric 
'.acid.-
A parallel assay was performed using Nunc Immuno Plates 
Grade I.
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xne colours were read on an Abbott ABA 100 bichromatic analyzer 
and results converted to absorbance for a 1 cm path length.
After correction for blanks, a plot of mean absorbance value 
against SP^ concentration was made.
k .b .2  Results and Discussion
The standard curves obtained are shown in Fig 4 v . All assays 
yielded increasing colour with increasing antigen concentration. 
The assay carried out on the microtitre plate yielded a sigmoid 
curve whilst those assays utilizing the beads gave parabolic 
curves. The curves obtained in ELISA assays are discussed
further in Chapter 5*
Although it would be possible to use polystyrene beads as a solid 
phase, it appears that the microtitre plates provide a more sen­
sitive assay as evidenced by the steeper standard curve. This 
might be expected on theoretical grounds as discussed in *t.3*3 *
Furthermore considerable difficulty was experienced in handling 
the beads. This, together with the less precise coating of 
antibody on the beads ( k .3-2) may account for the greater stand­
ard errors observed for this solid phase. ELISA based on beads 
would require specifically designed handling techniques.
By contrast, microtitre plates provide a convenient format for 
multiple tests. The plates are easily handled and plate readers 
are available which obviate the problem of reading individual 
tests.
Two commercial systems utilizing beads are now available - the 
Quantum System (Abbott Diagnostics, Queensborough, Kent) and a 
combined assay module/spectrophotometer (Kone Instruments, 
Stockport, Cheshire). It seems likely however that "in house" 
assays will continue to be based on the microtitre plate format.
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Table k VII
Antibody Binding to Nunc Immuno Plates I for a 
Variety of Antisera
Anti
SP1
Anti
hCG
Anti
PAPP-A
Anti
TSH
Mean % 
Binding 55-2 36. 8 56.8 17.2
SD 2.7 2 2.66 J>.Ok 1.77
CV % ^•9 ^.7 10.3
. ..
of Antibodies to 'Microtitre Plates
>.5.1 Method
Anti SP^, anti PAPP-A and anti-hCG were desalted on G25 Sephadex 
column and iodinated by a Chloramine T technique. Separation 
of the iodinated immunoglobulins from free iodine was achieved 
on a Sephadex G25 column (Fig k vi)• 10 drop fractions were
collected and counted in a Y  counter to identify the iodinated 
protein peak.
Antiserum to TSH was bound to cellulose and iodinated as » 
previously described.
After iodination, a 1/10 dilution of each iodinated antiserum 
was made in carbonate/bicarbonate buffer pH 9*6. Twelve wells 
cut from the microtitre plate (Nunc Grade I) were used for each 
antibody investigated. 100 pi of the diluted antisera were 
pipetted into each well and incubated overnight at *f°C. The 
following day the well contents were aspirated, the wells washed 
3 times with wash buffer and dried. The iodinated antibody 
bound to the wells was counted in a Y counter and compared with 
the counts given by 100 pi of the diluted antisera used to coat 
the plate.
*f.5»2 Results and Discussion
The # bindings achieved for each antiserum are shown in Table 
VII. There was no significant difference in binding between 
anti-SP^, anti-hCG or anti-PAPP-A (p^ 0.05)• Similarly there 
was no difference in binding between anti hCG and anti PAPP-A. 
The ability of various proteins to bind to polystyrene solid 
phases remains open to question. Lee et al (197A ) showed that 
adsorption was dependent on the protein and polymer used.
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suggested that the binding rate was. not protein dependent and 
that all proteins bound equally well. More recently Cantarero 
et al (1980) have adduced further evidence in favour of Lee's 
findings.
The data presented here may be interpreted as evidence that 
binding is dependent on the particular antibody only when there 
is a difference in purity. The commercial antisera were iodin­
ated without prior purification whereas the anti-TSH was init­
ially bound to cellulose before iodination.
Protein assay on the diluted antisera used to coat the wells 
showed that all wells received the same order of magnitude of 
protein (250-500 pg). Cantarero discussed a ’’region of indep­
endence” where the proportion of protein bound was independent 
of the amount added (1980). It is not possible to challenge 
these findings on the basis of the data obtained here.
Further, it is shown that the optimal antibody dilution for 
the ELISA systems seems dependent on the solid phase rather ' 
than the antibody. This is further evidence in favour of 
non-specific antibody binding ie all antibodies bind equally 
well when they are of equivalent immunopurity.
*f.6 Investigation of Loss of Antibody from Wells of Microtitre 
Plates during Enzyme Immunosorbent Assay
Jf.6.1 Method of Assessing Optimal Dilution for Iodinated 
Antibody
In order to optimize the assay system to approach as nearly as 
possible the antibody dilution used in routine assay, a series 
of ELISA standard curves were run with varying iodinated anti­
body dilutions.
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Fig 4 viii Flow Chart for Loss of Antibody Experiment.
Table 4 VIII
% Antibody loss from the wells of microtitre plates during ELISA
a) Antigen diluted in PBS citrate
Antigen 
Cone 
hr/ 1
Assay Stage
Overall 
% Loss
1 ■ 2 3 k 5 6
0 5-9 1 .2 1.3 1.6 2.9 1.1 14.0
■'1:31-25 6.4 0.7 0 .6 2 .5 2.1 1-3 14.6
62.5 5-4 2.0 1 .0 1-9 2.9 1 .2 14.4
125 ( 4.8 1 .8 0 .8 2.9 0.7 2 .6 13-6
250 5-4 2 .0 1 .0 1.9 2.9 1 .0 14.2
500 5-4 1.4 0.7 2.5 2.3 2.5 14.8
1000 6 .2 1-6 1-3 2.9 2 .0 0.9 14.9
Mean loss (%) 5-6 1-5 1.0 2.3 2.3 1.5 14.4
Table 4 IX
% Antibody loss from the wells of microtitre plates during ELISA
b) Antigen diluted in raw chicken serum
Assay Stage
Antigen
Cone
mk/i
1 2 3 4 5 6 Overall 
% Loss
■ o j 5-7 3.8 4.4 1.4 4.1 0.9 20.3
31.25 5-8 4.4 5.4 1.4 2.7 1.4 21.1
" 62.5 6.2 3 .5 2.9 3-5 1.6 2.7 20.4
125 7.0 4.4 2.3 2.2 2.9 0.7 19.5
250 6.2 4.9 2.4 1.5 1.8 2.9 19.7
500 4.9 4.1 2.5 2.8 2.8 1.1 18.3
1000 5-2 4.4 3.5 1.5 2.8 1.1 18 .2
Mean loss {%) 5.7 4.2 3.3 2.0 2-7 1.5 19.6
M e a  n °/o 
antibody bound
100
90
8 0
70
60
50
Assay Stage
Fig k ix Loss of bound iodinated antibody at 
various stages of ELISA. Antigen was prepared
in ( &------- ) PBS/citrate or ( ▼--- v ) raw
chicken serum.
Iodinated anti-SP^ was diluted in coating buffer pH 9*6 to 
give a range of dilutions 1/2 to 1/10. Nunc microtitre 
plate wells were coated with 100 jil of these dilutions over­
night at *f°C. Standards were then assayed following the 
routine assay protocol and graphs of absorbance against log 
concentration prepared-.
.6.2 Results
The standard curves obtained are shown in Figure vii.
Dilutions of greater than 1/Vresulted in absorbances too low 
to be measured reliably. A dilution Of 1/2 was selected for 
further experiments.
*f.6.3 Method of Assessing Loss of Antibody
Nunc microtitre plates (Grade I) were used. Other ELISA 
reagents as detailed in Appendix I.
A range of SP^ standards were prepared in diluting solution 
or chicken serum.
Microtitre plate wells (Nunc Grade I) were incubated with 100-jil 
of a 1/2 dilution of anti-SP^ in coating buffer overnight at 
4°C. The remaining steps of the experiment are shown in Fig 
k viii.
4 * 6 . Results and Discussion
Tables k VIII, IX and Fig k  ix show the loss of antibody com­
pared with the initial amount bound taken as 100$, for each 
standard preparation at each stage of the assay. Antibody 
was lost at each stage of the assay, the overall loss amounting 
to 1 kmkfc for antigen diluted in a non-protein matrix and nearly 
20$ for antigen diluted in chicken serum.
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The loss of immobilized protein from the solid phase has been 
*
the subject of a number of investigations. Engvall and Perl—
mann (1 9 7 2 ) first noted a ■"hook" effect which they suggested
was due to loss of the complex from the solid phase and also
reported a total leakage of 20-30% of bound material. Sim-
125
ilarly Lehtonen and Viljanen (1 9 8 0 ) reported a loss of I 
labelled BSA from the walls of polystyrene cuvettes. Antigen 
detachment x^ as shown to occur to a considerable degree for up 
to 6 washes in normal saline containing 0.05$ Tween 20.
During a complete ELISA, this group also found a loss of J>-&% 
of the initial bound antigen during serum incubation and a 
loss of 7-10$ at the first wash stage. Total leakage over 
the assay varied between 20-29$. Similarly Hendry and Herr­
mann (1 9 7 9 ) reported a loss of viral antigen of up to 68$ 
during an ELISA.
However, Cantarero et al (1 9 8 0 ) were unable to show loss of 
complex from the solid phase, although their data did exhibit 
a ,,hook,t effect which they suggested was due to insufficient 
reagents to develop the system.
The results obtained here favour the former concept ie there 
is a loss of antibody/complex from the solid phase. No 
antigen concentration dependence was shown however. • As. the 
'plates were coated at only a single concentration of antibody, 
it was not possible to shovr the reported difference, in loss 
wi'th varying protein uptake (Lehtonen and Viljanen 1 9 8 0 ) .
The major loss of antibody occurred at the initial washing 
stage (5*6$). Thereafter, for antigen diluted in PBS/citrate, 
loss at each stage was of the order of only 1-2$, with a mean 
overall loss of
68
In contrast however, when antigen was diluted in a protein 
matrix (chicken serum) the results obtained differed. Whilst 
the initial loss during the wash stage did not differ, during 
antigen incubation a further ^.2$ antibody was lost. This 
was significantly greater than the loss occuring with PBS/cit- 
rate diluted antigen as assessed by the t test (p < 0 .001). 
Similarly during the washing cycle succeeding this stage, a 
significantly greater loss of antibody was observed than at 
the same stage with PBS/citrate diluted standards (p<0.001).
At further stages however no difference was shown for antibody 
loss between the two sets of antigens.
It appears therefore that a high protein concentration leads 
to weakening of the antibody-solid phase bond resulting in 
greater loss of antibody at this incubation stage and the fol­
lowing wash stage.
Previously, Hendry had pointed out (Hendry and Herrmann 1980) 
that to prevent non specific adsorption, it is necessary to 
add .....’’protein solutions plus a non ionic detergent, but 
that these inhibitors caused desorption of both adsorbed anti­
gen and antibody”. - The results obtained here are in agreement 
with this finding.
These findings may have important consequences. Ideally sera 
should be diluted sufficiently in a non-protein containing matrix 
to cut down this leaching. This however is at variance with 
reducing NSB. Further,for work simplification, the exclusion 
of a diluting step is advantageous.
The difficulty is to ensure that the leached antibody does not 
set up a competitive effect with the incubated antigen, which 
will lead to decreased assay sensitivity and precision. Investi­
gation of the time course of all reactions remains an important
Table 4 X ■
Loss of Anti^SP^ from the Walls of Microtitre Plates with Pregnancy Pooled Serum 
and Chicken Serum
Pregnancy Pooled Serum Raw Chicken Serum
Time
mins
Initial
Counts
Final
Counts
Mean
io remaining
Initial
Counts
Final
Counts
Mean
% remaining
10 **6576**5871
41827
40335
88.8 4388246486
39207
40786 88.5
20 4880243287
41049
39566 87.8
45798
47711
41031
41726 88.5
30v 4735546657
41229
40938 87.4
47939
46229
42220
38785 86.0 '
4o 4811848034
42425
41774 87.1
49289
47315
42093
40363 85-4
30 4982649380
41039
41319 83.1
45773
46591
41125
39030 83-8
60 47070
47703
41111
41199
86.8 4830546822
40543
40481 85-2
?° 48459
47515
40519
40774 84.7
45607
46314
39464
39842 86.2'
80 4610748169
38074
41068 83.9
45261
47378
41465
40975 8 6 .5
90 4709347603
40337
40124 83.5
47654
45648
38395
38961 83.O
100 4759845466
38873
39127 83.9
45782
47050
39119
39193
84.4
110 4617447397
38571
39041 83.0
43308
45010
34894
3798O 82 .5
120 4818246784
40232
39786 84.2
41772 34226 82.0
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*f.7 Investigation of Time Course of Reaction Between Bound
labelled Antibody and Antigen
Materials and Method
A pool of sera from women in the third trimester of pregnancy 
was prepared. All other reagents were as given in Appendix I.
Wells of Nunc Microtitre I plates were coated overnight with 
125I labelled anti-SP^. The following morning, the antibody 
solution was aspirated, the plates washed 3 times with PBS, 
dried and counted (initial counts).
Duplicate aliquots (100 pi) of either the pooled pregnancy 
serum or raw chicken serum were added to the wells and incubated
for times varying between 10 and 120 minutes. At the end of
each reaction time the well* contents were aspirated and the 
remaining labelled antibody counted (Final C ounts).A graph 
of % labelled antibody remaining against time was drawn.
b .7 .2  Results and Discussion
Table X shows the counts and % bound antibody at various
incubation times, and Fig k x represents these results graph­
ically. A paired t test was performed on the mean % antibody 
remaining. No significant difference in the remaining anti­
body was demonstrated ( t = O.Mf p> 0 .1) between the wells 
containing pregnancy serum and those containing chicken serum.
The problem of antibody loss from the solid phase in relation 
to antigen content remains open to debate. Thus Lehtonen and 
Viljanen (I980) found detachment of coated antigen to be indep­
endent of the presence of specific antibodies. This finding 
was previously observed by Zollinger et al (1976).
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gen had taken place within 15 minutes and that after 2 hours 
incubation, almost three quarters of the total leaking antigen 
was detached (1980)•
Engvall's original finding of the hook phenomenon is often 
interpreted as evidence for loss of complex from the adsorbing 
surface. It seems more probable however that this effect 
relates to protein concentration during coating of the solid 
phase, a view reinforced by Cantarero et al (1980).
From the results obtained here there seems no reason to disagree 
with the previous findings by other groups of workers. No 
difference in loss of antibody over the 2 hour incubation 
period could be observed in those wells with a high antigen 
content compared to those with no antigen. Thus the loss 
of antibody from the solid phase appears from this experiment 
to be independent of antigen concentration.
A greater loss of antibody was observed during antigen incub­
ation compared with the previous experiment. This may be 
due to different batches of plates being used. Of a total 
loss of k to- 6% occurred in the first 10 minutes of
assay. Lehtonen however found that more than 50$ of the 
total loss during antigen incubation occurred during the first 
10 minutes. It is possible that a difference in character­
istics of the polystyrene solid phase could account for this.
It is apparent however that loss of antibody does occur from 
the solid phase throughout ELISA and that ideally improved 
solid phases must be developed in order to maximise the pot­
ential of ELISA.
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Table ^ XI
The Effect of Varying Ab-E concentration on NSB
Ab-E
Diln 1/2000 1/1000 1/500 1/100
Mean OD 0.037 0 .0^8 0.057 0.133
SD 0.006 0 .006 0.007 0.008
n 11 11 11 11
Abso rbance
•15
•10
•05
I
2000 1000 500 100 
Antibody-enzyme dilution
Fig 4 xi The effect of antibody enzyme 
concentration on Non Specific Binding*
Ab-E was diluted as shown in^PBS/25%  
chicken serum .containing 10~ mol/ 1  citrate,
  ----------- .------ - J .X I>  U J L l l U U i K '  V l^ O - D ^  i n  J j - L l b A
4.8.1 Investigation of the effect of varying: antibody enzyme 
concentration
Materials were as given in Appendix I for ELISA. Four series 
of zero standards (SP^) were assayed according to the routine 
protocol for SP^ assay except that Ab-E was added at different 
dilutions to each series of zero standards. Following colour 
development, the mean and SD for the blank standards, for each 
dilution of Ab-E were estimated.
4.8.2 Investigation of the Use of Albumin and Tween-20 in
the reduction of NSB
The routine protocol for the assay of SP^ was followed (3-4.2) 
reagents as specified in Appendix I with the following excep­
tions. 0 /ig/l standards were prepared in either diluting 
solution (PBS/citrate) or in PBS containing 1$ human serum 
albumin•
Microtitre plates (Nunc Grade I) were washed with either PBS 
saline or with PBS containing 0.1 ml Tween 20/litre of buffer 
(wash buffer)•
The effect of Tween in the antibody enzyme stage of the assay 
was investigated by incorporating 5 )il Tween 20 into 50 ml 
of antibody enzyme conjugate prepared according to Appendix I.
Plates were processed according to the routine protocol incor^ 
porating the variations above as necessary.
4.8.3 Results and Discussion
Reduction in Ab-S concentration leads to decreased NSB values 
(Table 4 XI and Fig 4 xi)• There is a significant increase 
in NSB at Ab-E dilutions of 1/1000, 1/500, 1/100 compared to
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Table 4 XII  ^ <
Reduction of NSB in ELISA by use of albumin and Tween 20. Results rep­
resent the optical densities obtained.for replicate background specimens.
Optical densities for the standard curve are after blank subtraction.
Well
PBS
Wash PBS
PBS + albumin 
Wash PBS
PBS
Wash PBS/Tween
PBS + albumin 
Wash PBS/Tween
1 - : .122 .106 .120 *,107
2 .122 .130 .107 -1°3
3 .120 .108 .108 .097
4 .115 .103 .101 >104
5 .125 .102 .098 .098
6 .116 .094 .115 ; .128
7 .121 .095 .107 -121
8 .123 .112 .121 -097:
9 .136 .122 .134 <099
10 ; -172 .106 .122 ,119
11 .174 -099 .108 ,113
'12 .186 .100 Il13 .101
13 .177 .111 .119 .09 5
14 .176 .089 .120 .094
15 .190 .096 .099 .-102
16 • 155 .094 .105 4.103
17 .189 .097 .107 .092
18 .142 .099 .110 c.087
19 -137 .118' .123 ,095
20 .108 .095 .130 .102
Mean 0.145 0.104 0.113 0.103'
SD 0.029 0.011 0.010 0.010,
CV % 19-7#' 10.1# 8.8# 10.0# !
STD
Curve
SP1Jig/l
‘,31-25 0.120 0.113
62.5 0.327 0.330
125 0.473 o.46o
250 • 0.563 0.572
500 0.593 0.590
1000 0.62*+ 0.617
•d
•d
-p to
-p ua.
</}
r-<
Table k XIII
Effect of Tween 20 in antibody-enzyme reagent on reduction 
of NSB. Results are absorbance values for standard curve 
(after blank subtraction) and replicate blank specimens.
SP
Cone11 jig/1
Ab-E in
PBS/chicken serum
Ab-E in PBS/chicken 
serum + Tween 20
.25 .110 .117
62.5 .300 .307
125 .kk3 .Mt9
250 •537 .517
500 •573 .363
1000 • VJ
l
00 _A .582
0 .113 .097
0 .112 •103
0 .097 .103
0 .105 .121
0 .097 .117
0 .098 .118
0 .117 .098
0 .120 .10 V
0 .108 .106
0 .110 .110
0 .103 •097
0 .102 .105
Mean blank OD 0.107 0.107
SD 7.8 8.3
CV % 7.3 7-8
«H
+>
CD r-I
IA
o  *=
O TJ
CL.
CO
rH
dilution of 1/2000 (t = 3 3 *7 i  7 *7 and 3*^ p <0.01) • The 
reduction in blank values with increasing dilution is probably 
due to decreased non specific binding of Ab-E to the poly­
styrene. The effect of chicken serum at this stage was 
shown to be effective in reducing NSB .,(Macdonald 1979) but does 
not completely negate the effect. Thus a low concentration 
of Ab-E must be used. This however offsets gains in sensit­
ivity possible with increased Ab-E concentrations ( 3 - 5 and 
a compromise is thus necessary.
Table -k. XII and Figure xii shows the results of absorbances 
for background specimens (0 pg/1  SP^) with and without albumin 
added and also the effect of washing plates in wash buffer as 
opposed to PBS alone.
Table k XIII and Figure h xiii shows, the effect on absorbance of 
adding Tween 20 to the antibody enzyme conjugate reagent.
Incorporation of albumin into the diluent resulted in a sig­
nificant decrease of NSB compared with PBS diluent alone (t = ...■:
6.1 p<0.001). Similarly incorporation of Tween 20 into the 
wash buffer led to a reduction of NSB compared with PBS as a 
diluent (t = k .7  p< 0.001) but not when PBS-albumin was used 
as a diluent (t = 0 .2 2 p> 0 .05) •
The addition of *\% albumin to diluent caused no effect on the 
standard curve position and NSB was reduced. Similarly 
addition of Tween 20 to the antibody enzyme reagent caused 
no shift in the standard curve, but neither was there any 
reduction in non specific binding (t = .07 p 7 0 .05)•
Most authors agree that some means of reducing non specific 
binding and interference in ELISA systems is necessary.
Hendry noted"that to prevent non specific adsorption of immuno- 
reagents it is necessary to use inhibitors such as protein
solutions plus a non-ionic detergent" (Hendry and Herrmann 1980). 
The stage at which these are used and indeed whether both pro­
tein and detergents are necessary has however varied greatly. 
Engvall and Perlmann (1972) used only Tween 20 both in their 
sample diluent and conjugate reagent, as did Hevey et al (Hevey 
et al 1976) \in an assay for AFP for their serum diluent, but 
added human serum albumin and Tween to their conjugate reagent. 
Other workers however have used albumin in their sample diluent 
and both albumin and Tween in their wash buffer (Linpisarn et 
al 1981)• Little study seems to have been carried out on the 
exact requirements for reduction of NSB and as this can often 
be a problem in ELISA, it seems central to the concept that 
an awareness of these conditions is necessary. Bullock and 
Walls (1977) investigated the use of Tween 20 and BSA and 
concluded that the addition of Tween had little effect in red­
ucing NSB when incubation in BSA were used. When BSA incuba­
tion was omitted however, Tween 20 in saline or water was as 
efficient in NSB reduction. With neither BSA or Tween 20, 
a weakly positive test became completely positive.
The results presented here are not at variance with these 
findings. Incorporation of albumin into the sample diluent 
resulted in a decrease of NSB as did use of Tween 20 when PBS 
alone was used as sample diluent. Use of Tween in the wash 
buffer conferred no extra advantage when the sample diluent 
contained albumin however.
Use of albumin in the sample diluent caused no shift of the 
standard curve compared to PBS diluent after allowance for 
blank values. Incorporation of albumin into the sample diluent 
thus provides an effective means of reducing NSB. It is poss­
ible that this may only be required where protein concentrations
7^
are low and the practice of diluting samples and standards 
in a serum matrix stripped of the antigen being assayed has 
much to commend it. This is particularly true if linearity 
problems are observed for samples.
This suggestion may be more pertinent with the finding by 
Samake et al (1983) that different proteins may affect an 
ELISA in different ways both on the maintenance of enzym­
atic activity and on the hapten-antibody reaction.
In the results obtained here the source of protein was human 
serum albumin. Although a relatively expensive source of 
protein, the low concentration (1 g/1) at which it is used 
makes this problem of less importance. The variation of 
assay results with different proteins has not been investi­
gated as there was no evidence that HSA had a deterious effect 
on any stage of the assay system.
Taking these findings into account, it is perhaps not sur­
prising that use of Tween in the antibody enzyme reagent had 
no effect in further reducing NSB, since the conjugate was 
diluted in a 23% chicken serum matrix. This concentration 
of chicken serum was taken from the literature (Macdonald et 
al 1979) snd further investigation of the ideal chicken serum 
concentration was not performed as assay systems functioned 
well with this concentration.
The use of chicken serum in the sample diluent in place of 
albumin has yet to be investigated and may provide a cheaper 
alternative to HSA.
Although investigated in an enzyme immunoassay system these 
findings must also be taken into account in solid phase assays 
utilizing radioactively labelled antibodies based on the same 
principles (IRMA).
4.9»1 Materials and Methods
A horseradish peroxidase conjugate of antiserum to PAPP-A was 
prepared by the method of Avrameas and. Ternynck (197*0 (3*7«3)* 
Other materials as given in Appendix I for ELISA systems.
The time course of the antigen/antibody reaction for these 3 
oncodevelopmental proteins was investigated (the antigens chosen 
to give a range of molecular weights - hCG 39*000 (Morgan et al 
197*0, SPn 90,000 (Engvall 1980)' and PAPP-A 750,000 (Lin et al 
197*0 ) • Pooled pregnancy serum was used as the source of anti­
gens. :
Binding of antigens was measured after 10-80 minutes incubation 
as described elsewhere for investigating the time courses of 
ELISA systems (3-7*7)- Neat serum and several dilutions in 
either diluting solution, chicken serum or horse serum (Well­
come III) were utilized,
100 /il of antibody diluted 1/1200 in coating buffer was added 
to the wells of microtitre plates (Nunc Grade I) and incubated 
overnight at *f°C. After washing the plate with wash buffer 
and drying, 100 pi of pregnancy serum at various dilutions was 
added and stood at room temperature for times ranging from 10- 
80 minutes. The serum was then aspirated, the plates washed 
and dried as before. 100 ;il of Ab-E (suitably diluted in 
PBS/25^ chicken serum containing 10 mmol/ 1  citrate) was then 
added to the wells and incubated at room temperature for 50 
minutes. Following a further aspiration/washing cycle,
100 jil of chromogen was added to the wells and incubated for 
60 minutes at room temperature, after which, 100jul of *t mol/ 1  
sulphuric acid was added to stop the reaction. The absorbance
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was measured at J+92 nm using a Titertek Multiskan Plate Reader 
(Flow Laboratories, Irvine).
A series of experiments were also carried out adjusting the 
above procedure as follows.
4.9*2 Investigation of serum protein effects on the system
Dilutions of raw (unheated) pregnancy serum were made in raw 
(unheated) chicken serum to investigate the effect of other 
serum proteins on the system.
4.9*3 Investigation of the effect of varying albumin content
Investigation of the effect of decreasing albumin content 
with increasing dilution of the pregnancy serum was made by 
preparing a 1/100 dilution of serum in PBS/citrate and adding 
to aliquots of this, sufficient human serum albumin to give 
concentrations of 1? g/1 and 35 g/1 These concentrations 
correspond to the albumin concentrations in a 1 /2 dilution of 
the pregnancy serum and undiluted pregnancy serum.
4.9.4 Investigation of the effect of varying calcium concen­
tration
Investigation of the effect of decreasing calcium concentration 
with increasing dilution was made in a similar way to that for 
albumin (b). A 1/4 and 1/10 dilution of BDH Calcium Standard 
for Atomic Absorption (10 mmol/l) was prepared in PBS to give 
calcium concentrations of 2 .5 mmol/l and 1 mmol/l respectively.
A 1/100 dilution of pregnancy serum was then prepared in these 
solutions. These calcium concentrations correspond to those 
in a neat and 1 /2 dilution of the pooled serum.
4.9*5 Investigation of possible interference by the complement 
system
Investigation of interference by the.complement system was
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Fig k Xlv The effect of Increasing concentration 
of PAPP-A upon the time course of the antigen-antibody 
reaction.
Pooled pregnancy serum was used (•-- ©) neat, or
diluted (a— ■&) 1/2, (h n) 1/10, (a a) 1/100 in
PBS citrate.
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Fig xv The effect of increasing concentration of 
SP^ upon the time course of the antigen-antibody 
reaction.
Serum dilutions as in Fig k xiv.
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Fig k xvi The effect of increasing concentration 
of SP.j upon the time course of the antigen-antibody 
reaction.
Serum dilutions as in Fig h xiv.
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Fig k xviii The effect of increasing concentration 
of PAPP-A on the time course of the antigen-antibody 
reaction.
Serum dilutions as given in Fig 4 xiv but diluted in 
heat inactivated horse serum.
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Fig h xix The effect of varying calcium concentrations 
on the time course of antigen (PAPP-A) with antibody. 
Pooled pregnancy serum was diluted 1/100 in PBS/citrate
(O— o) and calcium added at 1 mmol/l (®-- ©) or
2 .5 mmol/l (v— ▼) .
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Fig xx The effect of varying albumin concentrations 
on the time course of antigen (PAPP-A) with antibody. 
Pooled pregnancy serum was diluted 1/100 in PBS/citrate
(A— *) and albumin added at 17 g/ 1  (a a ) o r 35 g/ 1
(a— a).
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Fig xxi The effect of reducing coating antibody concentration 
on the time course of antigen (PAPP-A) with antibody. The 
antiserum concentration used was 1/5000 instead of 1/1250 used 
previously.
Antigen was used neat (e ■ ), diluted 1/2 (□— Cl ) or 1/10
(a a,) in PBS/citrate.
carried out by heat inactivating both pooled pregnancy serum 
and horse serum at 56°C for 1 hour. Dilutions of the pregnancy 
pool were then made in the horse serum.
4.9.6 Investigation of the effect of varying antibody concen­
tration
This was investigated by increasing the dilution of antibody 
used to coat the plates to 1/5000.
4.9*7 Results
All 3 antigens in undiluted serum showed enhanced binding with 
increasing length of incubation up to a maximum value, followed 
by a decrease. When the serum was diluted in PBS/citrate, 
maximum binding appeared later than v/ith undiluted serum and 
in,some instances at the highest dilutions there was no sub­
sequent decrease in the apparent bindings (Fig 4 xi.v - xvi) .
Similar results were obtained for PAPP-A with dilutions of 
pregnancy serum made in raw chicken serum (Fig 4 xvii) or with 
preheated pregnancy serum diluted in preheated horse serum 
(Fig 4 xviii)•
Increasing the concentration of either calcium or albumin in 
the 1/100 dilution of pregnancy serum did not cause decreased 
colour development at any time. Conversely enhanced colour 
development with increasing albumin concentration was observed 
(Fig 4 xix and xx).
When the dilution of antiserum used to coat the microtitre plates 
was increased from 1/1200 to 1/5000, maximum binding occurred 
much earlier than at the low-dilution (Fig 4 xxi).
4.9.8 Discussion
The diminution of the measured antigen binding may be due
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the antibody enzyme or to detachment of immobilized antibody 
from the solid phase. The simplest form of inhibition envis­
aged is some type of steric hindrance which prevents the anti- 
body-enzyme conjugate gaining access to the-bound antigen, so 
that the amount of antigen bound is underestimated.
If the steric hindrance is due to antigen bound so closely 
as to prevent the antibody enzyme conjugate gaining access 
to immobilized antigen sites, the effect should be more pro­
nounced with large antigen molecules. This does not seem 
to be the case with the antigens under investigation here, 
for which there was a 19 fold difference in size between the 
smallest and largest molecules.
An alternative cause of steric hindrance may be interactions 
with the component of the complement system (Belfield and 
Macdonald 1979)• This heat-labile macromolecule is composed 
of subunits held together by calcium ions, and in vivo is able 
to attach itself to the F^, portions of IgM and IgG. The imm­
obilized antibodies in ELISA may have a conformation appropriate 
for reaction with and if this takes place, the which has 
a molecular weight of more than 500,000 daltons may prevent 
antigen gaining access to the immobilized antibody. However 
this reaction depends on calcium ions. The inclusion of citrate 
in both sample diluent and antibody enzyme conjugate should 
avoid this problem by chelation of calcium. The fact that 
no diminution in antigen binding could be achieved by addition 
of calcium to a diluted serum sample is further evidence that 
this effect is not related to the complement system.
Moreover is heat labile and the experiments in Figure k xxii
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unlikely that the complement system is involved.
It is also possible that displacement of immobilized antibody 
may occur by relatively large amounts of serum protein. If 
this was so, increasing dilution of the sample in anon protein 
matrix (PBS/citrate) would be expected to show a lessening of 
this effect. However dilution in a protein matrix (chicken 
serum) should cause persistence of this effect due to the 
relatively constant protein concentration. Dilutions in 
chicken serum however did not show accentuation of the effect.
Similarly when albumin at two different concentrations was 
added to the diluted serum specimen in PBS/citrate, no dim­
inution in antigen binding was observed. Indeed the even­
tual colour developed at all stages of incubation was enhanced 
by this process. This is possibly due to the reduced NSB's 
observed previously on addition of albumin to the sample 
diluent ('4.8)’.
Lehtonen and Viljanen(1980) reported leakage of antigen from 
the solid phase (polystyrene and nylon) at all stages of an 
ELISA for serum antibodies but particularly during the sample 
incubation stage. This finding was confirmed in the experiments 
in section 4.6 and 4.7* In contrast with the findings pre­
sented here however, their loss was less marked at high serum 
concentrations. They concluded that serum was not an essential 
factor in this leakage and that binding of antibody to antigen 
was not responsible for this detachment.
The findings presented here are not in agreement with this.
Since the decrease in binding was observed only at high serum 
concentrations and hence relatively high antigen concentrations 
and was more rapid when the antibody used to coat the solid
phase was more dilute, it is concluded that it is the reaction 
between antigen and antibody which is responsible for apparent 
decrease in bound antigen*
Many years ago Dean and Webb (1926) demonstrated that an optimal 
antigen-antibody ratio exists for the precipitation of antigens 
in the presence of antibodies. Their studies demonstrated that 
for a constant dilution of antiserum, addition of antigen in 
increasing dilutions showed at first a clear mixture, becoming 
opalescent as antigen dilution increased and finally becoming 
clear at high antigen dilutions ("prozone effect’^. In an 
analagous manner, prolonged incubation with large amounts of 
antigen may solubilize the antigen-antibody complex which is 
bound to the solid phase by weak physical forces (Marrack et 
al 1951).
However it was shown in section 4*7 that using a direct measure 
of bound antibody viz a radiolabelled antibody, no difference 
in antibody loss could be shown for wells incubated with serum 
containing no antigen to those containing high antigen concen­
trations. Taking into account the fact that the wells were 
counted in a Y counter for short periods of time, it is poss­
ible that no. significant difference in loss was observed. 
However the amplification effect of the enzyme system in ELISA 
may unmask the effect.
Several conclusions follow from these findings. When new 
assays are being established, investigation of the antigen- 
antibody time course is essential in order to ensure that an 
optimal antigen-antibody ratio is achieved. Improved solid 
phases may need to be developed with higher antibody binding 
capacity. To achieve this increased binding capacity it may
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prove necessary to develop simple chemical methods of binding
m
antibodies to the solid phase.
4.10 The Effect of Molecular Heterogeneity on the measurement 
of SP1 by ELISA
4.10.1 Introduction
The initial discovery of SP^ reported molecule of molecular 
weight about 100,000. It was later shown however that SP^ 
existed as heterogeneous forms (designated SP^<^ and SP^ ^  )
(Teisner et al 1978)• This was followed by the observation 
that reaction of the component antigens with antisera differed 
(Towler et al 1978, Schultz-Larsen et al 1979? Ho and Jones
1980). These problems make necessary an investigation into 
the characteristics of SP. assay by ELISA. It is first nec-
i I
essary to obtain SP^cC free from SP^ft and vice versa.
4.10.2 Separation of SP^ cfi and SP^ /> by gel filtration 
Materials and Methods - Preliminary attempts to separate the 
two components were made using gel filtration utilizing two 
different packings.
Chromatography columns were prepared using either Ultragel 
ACA34 or Sephacryl S200. After equilibration with phosphate 
buffered saline, the columns were calibrated with proteins 
of known molecular weight. Pooled pregnancy serum was then 
applied to the column and eluted with PBS. The eluant 
fractions were collected and assayed by ELISA for SP^ content.
Several runs on each column were performed; fractions containing 
SP^ were pooled and concentrated against PEG 6000 for further 
experimentation.
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FigVxxiii Calibration line for Sephacryl S200 Chromato­
graphy column. The calibrating proteins used were:-
1) Ribonuclease A MW 13 700
2) Chymotrypsinogen A 11 25 000
3) Ovalbumin " ^3 000
k) Albumin " 67 000
5) Aldolase ■"■158.000
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4*10.3 Separation of SP^ c£ and SP^/2 by chromatography on
hydroxyl apatite
Materials and Methods - A column measuring 150 mm x 9 mm was 
packed with hydroxyl-apatite and equilibriated with 0 .0 0 5mol/l 
potassium dihydrogen phosphate pH 6 .8. 200 ;ul of pooled
pregnancy serum was applied to the column, and eluted in the 
same buffer. The protein content of the eluant was monitored 
at 280 nm and when the trace returned to the baseline, the 
eluting buffer was changed to 0.2 M potassium dihydrogen 
phosphate pH 6 .8 and further protein eluted from the column.
1 ml fractions were collected throughout and the SP^ content 
of these fractions assessed by ELISA.
W.1 0 . Estimation of molecular weights of SP^ moieties
Calibration of the gel filtration columns was carried out
with the use of a protein calibration kit purchased from
Pharmacia Chemicals London. After assessing the column void
volume by the use of Dextran Blue 6000, the elution volume
of each protein was measured and Kav calculated as follows:-
K - Volume - Void Volume
aV Column Total Volume - Void Volume
A calibration line of Kav against log^ molecular weight was 
made from which the molecular weight of the SP^ moieties could 
be estimated (Fig k xxii, 4 xxiii).
^.10.5 Results
Fig k xxiv shows the SP^ elution profile from pregnancy serum 
applied to the Ultragel column. Peaks 1 and 2 were then run 
separately on the Sephacryl S200 column for improved resolution 
(Fig 4 xxv and *+ xxvi). The elution profile obtained when 
pooled pregnancy serum was applied to the Sephacryl column 
is shown in Fig k xxvii.
Table k XIII
Kav Values and Molecular Weights of SP^ cC / Separated on Ultragel 
ACA 3*f and Sephacryl S200 as shown in Figs xxiv to k xxvii.
Column
Material
Loaded Peak 1 Peak 2
Kav MW Kav MW
Ultragel 
ACA 3*f
2ml Pooled 
Pregnancy Serum 0,24 370,000 0.73 8^,000
Sephacryl
S200
0.3 ml Pooled 
Pregnancy Serum 0 0.19 .95,000
it Peak 1 from 
Ultragel column 0.06 180,000 0 .18 93,000
tt Peak 2 from 
Ultragel column - - 0.11 125,000
<r
j.Or Absorbance
0-0
O— o
4 8 12 16 20 24 28 32'
Fraction Number
Fig xxviii The elution profile of SP^ from pooled 
pregnancy serum applied to hydroxyl-apatite column 
and eluted with increasing molarity buffer as shown.
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given in Table 4 XIII.
Figure 4 xxviii shows the elution profile of SP^ from the 
hydroxy apatite column. Several column runs were performed 
and pools of each peak prepared,
4.10.6 Confirmation of Separation of SP^cC and SP^ £ - Method
Pooled fractions from the two peaks obtained by hydroxylapatite 
chromatography. After concentration against PEG 6000, 200 ;il 
of the peak materials were applied in separate chromatographic 
runs to the calibrated Sephacryl S200 column and eluted with 
PBS. The SP^ content of the eluant fractions was measured 
by ELISA.
4.10.7 Results
The results of the SP^ concentrations of the eluant fractions 
obtained from the Sephacryl S200 column for each pooled material 
are shown in Fig 4 xxix. The Kav for each peak on the Sepha­
cryl column was calculated as follows:-
Column Total Volume =38.2 ml
Void Volume (assessed by Dextran Blue) =16.5 ml
Peak 1 from hydroxyl-apatite column
_ P0»5 ~ 16.5 — n 1ft
38 .2 - 16.5
From the calibration curve for this column, this corresponds 
to a molecular weight of 98,000.
Peak 2 from hydroxyl-apatite column - eluted in the void volume 
and it is thus not possible to assign a molecular Weight to this 
component, other than to state that it is in excess of 160,000.
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Neither peak however showed evidence of a secondary SP protein 
on the Sephacryl separation. It appears, therefore, that the 
hydroxyl-apatite column chromatography has achieved a clean 
separation of SP^cC from SP^ p .
^.10.8 Discussion
Various methods for the separation of S P ^ X  from SP^ p have been 
proposed. Thus gel filtration using a variety of gels has been 
described (Ahmed and Klopper 1 9 8 0 , Ahmed, Toop and Klopper 1 9 8 1 , 
Hindersson et al 1 9 8 1 ). The results obtained here however 
suggest that gel filtration is not the ideal method of separation. 
Although the P component can be obtained apparently free from 
SP^ dC , the reverse is not true and the SP^ ^  preparation was 
contaminated by SP^ p as evidenced by the double peak obtained 
on further chromatography of the A.CA J>k fraction.
The use of Sephacryl S 200 in the separation of SP^ cC and p from 
serum had been reported (Griffiths and Godard 1 9 8 1 , Ahmed and 
Klopper 1 9 8 0 ). Ion exchange chromatography has also been 
utilized (Ahmed et al 1 9 8 1 , Ahmed and Klopper 1 9 8 0 ). However 
a later statement by this group suggests that in fact they did 
not achieve a clean separation by any of these techniques - in 
accordance with the present findings.
The use of hydroxyl apatite reverts to the original work on this 
protein (Bohn 1972) and was also used by Ahmed and Klopper (1 9 8 2 ). 
Using Laurell rockets as their method of monitoring, they sugg­
ested this material allowed clean separation of the moieties.
This method of assessing resolution has been criticised (Teisner and 
Grudzinskas 1 9 8 2 ). The use of ELISA as a. monitor however gives 
similar findings in a more objective assay® The molecular* 
weight estimates of 9 6 , 0 0 0  and / 1 6 0 , 0 0 0  are in agreement with 
the known facts about these moieties® Controversy however
exists as to the exact nature of the components. Klopper1s 
group suggest a single - high molecular weight component (MW 
A30,000) (Ahmed and Klopper “1980). However Hindersson and 
Teisner (1981) have adduced evidence that an intermediate 
moiety exists with MW 200,000. The exact situation is not 
of direct importance to the present study. The question that 
remains is the way in which the various moieties are recognised 
by the antiserum used in ELISA.
A.10.9 Measurement of SP^ sA- and SP^ by ELISA - Materials
and Methods
SP^ oC and ft were prepared from pooled pregnancy serum on hydr­
oxyl apatite columns as previously described. Four series of 
specimens were investigated:-
a) SP^ cL alone in varying concentrations. The following 
volumes of SP^ (100 pi, 200 pi, 300 pi, A00 pi and 600 pi) 
were made up to a volume of 1000 pi with the requisite 
volume of PBS.
b) SP^ p alone in varying concentrations - prepared as in a).
c) SP^ ft constant at 20% of final volume and SP^ al varying 
between 0 and 60% of the final volume.
d) SP^ ^  constant at 20% of final volume and SP^ varying
between 0 and 60% of the final volume.
The method of assay used was that of Macdonald et al (1979) as 
described in Chapter 3-
A.10.10 Results
Fig A xxx shows the results for SP^ <A alone at varying concen­
trations, and Fig A xxxi shows the results for SP^ ft alone. 
Measurement of SP^ ft with and without SP^ &L is shown in
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Fig 4 xxx The assay of SP^dC by ELISA.
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Fig k xxxi The assay o f SPi p> by ELISA
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Fig M xxxii The measurement of SP. p in 
the presence of SP. cC (»----a) and without 
addition of SP^cC (!e--- ■ ).
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S PjOC(jj I added)
Fig xxxiii The measurement of SP. ^
in the presence of SP. f i (□--- □)
and v/ithout addition of SP1 p (□-- □ ).
Fig k xxxii. Addition of SP^ JL causes an increase in the 
measured SP^. There is a suggestion that at higher levels 
of SP^ f> 7 the addition of SP^ causes a significantly greater 
increase in the SP^ f reading ie an apparently higher overall 
SP^ total. The effect of measuring SP^ ot. with and without 
SP^ is shown in Fig k xxxiii. Again this does not seem to 
be a purely additive effect ie the addition of 100 jil of SP„j 
caused an increase in the total SP^ of 95 pg/1. However 
the addition of 600 pi of SP^ cC caused an increment of 1*f0 jig/l 
in the apparent SP^ total.
A-.1Q.11 Discussion
With the discovery of the heterogenous nature of SP^ (Teisner 
et al 1978) it became apparent that the reaction of these com­
ponents with antisera varied. Thus Towler et al reported 
problems encountered in measuring urinary SP^ by RID, 
and RIA (1978). Thereafter a number of publications
followed along similar lines (Teisner et al 1979? Schultz- 
Larsen et al 1979» Ho and Jones 1980, Dati et al 1982, Ahmed 
et al 1982b). All authors are in agreement that the hetero­
geneous nature of SP^ is reflected in its assay methods. Thus 
to visualize S P ^ p e a k s  on Laurell rocket electrophoresis 
it is necessary to incorporate PEG^OOO into the gel (Hindersson
1981). The problem however is complicated by the fact that 
SP^ variants give differing dose-response curves in RIA and 
seem to cause artificially low SP^ levels when measured by 
this technique (Schultz-Larsen et al 1979)* It is shown 
elsewhere in this study that Whilst a significant correlation 
exists between SP^ concentration determined by ELISA and RID,
.the slope of the regression line was only 0.32. This difference
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is perhaps explainable in the light of results obtained in these 
experiments. Ahmed et al postulate that their findings for the 
differing slopes in RIA and EIA of SP^ are explained by two 
extreme forms within a population of SP^ antibodies.(Ahmed et 
al 1982). Their explanation depends on both forms binding 
SP^ d . and ft but differing in their affinities for SP^ f> .
Thus in a competitive binding such as RIA or the EIA used in 
Ahmed*s work the findings can be explained.
However, the ELISA used here is not of the competitive type.
The fact that the results obtained are similar to those of 
Ahmed suggests that the hypothesis as given is incorrect. It 
is difficult to see how the results can be explained in terms 
of displacement from low affinity antibodies as suggested for 
competitive systems.
However it is unlikely that the antibody used for coating the 
plates is sufficient to bind all SP^ molecules present.
Thus a degree of competition may exist at this stage of the 
assay. It remains to be seen if measurement of the indiv­
idual components will be useful in clinical practice.
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CHAPTER 5
AUTOMATED CURVE FITTING IN ELISA SYSTEMS
5*1 Introduction
Although ELISA is a versatile technique applicable to measurement 
of a wide variety of antigens (O'Beirne and Cooper 1979* Mac­
donald et al 19791 Pledger and Belfield 1983)v  to obtain maximum 
advantage from rapid analytical throughput, results should be 
calculated on-line. To achieve this, it is necessary to est­
ablish the mathematical relationship between colour produced 
and antigen concentration.
Whilst hand drawn curves may be suitable for small amounts of 
data, if the full potential of ELISA is to be exploited, auto­
mation of curve fitting will be necessary.
There are two stages of an ELISA which involve antigen-antibody 
reactions. Firstly antigen is incubated in the presence of 
immobilised antibody, secondly antibody enzyme conjugate is 
allowed to react with bound antigen. Neither reaction is 
allowed to proceed to equilibrium.
These two reactions were investigated in an ELISA for SP^ 
(Macdonald et al 1979)• Initially an investigation of the 
reaction between careinoplacental alkaline phosphatase and 
its antibody was carried out. This is a. simple system to 
investigate because the bound alkaline phosphatase retains 
its catalytic activity and no second indicator is needed.
Based on the experience of these experiments^computer pro­
grammes were designed to investigate the various methods of 
curve fitting.
5.2 Investigation of mathematical relationships for the 
antigen-antibody reaction
5*2.1 Materials
Antisera - Antiserum to pregnancy specific  ^glycoprotein
emu xu£» i;uujugcii,e wnfl norseraaisn peroxidase, as 
detailed in Appendix I.
Anti-carcinoplacental alkaline phosphatase (anti-CPAP) was 
raised in rabbits as described previously (3 *8*2).
Antigen - A standard preparation of SP^ (OTFL 03) * obtained 
from Hoechst Pharmaceuticals, was used,in the experiments 
described below. Pooled pregnancy serum was used as a source 
of carcinoplacental alkaline phosphatase. This serum was 
heated to 56°C for one hour and then assayed in accordance 
with the recommendations of the Scandinavian Society for 
Clinical Chemistry (197*0 using reagents obtained from 
Boehringer Corporation Ltd.
5*2.2 Time Course of antigen-antibody reactions - Methods
a) CPAP - anti-CPAP - A range of dilutions of pooled 
pregnancy sera were pipetted into the wells of 
microtitre plates (Nunc Grade I) previously coated 
with antibody. Each dilution was incubated for the 
the same time at room temperature and the enzyme 
activity measured using the alkaline phosphatase 
reagents. The colour produced was measured in a 
Titertek Multiskan.
b) SP^ j and anti-SP^ - A range of solutions containing 
varying amounts of SP^ were pipetted into the wells 
of microtitre plates previously coated with anti-SP^. 
These solutions were incubated at room temperature 
for times ranging from 10-80 minutes. After each 
incubation period the SP^ standards were replaced
by the anti-SP^ peroxidase conjugate and allowed to
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antibody-peroxidase conjugate, chromogen was added 
and the colour produced measured in a Titertek 
Multiskan.
c) Immobilised SP,j-antibody enzyme - A range of SP^
standards were pipetted into the antibody coated 
wells of microtitre plates and incubated for a 
constant time, 30 minutes• After incubation the 
SP^ solutions were replaced by anti-SP^ peroxidase 
conjugate. The time of incubation with anti-SP^ 
peroxidase conjugate was varied from 10-80 minutes 
after which the colour was developed and measured 
in the manner described above.
5*2*5 Results
Reaction between alkaline phosphatase and its antibody - An 
apparently hyperbolic relationship was observed between 
increasing amounts of immobilised alkaline phosphatase activity 
and colour produced (Fig 5 i) • When the reciprocal absorb­
ance was plotted against reciprocal alkaline phosphatase 
activity a straight line was produced (Fig 5 ii)•
5*2.4 Time course of SP^-anti-SP^ reaction
At all concentrations of SP^ examined, the amount of colour 
development increased with duration of incubation. A maximum 
colour development was not achieved although the rate of increase 
diminished with increasing time.
5.2.5 Reaction between antibody bound SP^ and antibody enzyme
The amount of colour produced increased with duration of incub­
ation but again no maximum colour development was attained
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(Figure 5 iii)• Inspection of the curves suggested an hyper­
bolic relationship between colour produced and time of incubation. 
A reciprocal plot of absorbance against time revealed a family 
of straight lines at each SP^ concentration (Figure, 5 iv) - 
with an intercept corresponding to the reciprocal of the theo­
retical maximum colour production at that concentration. The 
intercepts on the vertical axis were replotted against recip­
rocal concentrations and again a linear relationship was 
demonstrated (Figure 5 v).
5*2.6 Discussion
Historically, workers employing radioimmunoassay have been 
concerned with the equilibrium between antigen and antibody, 
their main concern being to demonstrate that the behaviour 
of labelled antigen reflects accurately that of the unlabelled 
antigen which is to be quantified. In ELISA, reactions 
rarely proceed to equilibrium; careful timing of the reaction 
and a knowledge of the reaction kinetics are therefore impor­
tant.
Consideration of the CPAP reaction is uncomplicated by the 
need for subsequent antibody reactions necessary to label 
bound CPAP so that it may be detected. Over the range of 
activities considered the results indicate an hyperbolic 
relationship between amount of enzyme bound (x) and colour 
produced (A):-
(A) = (A) ------- -max x + const
This equation is analogous to the Hill equation describing 
the relationship between oxygen pressure and myoglobulin 
bound oxygen (Wharton and Eisenthal 1981).
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The SP,j assay system is more complex. Antibody-antigen 
reactions occur in the preliminary capture of antigen and 
in the subsequent labelling with the antibody-enzyme con­
jugate.
The reciprocal plots (Figure 5 iii) of absorbance against
time enable a theoretical maximum optical density of each 
antigen concentration to be obtained from the intercept on 
the vertical axis. This intercept, when replotted against . 
reciprocal concentration (Figure 5 iv), confirms the hyper­
bolic relationship demonstrated for the CPAP-anti-CPAP reaction 
and demonstrate that the extent to which the reaction has 
proceeded towards equilibrium is independant of antigen 
concentration.
As the objective was to look for a simple numerical relation­
ship between antigen concentration and colour produced, no 
attempt has been made to provide a theoretical justification 
for the observations. Over a wide range of antigen concen­
trations modifications of the affinities of the antibodies 
for the antigen may occur and the simple hyperbolic relation­
ship may no longer hold. Where the hyperbolic relationship 
is obeyed, simple derivatives such as the log-logit trans­
formation may form the basis for on-line computation of test 
results. -dT- ■
5*3 Data Reduction
5.3.1 Introduction
Based on the investigation of kinetics carried out previously 
a variety of methods were investigated which would allow auto­
mated curve fitting.
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Experience gained during this study suggests that ELISA calib­
ration curves obtained by plotting absorbance against log con­
centration are of two main types (Figures 5 vi and 5 vii) and 
may reflect differing optimisation of assays. Each type of 
curve was considered for a variety of algorithms.
The direct type assay of CPAP when plotted as absorbance against 
concentration gave a straight line and is amenable to linear 
regression techniques and will not be discussed further.
5.3 .2  Methods
Calibration curves obtained from ELISA for SP^ and PAPP-A and 
calibration lines obtained from the immunoassay of CPAP.were 
investigated. The ELISA system consisted of a Multiskan micro­
titre plate reader (Flow Laboratories, Irvine, Scotland) inter­
faced with a TNW 2000 interface to a Commodore PET Model *+032 
with associated disc drives and printer. Using a data capture 
system supplied by Flow Laboratories a series of "BASIC" 
programmes were developed based on this system to allow curve 
fitting (Appendix 2). The following algorithms were considered. 
In each case the- X- axis represents absorbance (A) and the Y 
axis concentration (or log concentration). No weighting 
procedures were utilized.
a) For Type I curves (Sigmoid Curves)
i) Hand drawn curve plotted as absorbance against 
log^O concentration by an experienced operator 
using French Curves.
ii) Log-logit transform of the data followed by straight 
line regression of logit A against log^Q concentra­
tion where logit A =
A
ge T T X
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iii) Healy equation of the form
Y = A + B . Exp “ D * loge ^
1 + Exp ( C - D . log X)e
b) For Type II Curves (Parabolic Curves)
i) Hand drawn curve plotted as above.
ii) Log-logit transform as above.
iii) Quadratic equation of the form
2Y = A x + Bx + C
iv) Cubic equation of the form
Y = Ay? + Bx^ + Cx + D
v) Power curve of the form
Y = A x^ involving linearization to
log Y = b.log x + log A followed by 
■! e e e
linear regression.
Curve fitting was performed where applicable by solution of 
the simultaneous equations by derivation of the triangular
matrix using the square root method (Kenney and Keeping 195*0 »
and the Healy equation by Newton’s reiterative process for 
complex equations.
Assessment of "goodness of fit" was made by estimation of the
mean sum of residual squares (MRS) where
(Calculated A - Actual A)^MKo = ■ ■ ...... v  ■■N
and n is the number of points in the standard curve.
Statistical comparison of goodness of fit was made by means 
of a variance ratio (F) test on the MRS. To investigate the 
distortion patterns generated during curve fitting, absorbance 
values covering the entire range of a typical calibration curve 
were entered manually into the various curve fitting programmes.
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Table 5 I
The Mean Residual Squares obtained from 10 assays 
for SP^ (Sigmoid type curve)
Assay No
Hand Drawn 
Curve
Log logit 
transform
Healy
Equation
1 1 . 8  x  1 0 “ 3 2 . 1  x  I Q ' 3 2 . 9  x  1 0 “ ^
2 8 . if  x  1 0  V 6 . 0  x  1 0 " ^ 2 . 6  x  1 0 “ ^
3 3 - 5  x  1 0 - 5 1 . 1  x  1 0 " 5 ..' 2 . 7  x 1 0 4
if
- i f
i f  . 7  x  1 0 1 . 0  x  1 0 “ 5 2 . 1  x  10*“^
5
- i f
3 . 1  x  1 0 1 . 2  x  I Q " 3 8 . 6  * i o - 5
6
^ - i f  
6 . 1  x  1 0 1 . 3  x  1 0 ~ 5 1 . 3  x  1 0 - i f
7 7 - 2  x  I Q " 5
- i f
3 . 3  x  1 0 6 . 9  x  1 0 - 5
8 1 . 6  x  1 0  ^ 9 . 3  x  10" ^ 1 . i f  x  1 0 ^
9
- i f
1 . 1  x  1 0 8 .3  x  10"*^ 7 . 1  X 1 0 - 5
1 0 6 . 3  x  1 0 “ 5 9 . 2  x  1 0 " ^ 5 . 0  x  1 0 “ 5
Table 5 II
The Mean Residual Squares obtained from 10 assays for PAPP-A 
(parabolic type curve)
Assay No
Hand Drawn 
Curve
Log-logit
transform
Quadratic
Equation
Cubic
Equation
1 1 .5 x 10"^ 1 .8 x10-5 3.0 x 10"5 9-1 x 10~5
2 .1.4 x io-lf 1.1 x IQ" 5 -41 .3 x 10 5.1 x 10
3 1.1 x 10-5 1 .2 x 10-5 4.3 x 10“** 1.4 x 10"^
4 2 .2 x 10”** 1.1 x IQ’ 5 1 .5 x 10^ 3-5 x 10~5
5 1 .5 x 10*5 1 .2 x 10“5 2 .0 x 10 -4
-41 .3 x 10
6 1.4 x 10"^ 9.3x 10"V 6.5 x 10 5 5*4 x 10"5
7 4.0 x 10-5 1.1 x 10-5 4.7 x 10*5 2 .2 x 10"5
8 3 .0 x 10~5 1.7 x 10“5 1.7 x 10“5 1.7 x 10-5
9
-41.1 x 10 1.1 x 10“5 4.7 x 10~5 3.4 x 10"5
10 1 .8 x 10“^ -47-0 x 10 3 .6 x IQ” 5 3*4 x10-5
Table 5 H I
Comparison of Goodness of Fit by F test for Type I Curve
F=
Assay Log Logit/ Healy/Hand Healy/Log-
No Hand Drawn Drawn logit
1 1 .2 6 .2 7.2
2 1.4 3.2 2.5
3 3-2 13.0 p < 0.01 4.1
4 2.1 1.9 4.8
5 3-9 3.6 14.0 p < 0.01
6 2.1 4.1 8.7
7 7.4 1.0 7.7
8 5.8 1.1 6 .6
9 7.6 1 .6 11.7
10 14.6 p < 0.01 1*3 18.4 P < 0.01
Table 5 IV
Comparison of Goodness of Fit by F test for Type II Curve
■ F=
Assay Quadratic/ Cubic/Hand Log-logit/
No Hand Drawn Drawn Hand Drawn
1 20.0 p < 0.01 1.7 12.0 p < 0.01
2 1.1 3-6 7.9
3 3 .0 2 7-9 1.1
4 1.5 6 .3 5.0
5 7-5 11.5 p<o.oi 1.3
6 2 .2 2.6 6 .6
7 1 .2 1 .8 27.5 p < 0.01
8 1.8 1 .8 56 .7 p< 0.01
9 2.3 - * 3.2 10.0 p < 0.01
10 5-0 5-3 3.9
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Table 5 V
Mean and Standard Deviation of Percentage Distortion for Sigmoid Curves from 
the Distortion Patterns shown in Figure 5 viii.
Mean % Standard Range of
Distortion Deviation . % Deviation
Healy/Hand Drawn -2.5 7*1^ -1*f.6 to 9
Log-Logit/Hand Drav/n +1«3 '11.31 -15.8 to 16
(For the range of standards normally employed in the calibration curve)
Table 5 VI
Mean and Standard Deviation of Percentage Distortion for Parabolic Curves from 
The Distortion Patterns shown in Figure 5 ix.
Mean % Standard Range of
Distortion Deviation . % Distortion
Quadratic/Hand Drav/n +1.1 10.5 -28 to +9*1
Cubic/Hand Drawn . +2.0 13»3 -38 to +13*7
Log-Logit/Hand Drawn -6 .5 11.0 -17-3 to +19
(For the range of standards normally employed in the calibration curve)
The computed concentrations obtained were expressed as positive 
or negative % deviation from the results obtained from the hand 
drawn curves. The mean and SD of the percentage deviations 
from the hand drawn results were calculated for the various 
algorithms over the range of standard concentrations normally 
present in the calibration curve.
5*3*3 Results and Discussion
Tables 5 I and 5 II show the results of the HRS obtained over 
10 typical assays for each antigen and tables 5 H I  and IV 
show the results of the F tests on the MRS between various 
methods of fitting. The MRS for log-logit versus hand drawn 
curves was significantly worse on one occasion (Assay 10) and 
for Healy versus hand drawn was significantly better on one 
occasion (Assay 3)* -For type II curves both quadratic 
(Assay 1) and cubic (Assay 5) gave significantly lower MRS 
on these two assays. The power fit for type II curves provided 
totally unacceptable MRS values.
Figures 5 viii and ix show the distortion patterns generated 
by application of the algorithms compared with the results 
obtained from the hand drawn curves and tables 5 V and VI show 
the mean, standard deviation and range of % distortion from 
these figures. For type I curves, the Healy equation showed 
a smaller range of deviation and for type II curves, the smallest 
range of deviation was observed for the quadratic equation.
In order to automate ELISA systems, it is necessary to utilize 
suitable curve fitting techniques. For small amounts of data, 
it is common to use a manual plot of absorbance against log concen­
tration and this type of plot is widely used in immunoassay as 
it provides a convenient way of handling the wide range of 
concentrations encountered.
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xu cLjjjjvtxrta xrom taoie p x /x x x mat in terms of goodness of 
fit, there is little difference in the fit achieved using the 
Healy or log-logit approach compared with a hand drawn curve. 
Taking the hand drawn curve as a baseline, either approach 
appears satisfactory.
However, complex distortion patterns were induced by both methods 
of fitting the Gurve (Fig 5 viii and ix). Major distortion 
in the Healy equation was observed only at values below those 
normally encountered in pregnancy, and over the standard range 
provided a reasonable fit. Maximal distortion of the log-logit 
results was observed at both extremes of the standard curve, 
but also a large positive distortion at the mid point of the 
.curve. ■
From tables 5 I and 5 IV it appears that either quadratic or 
cubic equations may be used to describe the type II curve, 
whilst the log-logit approach differed from the hand drawn 
curve hO% of the time.
Again considerable distortion was engendered (Fig 5 iv).
Whilst the pattern for quadratic and cubic fits was similar, 
that for the log-logit is more complex. For the polynomial 
fits, maximal distortion was observed only at lower standard 
values whilst the log-logit results showed distortion at both 
extremes.
The method of fitting chosen thus depends on assay conditions. 
Ideally the distortion imposed over a manually plotted curve 
should be minimal over the concentration range of interest and 
particualrly at action limits, where bias in calculating results 
could have serious implications. The distortion pattern may 
be reduced by suitable weighting factors (Frazier and Rodbard 
1973? Rodbard and Lev/aid 1970). However, Challand points out
97 ’ ;
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point of the standard curve, it will not change the overall 
pattern (Challand et al 1976). Weighting was not applied 
in the present study. The variation in distortion patterns 
imposes one important constraint on the user. It is important 
that once an algorithm to describe the curve it decided upon, 
that this method is adhered to. Changing methods merely on 
the grounds of a reduced MRS will lead ultimately to poor 
precision and confusion in the results produced.
Providing these constraints are borne in mind, simple algorithms 
such as those decribed, may be used for data reduction in 
ELISA systems of this type.
98
CHAPTER 6
SERUM HPL, SP AND PAPP-A CONCENTRATIONS DURING THE THIRD 
TRIMESTER OF NORMAL PREGNANCY
One of the miles'tones of the history of medicine has been the 
reduction of mortality and morbidity connected with pregnancy.
With the virtual elimination of maternal mortality, attention 
has turned to ensuring optimum development of the foetus. The 
overall improvement in maternal health has greatly facilitated 
this. Problem pregnancies however still exist eg diabetic, 
hypertensive etc. The objectives of biochemical placental 
function testing are to alert the obstetrician to the possible 
development of problems affecting the foetus or conversely to 
issue reassurance viz.that foetal conditions are satisfactory.
A variety of foetal or placental products have been used in 
this context for a number of years (Wilde and Oakey 1975)•
It is possible that the measurement of maternal concentrations 
of the "new" placental proteins may offer certain advantages 
over hPL measurements. This study investigates the use of 
SP^ and PAPP-A in certain pregnancy associated problems.
6.2 Clinical Material
The normal group comprised patients attending routine antenatal 
clinics at the Royal Maternity Hospital. Patients attending 
these clinics prior to 25 weeks gestation were admitted to this 
survey after giving their informed consent. Thereafter patients 
were followed throughout the duration of their pregnancy. Venous 
blood specimens were drawn at each clinic attendance.
Following delivery, the baby was weighed and the undrained placenta 
also weighed.. Retrospective classification into the normal group 
was made with the assistance .of the consultant obstetrician whose 
clinic the patient attended.
The normal group was defined as patients having no evidence of 
pregnancy induced hypertension (PIH), oedema or proteinuria, no
99 . :
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* thpregnancy. The delivered baby had a birth weight > 10 cen­
tile corrected for maternal weight and height according to 
Thomson’s figures (Thomson et al 1968). Ninety-one patients 
were included'in this group.
6*3 Analytical Methods
Blood specimens were centrifuged and the serum separated from 
the clot as soon after collection as possible. Sera were stored 
at -20°C until assay. HPL, SP^ and PAPP-A were assayed accord­
ing to the methods described in chapters 2 and 3 *
All specimens from an individual patient were assayed in the 
same batch to minimize assay variation. Specimens were assayed 
in duplicate and the mean concentration taken.
6 . k Numerical Analysis of Data
Standard statistical analyses of placental and birth weights 
were made to give a mean and standard deviation. Standard reg­
ression analysis of this data was also performed. Serum protein 
concentrations obtained from this group of patients were used 
to construct normal ranges. Although more than one specimen 
was obtained from some patients, all data points were considered 
independently.
Normal ranges were prepared in two ways. Initially ranges 
were expressed as centiles. However, further examination of 
the data suggested that serum SP^ and PAPP-A concentrations were 
positively skewed. A logarithmic transformation was made before 
mean and SD were calculated for future use. HPL concentrations 
were normally distributed and untransformed data was used through­
out.
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Table 6 I
Characteristics of the normal population
a) Birth weight
Corrected for
anthropomorphic
factors Uncorrected
Mean
Weight (kg) 3.35 3.41
Std
Deviation O .36 0.42
Number of
Patients 91 91
b) Placental Weight
Mean V/eight (g) 664
Std Deviation 121
Number of patients 67
c) Linear Regression
Placental Weight with 
Corrected Birth Weight
Placental Weight with 
Uncorrected Birth Weight
Correlation
Coefft. 0 .4 9 (p<.001) 0.64 (p< .001)
Gradient 162 185
Y Axis Int 116 27.8
SE Grad 36.6 27 .2
SE Int 123.6 94.2
Number of 
Patients 67 67
PLACENTAL
WEIGHT(g)
1000 r
500
BIRTH W E IG H T (k g )
Fig 6 i The correlation between placental weight and
birth weight in a normal population.
PLACENTAL 
WEIGHT (g)
1000
500
BIRTH WEIGHT (kg)
corrected for maternal 
weight and height
Fig 6 ii The correlation between placental weight 
and birth weight (corrected for maternal weight and 
height) in a normal population.
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Table 6 II
The Relationship between peak hPL, birth weight (corrected and 
uncorrected) and Placental Weight.
Corrected 
Birth Weight
Uncorrected 
Birth Weight
Placental
Weight
Mean hPL 8 .6 (mu/L) 8 .6 (mu/L) 8 .6 (mu/L)
Standard Deviation 1.9 2.0 1 .8
Standard Error 0.21 0 .2*f 0 .2 k
Mean Weight 3-35 (kg) 3.^2 66k (g)
Standard Deviation 0.36 O.Vi 121
Standard Error 0 .0*f 0.05 15
Correlation Coefft. 0 .36 (p<0 .01) 0 .3 k 0 .5 2 (p<0 .0D
Gradient 2.11 1.66 3^.01
Y Axis Intercept •1.55 2.92 373.1
SE Gradient 0 .66 0 .56 7 .0
SE Intercept 2.22 1.93 61
Number of Patients 71 71 67
b.5 Results:
Table 6 I shows the statistical analysis of placental weights 
and birth weights, and Figs 6 i and 6 ii show the regression 
analysis of this data. There was a significant correlation 
between both actual birth weight and corrected birth weight 
with placental weight.
Figures 6 iii - 6 v show the normal ranges for the 3 proteins 
expressed as centiles. For all 3 proteins, an increase in 
concentration was noted with increasing gestation, although for 
hPL and SP^ a plateau was noted at about 38 weeks followed by 
a decrease in concentration.
Figures 6 vi - 6 viii show the distributions of data.'points used 
to construct the normal ranges and on which the logarithmic 
transformation was based.
Regression statistics between placental weight, foetal weight 
and each of the pregnancy proteins were calculated (Table 6 II). 
Only for hPL was a significant association with either foetal 
or placental weight found.
No correlation between the peak concentrations (taken between 
36 and 38 weeks gestation) of any pair of proteins found.
6 .6  Discussion .
The supreme test of placental function may be regarded as the 
birth of a well nourished, adequately oxygenated baby. Since 
the placenta is the organ responsible for transfer of nutrients, 
it seems likely that a large placenta has a greater transfer 
capacity than a small placenta (Fox 1979). However, to what 
extent placental adequacy can be inferred from placental weight 
is questionable (Baird and Walker .1959i Aherne 1986, Browne 1973* 
Dawes 1968). In an extensive survey of births, Thomson found
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correlation coefficients of between 0.5 - 0.6 indicating that 
birth weight is rather poorly predicted by placental weight 
(Thomson et al 1969)• The results obtained in the present 
study although drawn from a smaller population accord well with 
Thomson’s figures (Birthweight mean 3 *^ 1 kg compared with 
Thomson’s value of 3*30 kg and mean placental weight 66k g 
compared with 6^9 g)• Younozzai and Haworth (I969) found 
similar birthweights but a lower mean placental weight. This 
difference may be accounted for by the thoroughness with which 
blood and membranes are removed before weighing (Garrow and 
Hawes 1971).
The low correlation coefficient between birth weight and placental 
weight is perhaps not surprising in view of the fact that the 
placenta has considerable functional reserve. If foetal growth 
were rigidly limited by placental mass, it would imply that the 
placenta is normally working at full capacity - a concept that 
appears incorrect. It seems more probable that the small pla­
centa is small because the baby is small and placental function 
is therefore adequate for a foetus the growth of which is ret­
arded by extraplacental factors. Correction of foetal weight 
to obviate these maternal effects will lower the predictive 
value of placental weight.
The pattern of pregnancy protein concentrations observed for the 
3 proteins under consideration should be considered in the light 
of previous findings.
The wide range of normal has been recognized by many groups of 
workers in this field (Sciarra et al 1968). Many groups have 
found skewed distributions for hPL concentrations, (Letchworth 
et al 19711 Guibal et al 1980, Pluta et al 1980) although some 
have not (Janisch and Spona 1980).
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The skewed distribution observed for SP^ is also in accordance 
with other groups and the normal range is in agreement with that 
previously obtained by this method (Pluta et al 1979, Chard and 
Grudzinskas 1980, Gordon et al 1977, Macdonald et al 1979 and 
Gemmell 1982). The median peak value also agrees with that 
of Gordon et al (1977) using RIA. Other groups however have 
found lower peak values (Karg et al 1981, Pluta et al 1979)- 
These differences may result from the use of different mass 
standards - a problem seen with many of the pregnancy proteins.
For SP^ however, the problem is even greater because of the 
molecular heterogeneity (Towler et al 1978, Teisner et al 1978) * 
This fact and the differing assay systems used makes strict
comparison of results almost impossible. The future use of
an International Reference Preparation may obviate this problem.
At present the continued use of. mass standards for SP^ may be 
considered acceptable. This problem is discussed further in 
Chapter b . In contrast to the results obtained for hPL and 
SP^, serum PAPP-A concentrations increased with advancing preg­
nancy in a less marked manner, and no peak concentration was 
observed. A similar pattern has been observed previously
( Smith et al 1979, Bischof et al 1982a).
Synthesis of hPL appears related to placental mass as shown by 
the elevated serum levels found in pregnancies complicated by 
diabetes mellitus or Rhesus isoimmunisation (Selenkow et al -1971) • 
The correlation of hPL concentrations with placental and foetal 
weight is not unexpected therefore, although not all groups of 
workers have found a correlation (Grumbach et al 1968, Sciarra 
et al 1988, Letchworth et al 1971b, Spellacy et al 197*1) •
Similar disagreements exist over the correlation of SP^ with 
placental and foetal weight, some groups finding a correlation
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( Braunstein et al ^980, Vermeulen et al 1982, Gamberini et al
1977) or no correlation (Chapman et al 1981, Mandruzzato et 
al 1980)• The discordance of results between hPL and SP^ 
may be explained by differing modes of production.
A clear concentration gradient from the retroplacental blood 
to peripheral blood has been shown for hPL (Klopper and Hughes
1978). SP^ however has been shown to exhibit a reverse grad­
ient (Smith et al 1979, Grudzinskas et al 1980b) . These 
findings led Klopper et al to hypothesize that very little of 
the SP^ found in the maternal circulation is directly secreted 
by the villous trophoblast, but rather is the effect of lysis 
of the maternal trophoblast. If this is so, the lack of 
correlation of maternal SP^ concentration with placental weight 
is hardly surprising. The lack of correlation between hPL 
and SP^ concentrations is also explainable.
PAPP-A has also been shown to exhibit a reverse concentration 
gradient similar to that for SP^. It is interesting that no 
correlation between PAPP-A and foetal or placental weight was 
found. By analogy with SP^, this lack of correlation can be 
explained and similarly the lack of correlation between PAPP-A 
and the other pregnancy proteins is also explained.
The consistency of comparisons between this and other surveys 
suggests that although relatively small in numbers, this normal 
group represents a suitable basis for construction of reference 
ranges•
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CHAPTER 7
THE USE OF PREGNANCY ASSOCIATED PROTEINS IN MONITORING 
PLACENTAL FUNCTION IN, LIGHT FOR DATES PREGNANCIES' AND 
IN PATIENTS WITH POOR WEIGHT GAIN
7*1 The Light for Dates Pregnancy 
7,1.1 Objectives
The detection of the LFD baby and the monitoring of this type 
of pregnancy has been the aim of obstetricians and biochemists 
for many years. The reasons behind this are several. The 
obstetrician^ concern is directed towards causation* placental 
failure towards the end of gestation carrying intimations of 
mortality (Brook 1983)• Furthermore these babies are at 
increased risk in the neonatal period and are also disadvantaged 
into childhood, being less well developed both physically and 
intellectually (Neligan et al 1976). The clinical evaluation 
of fetal risk due to IUGR remains difficult however. Only the 
most severe cases of poor fetal growth are likely to be recog­
nized clinically (Aickin et al 1983)* Even the advent of 
ultrasonographic monitoring whilst being an ideal non-invasive 
technique has problems with the number of patients that can be 
screened. Furthermore this type of examination facility tends 
to be confined to major centres.
Biochemical methods therefore still play an important part in 
the detection and monitoring of the LFD pregnancy* .
7*1*2 Clinical Material
thPatients who delivered a baby of < 10 centile for weight 
corrected for gestational age (Thomson et al 1968) were included 
in this group. ' Some pregnancies were normotensive whilst 
others were hypertensive - all were considered as a single LFD 
group however.
7*1*3 Analytical Methods
The assay methods given previously (Chapters 2, 3) for hPL,
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Table 7 I ~
Characteristics of LFD Pregnancies
LFD Normal
Mean Birth Weight (kg) 2.38 3.40
SD 0.46 0.42 t = 12.0
SE 0.07 0.05 p < 0.01
n 38 91
Mean Placental Weight (kg) 464 632
SD 111 145 t = 6.1
SE 18.4 17.3 p< 0 .001
n 35 67
Table 7 II
Definitions of the terms used in comparing LFD and normal 
pregnancies.
True Positive (TP) A serum pregnancy protein concentration 
below the decision threshold with subsequent delivery of a 
LFD baby.
False Positive (FP) A serum pregnancy protein concentration 
below the decision threshold with subsequent delivery of a 
normal birth weight baby.
True Negative (TN) A serum pregnancy protein concentration 
above the decision threshold with subsequent delivery of a 
normal birth weight baby.
False Negative (FN) A serum pregnancy protein concentration 
above the decision threshold with subsequent delivery of a 
LFD baby.
Specificity The proportion of subjects without the disease
who give a negative result =
. 1 TN 
TN + FP
Sensitivity The proportion of subjects with the disease who 
give a positive test result =
TP .
: ' TP + FN
Predictive value of a positive test result = TP
TP + FP
Predictive value of a negative test result = TN
TN + FN
Prevalence The proportion of the population under investi­
gation who have the disease which we wish to detect.
and FAFF-A were used. The weight of the baby and the weight 
of the placenta were noted at delivery and the characteristics 
of these pregnancies compared to the normal group are shown in 
Table 7 1* Birth weights were not corrected for maternal weight 
and height for the reasons described previously (Chapter 6).
7*1**f Numerical Analysis of Data
Comparison of the pregnancy protein concentrations in LFD and 
normal pregnancies were made by comparing the median concen­
tration at each week of gestation. For objective assessment 
of the usefulness of an individial protein in detecting a LFD 
baby, the following approach was adopted:-
All samples were considered independently although several 
samples were obtained from most patients throughout gestation, 
the objective being to assess the value of an individual measure­
ment rather than a series. The serum concentrations of the 
3 proteins considered are all dependent on the duration of 
pregnancy, so the decision thresholds used to predict IUGR were 
expressed as centiles of the control distribution. Prediction 
of IUGR may thus be made at any week of gestation. Centiles 
v/ere calculated at each weeks gestation using standard stati­
stical methods. Logarithmic transforms of serum SP^ and PAPP-A 
concentrations were made before calculation of the mean and SD. 
For hPL, untransformed data was used.
After calculation of true/false positives and negatives^ , sensit­
ivity, specificity and predictive values for each test were 
calculated in accordance with the methods described by Galen and 
Gambino (1975)• These parameters are defined in Table 7 II*
7*1*5 Results
There was a significant difference in birth weights between the
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Table 7 H I
Intersextile Ranges for Concentrations of hPLt SP^ and PAPP-A in LFD and Normal Pregnancies
Veek of 
Gestation
LFD Group Normal Group
Lower Sextile Median Upper Sextile Lower Sextile Median Upper Sextile
28 3.1 4.0 4.8 3.6 5.0 6 .2
29 3.2 4.4 5-1 4.4 5-4 6 .8
30 3-2 4.1 4.5 4.9 5.8 .7 .5
31 4.4 **.6 5.0 5-0 6 .8 7.4
32 3-9 5.1 6.5 5.7 6.9 9.2
33 3.2 5.5 6 .1 6 .3 7.0 8.3
34 3-7 4.9 5.6 5*5 8 .1 8.9
35 4.4 5-5 5.9 6 .1 7.9 9-2
36 4.3 4.8 6 .1 6 .6 8.4 9.8
37 3.6 4.7 6 .6 7.0 8.7 9.8
38 3.0 4.8 7.4 6.5 8.3 10.4
39 3-5 4.9 6 .0 6.4 7.2 9.4
40 2.3 4.0 4.3 6.4 8.9 10.4
28 75 97 151 85 112 200 '
29 96 137 179 87 152 207
30 112 171 196 107 190 230
3V 109 143 390 83 127 264
32 122 190 219 73 218 284
33 113 144 238 109 181 282
34 111 149 203 102 167 359
35 97 130 332 113 245 355
36 105 131 183 74 226 350
37 10*t 164 273 145 259 309
38 106 151 235 95 222 411
39 11? 142 267 141 230 382
40 95 157 167 64 185 331
28 32 54 122 56 86 106
29 54 89 199 55 67 107
30 21 70 107 44 74 102
31 20 55 123 56 68 97
32 48 72 105 41 77 145
33 4o 124 190 ' 54 84 119
34 41 87 159 56 74 165
35 8o 128 176 62 96 128
36 45 70 107 57 101 167
37 Go 127 194 68 96 154
38 57 87 110 73 109 167 '
39 48 87 133 51 93 141
40 •14 115 191 79 123 184
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normal and LFD group and also in placental weights (Table 7 1)
(p<0 .01).
HPL in the normal group was significantly higher at each week 
of gestation than in the LFD group (p^f0.01) (Figure 7 i, Table 
7 III)• There was no significant difference in SP^ and PAPP-A 
concentrations (Figure 7 ii, 7iii and Table 7 III).
Figures 7 iv - 7 vii show the values for sensitivity, specificity 
and predictive values of positive and negative results at several 
decision thresholds and Figure 7 viii depicts the dependence 
of predictive value upon prevalence of the disease in the pop­
ulation examined.
7.1.6 Discussion
The need for objective assessment of predictive placental function 
tests has been emphasized (Chard and Klopper 1982). All too 
often a subjective opinion is formed based on the observation 
that hPL is generally higher in 1 group of patients than another.
Three variables determine the predictive value of a test - speci­
ficity, sensitivity and prevalence (Table 7 II)• Because the 
serum concentrations of the three proteins under investigation 
are dependent on the duration of pregnancy, decision thresholds 
have been described as centiles of the distribution of the control 
results. Therefore specificity has been defined by selection 
of the decision threshold.
hPL clearly provides the most sensitive test when using this 
approach. As the decision threshold approaches the median, 
more growth retarded babies'are included in the group as a whole 
but at the cost of including a number of normal subjects. The 
value of a test in assessing the individual patient is best 
described in terms of the prevalence of the disease. Assuming
«. ^icvaxcuuc ui iu,uuu per iuu,uuu population SP^ and
PAPP-A are of less value than hPL in predicting IUGR.
For the individual patient, hPL remains the most useful of the 
pregnancy proteins under study in the detection of the growth 
retarded foetus. Whilst hPL is clearly of use in detection of:' 
the LFD foetus, it remains to be seen whether it will be super- 
ceded by physical techniques. Whilst these methods may have 
certain attractions their use at present remains limited to 
specialized centres. Conversely hPL assays are easy and cheap 
to perform and are likely to remain an important part of the 
biochemical approach to the LFD pregnancy.
7.2 Poor weight profile pregnancies
7-2.1 Objectives
The patient with eitherHow weight gain throughout the duration 
of pregnancy, or with a static weight for several weeks poses 
a problem for the obstetrician. Does this syndrome represent 
a growth retarded foetus, a foetus that has initially grown at 
a satisfactory rate and then ceased growth for some reason, or 
is the foetus healthy and of good size with only a lack of 
maternal weight gain to concern the physician? It is in this 
light that monitoring should be seen. Primarily monitoring 
in this.situation will be carried out to reassure the physician 
that placental function is proceeding apace.
7*2.2 Clinical Material
A poor weight gain was defined as a static weight over a 2-3 
week period or an overall weight gain of < 8 kg throughout 
pregnancy regardless of the weight of the baby.
7.2.3 Analytical Methods w
HPL, SP^ and PAPP-A were measured by the methods described
Table 7 IV
Characteristics of Patients with Poor Weight Profile 
During Pregnancy
Poor Weight 
Profile Normal
Mean Birth 
Weight (kg) 3-30
SD 0.5 0 .k 2 p> 0.1
n 18 80
Mean Placental 
Weight (g) 65^ 66k
SD 150 121 p 7 0.1
n 18 67
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Table 7 V
Intersextile Ranges for concentrations of hPL, SP^ and PAPP-A in Poor weight Profile and 
Normal Pregnancies
Week o f 
Gestation
Poor Weight P ro file  Group Normal Group
Lower S ex tile Median Upper S e x tile Lower S ex tile Median Upper S e x tile
28 3.7 4.5 4.8 3.6 5.0 6 .2
29 4.3 4.8 5.8 4.4 5.4 6 .8
30 3.8 4.5 6 .3 4.9 5.8 7.5
31 5.1 6.7 7-6 5.0 6 .8 7.4
32 5.2 6.4 7.6 5.7 6 .9 9.2
33 4.9 7.1 8 .8 6 .5 7.0 8.3
'34 5.8 7.1 8.7 5.5 8 .1 8.9
35 4.9 6.7 8.7 6 .1 7.9 9.2
36 5-4 6.7 7*8 6 .6 8.4 9.8
37 5-9 7.8 9.4 7.0 8.7 9.8
38 6 .3 7.8 8 .2 6.5 8.3 10.4
39 6.3 7.5 9-4 6.4 7.2 9.4 .
6 .6 7.6 10 .8 6.4 8.9 10.4
28 85 131 202 85 112 200
29 97 156 188 87 152 207
30 171 240 277 107 190 280
31 99 128 242 85 127 264
32 218 255 396 73 218 284
33 135 157 313 109 181 282
34 161 250 296 102 167 359
35 163 227 368 .1.13 245 355
36 128 268 351 74 226 350
37 139 298 350 145 259 309
38 130 199 307 95 22 2 411
39 153 238 469 141 230 382
4o 151 213 230 64 185 331
28 53 65 89 56 86 106
29 27 87 91 55 67 107
30 43 50 94 44 74 102
31 69 69 142 56 68 97
32 70 108 158 41 77 145
33 67 106 140 54 84 119
34 48 71 96 56 74 165
35 65 110 155 62 96 128
36 51 83 181 57 101 167
37 61 84 146 68 96 154
33 89 107 160 73 109 167
39 98 112 142 51 93 141
40 77 116 158 79 123 184
previously,all specimens from an individual patient being assayed 
in a single batch.
7 * 2 . Numerical analysis of Data
Comparison of the pregnancy characteristics between the poor 
weight profile and normal groups was made by use of gaussian 
statistics. Uncorrected birth weights were used throughout. 
Comparison of the pregnancy protein concentrations was- made 
by use of the median concentration at varying weeks of gest­
ation, and the Mann Witney U test.
7*2*5 Results
The characteristics of the poor weight profile group compared
with the normal group are shown in Table 7 IV. No significant
difference in either placental weight or birth weight was
observed between the two groups (p> 0.1) . Figures 7 ix - xi
show the median pregnancy protein concentrations throughout 
rd
the 3 trimester of pregnancy in the two groups and Table 7*V, 
the intersextile ranges. For SP^ and PAPP-A no significant 
difference in concentrations was observed, whilst for hPL a 
significant difference was observed only at 1 week (36 weeks 
gestation p <.05)•
7.2.6 Discussion
It has been observed that a negative finding in placental 
function testing may be as useful as a positive result (Chard 
1982 b) • This situation is ideally seen in the present context - 
reassurance can be issued to the clinician based on a normal 
hPL concentration in a woman with poor weight gain or static 
weight. The poor weight group had babies of an equivalent 
weight to the normal group, suggesting that their lack of mat­
ernal weight gain was not central to foetal growth. The
109
coronary 01 course is that a low maternal hPL concentration 
in a woman with poor weight gain is suggestive of placental 
malfunction and reduced foetal growth. It is shown elsewhere 
that SP,j and PAPP-A concentrations do not correlate with pla­
cental or birth weight. Therefore these proteins would be 
or less use in delineating the poor weight profile pregnancy 
truly at risk as an IUGR pregnancy.
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CHAPTER 8
THE USE OF PREGNANCY ASSOCIATED PROTEINS IN THE MONITORING 
OF PLACENTAL FUNCTION IN THE THIRD TRIMESTER OF PREGNANCIES 
COMPLICATED BY PREGNANCY INDUCED HYPERTENSION OR DIABETES 
MELLITUS
8.1 Hypertensive Patients
8.1.1 Objectives
Hypertension in pregnancy has been recognized for many years 
as jeopardizing the foetus. In hypertensive pregnancies, 
placental function may become impaired due to pathological 
narrowing of the spiral arterioles which supply the inter­
villous space (Robertson et al 19&7) 311 d may result in reduced 
placental perfusion by maternal blood. This in turn may lead 
to the development of a dysmature baby or more acutely, fetal 
hypoxia and distress. Monitoring of placental function in 
this disorder should therefore be able to predict the develop­
ment of these problems and varying claims have been made ( for 
a review see Curzon 1979)- The possible use of SP^ and PAPP-A 
in monitoring hypertensive pregnancies is less clearly defined 
although it has been claimed that PAPP-A is elevated before 
clinical sdgns of pre eclampsia occur (Lin et al 1977* Hughes 
et al 1 9 8 0 , Klopper and Hughes 1 9 8 0 ).
8*1-2 Clinical Material
Patients comprising this group vjere drawn from clinics held 
at the Royal Maternity Hospital and Stobhill Hospital, Glasgow. 
Patients from Stobhill Hospital were also involved in a trial 
of the drug Atenolol ( apblocker) in the reduction of hyper­
tension. Thus some Stobhill patients were on drug treatment 
and others received a placebo. Preliminary investigation 
had shown that the varying treatments did not affect the para­
meters under discussion here*.
Pregnancy induced hypertension (PIH) was defined either as a 
sustained diastolic blood pressure of >  90 mmHg with or with­
out evidence of oedema or proteinuria, or for Stobhill patients
111
as a systolic pressure of y 1*f0 mmHg/diastolic pressure of 
y  90 mmHg on 2 occasions 2b hours apart*
Venous blood specimens were taken at several stages throughout 
pregnancy*
Hypertensive pregnancies resulting in a light for dates baby 
(LFD) were excluded from this data as they will be considered 
elsewhere (7* •
8*1*3 Analytical Methods
HPL, SP^ and PAPP-A were measured by the methods given previously, 
all specimens from an individual patient being assayed in a 
single batch.
8*1 **f Numerical Analysis of Data
Comparison of the hypertensive pregnancy characteristics with 
normal pregnancies was made by use of gaussian statistics.
As the serum concentration of SP^ and PAPP-A was found to be 
skewed (Chapter 7), comparison of protein concentrations was 
made by use of the median and Mann-Witney test*
8.1*5 Results and Discussion
The hypertensive population comprised a heterogeneous group 
in that some were treated with Atenolol, some with placebo and 
some were not involved in any drug trial. However no signif­
icant differences could be shown between these groups for any 
of the parameters under consideration. It is thus valid to 
combine these patients into a single group. Further since 
many of the patients in this group were under ’’shared care” 
with their GP, it was not possible to obtain the maternal weight 
details required to correct the baby’s birth weight. Actual 
birth weights have therefore been used in this section.
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Table 8 I
Characteristics of Hypertensive Pregnancies and Normal 
Pregnancies
Hypertensive Normal
Mean Birth 
Weight (kg) 3-27 5. VI
SD 0.5 0.**2 P>0.1
n 82 80
Mean Placental 
Weight (g) • 587 66k
SD 15** 121
t = 2 .9
■ ■ p < 0.01
n 76 67
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Table 8 II
Intersextile Ranges for Concentrations of hPL, SP^ and PAPP-A in PIH and Normal Pregnancies
Veek o f 
Gestation
PIH Group Normal Group
Lower S ex tile  - Median Upper S ex tile Lower S extile Median Upper S e x tile
28 2.9 4.2 5.4 3.6 5-0 6.2
29 4.2 4.9 7-1 4.4 5-4 6.8
30 2.5 5.4 6.3 4.9 5.8 7.5
31 4.8 5.9 6-5 5.0 6.8 7.4
32 4.2 4.8 6.7 5.7 6 .9 9.2
33 4.7 5.4 7.3 6 .3 7.0 8 .3
34 4.9 6.6 8.2 5.5 8.1 8 .9
35 5.0 6.9 9-2 6.1 7.9 9-2
36 4.5 7.7 10.3 6.6 8.4 9.8
37 4.7 7.4 9.8 7.0 8.7 9.8
33 4.2 7.0 8.9 6.5 8 .3 10.4
39 4.0 6.3 7-9 6.4 7.2 9.4
40 4.1 7.0 8.5 6.4 8.9 10.4
23 88 112 186 85 112
i
200
29 93 122 149 87 152 207
30 104 161 199 107 190 280
31 103 165 293 83 127 264
32 112 195 246 73 218 . 284
33 96 120 256 109 151 232
34 147 225 270 102 167 359
35 116 212 .275 113 2^5 355
36 121 214 330 74 226 350
37 120 213 333 145 259 309
38 137 221 350 95 222 411
39 136 179 267 141 230 382
40 157 178 373 64 135 331 j
23 24 56 98 56 66 106
29 45 79 108 55 67 107
30 10 68 131 44 74 102
31 49 86 116 56 68 97
32 48 74 131 41 77 145
33 25 56 110 54 84 119
34 41 100 119 56 74 165
35 53 90 128 62 96 128
36 66 98 135 57 101 167
37 72 115 158 68 96 154
33 63 114 151 73 109 167
39 71 117 170 51 93 141
40 44 113 134 79 123 184
Table 8 I shows the characteristics of the hypertensive group 
compared with the normal group* Although placental weight 
was significantly lower in the hypertensive group, no signifi­
cant difference in birth weight was found.
A positive correlation between peak (36-38 week) hPL concen­
tration and birth weight was obtained (r = 0*35 p<0.01
n = 76), but no correlation between birth weight or placental 
weight and either SP^ or PAPP-A was found.
Figures 8 i - iii show the trend in placental protein concen­
tration in the hypertensive group compared with the normal 
population and Table 8 II shows the intersextile ranges.
From week 32 onwards, for hPL there was usually a significant 
difference in concentrations between the two groups, the hyper­
tensive population having lower concentrations. No difference 
in SP^ or PAPP-A concentrations was found between the groups.
The decreased hPL concentrations in the hypertensive group 
may be related to the significantly lower placental mass observed 
for this group. As SP^ and PAPP-A have been shown not to 
correlate with placental weight, the lack of difference is not 
surprising. However, several reports have alluded to elevated 
serum PAPP-A concentrations in hypertensive patients (Lin et 
al 1977V Hughes et al 1980, Klopper and Hughes I98O)•
This finding is not confirmed here and is in agreement with 
Westergaard and Teisner (1982). The differences cannot be 
accounted for by the fact that some patients were treated with 
antihypertensive agents, as no differences in PAPP-A concen­
trations were found comparing placebo treated patients with 
drug treated patients. The answer may lie in the fact that 
many earlier studies utilized plasma specimens. The observation
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that heparin levels affect the PAPP-A concentrations must cast 
doubt on the original hopeful observations regarding PAPP-A in 
hypertensive pregnancies*
From the findings presented here it is apparent that SP^ or 
PAPP-A concentrations have little to offer in the monitoring 
of placental function in hypertensive pregnancies* HPL is 
likely to remain the mainstay therefore.
8*2 Diabetic Patients
8.2*1 Objectives
The advent of insulin therapy for diabetics meant that more 
diabetic women reached childbearing age. The pregnant 
diabetic however posed many problems. She was at risk of 
developing ketoacidosis, the foetus was at risk of congenital 
malformation or intrauterine death. If delivered successfully 
the baby often encountered problems of respiratory distress 
and hypoglycaemia.
With improved preparations of insulin, improved dietary inst­
ruction and obstetric care many of these problems are no longer 
as serious. However most obstetricians still monitor their 
pregnant diabetic patients very closely.
There is however ho consensus opinion on what levels of hPL 
represent ’’normality” for the diabetic. There have also been 
links suggested between SP^ and carbohydrate metabolism (Tatra 
1976, Singh 1979)-
The possible use of pregnancy proteins in monitoring diabetic 
pregnancies still requires further investigation.
8.2.2 Clinical Material
27 pregnancies complicated by diabetes mellitus were studied,
11^
Table 8 III
Characteristics of Patients Studied
a) Diabetic patients with placental weight ^  90th centile
Placental. 
Weight (g)
Corrected 
Birth Weight (kg)
Gestation
(weeks)
Peak hPL 
(mu/1)
Peak SP. 
(mg/1)
Peak PAPP-A
(iu/l)
1 680 3-39 38 15.6 331 199
2 800 3.27 38 12.0 2o2 70
3 820 3.27 37 11.5 568 113
k 1000 **.18 38 11.2 687 15*+
5 700 **.03 38 1**.** 267 68
6 730 2.6** 36 11.6 392 225
7 730 3-3V 36 12.8 634 16**'
8 630 2.43 37+ 12.0 155 55
9 950 3-7** 38 6 .3 **86 11** -
10 860 3.63 37 10.3 527 117
11 670 **.18 38 7.6 **83 163
12 8**o 3.69 38+ 9-2 377 97
^3 700 3.26 38 9.0 233 177
b) Non diabetic controls with placental weight^ 90^ centile
1 680 3-**3 39+ 8 .2 276 87
2 800 3 .60 39 9.1 390 1**1
3 770 3.71 **0 9.7 287 90
** 900 **.16 38 9-5 >33 2***f
5 690 3.10 **0 10.** 210 113
. 6 775 3 .17 **0 7.7 289 96
7 '763 **.21 **0+ 6 .5 123 109
8 590 3.50 37+ 8 .6 **00 1*+1
9 920 3.58 39+ 9.0 125 101
10 800 **.03 **0 9-9 32** 128
11 650 3.23 39+ 8 .0 376 78
12 775 3.07 **0 7-8 287 1**0
13 770 3.71 **0 9.7 269 88
Table 8 IV
Characteristics of Patients Studied
a) Diabetic patients with placental weight ^  90*h centile
Placental 
Weight (g)
Corrected 
Birth Weight (kg)
Gestation
(weeks)
Peak hPL 
(inu/1)
Peak SP 
(mg/1)
Peak PAPP-A 
(IU/L)
1 430 3.1*1 38 6 .8 f*37 8ft
2 ^50 3.30 37+ 5.9 130 78
3 620 2.77 37+ 9.6 362 80
h 600 3.05 37 6 .0 470 27
5 610 3.f<o 38 8 .8 ft85 196
6 ^50 2.20 37 6 .9 326 70
7 5^0 3.72 38 7.8 36ft 120
8 580 3.75 38 5.1 279 129
9 630 3 .06 38 5-2 555 90
10 520 2.92 38 6.3 202 181
11 620 2.93 fto 9.7 k95 1ft 2
12 6ho 3.39 37+ 6 .8 183 89
13 530 3.13 37+ 5-3 213 127
1ft 580 3 .66 7.1 f*75 38
b) Non diabetic controls with placental weight X. 90^  centile
1 ftftO 3 .2ft . 39+ 5.^ 306 130
2 ft90 2.72 38 8.9 1ft 5 129
3 600 2.9ft fto 8.1 166 104
ft 580 2.80 fto 9.3 60 128
5 600 3.21 38f 6.3 175 175
6 ft70 2.56 37+ 7.9 261 128
7 550 3 .0ft 39+ 5-7 181 129
8 5fto 2.96 ho 7.7 300 124
9 620 3.31 ffO 6 .1 20ft 91
10 500 2 .98 39+ 7.1 216 1*t5
11 600 3 .2ft 39 5.2 2ft3 17
12 650 3-ft3 ftOf 8 .0 300 107
13 6ft0 3-77 ho 7.0. 125 113
1ft 590 3 .6ft 37 5.9 235 80
Birth v/eiqht
(kg)
SB
e©
SB
Figure 8 iv Birth weight of babies born to diabetic mothers
with placental weight> 90 centile ( 0 ) and their non­
diabetic controls ( © )• The bars represent mean + SE.
Birth weight 
(kg)
t = 0-3 
p>0*l
CD
Figure 8 v Birth weights,of babies born to diabetic mothers 
with placental weight < 9 0  centile ( □ ) and their non­
diabetic controls ( O ). The bars represent mean + SE.
Birth weight 
(kg)
t = l-5 
P>0-1
Figure 8 vi Birth weight|^of babies born to diabetic mothers 
with placental weight < 90 centi^g ( □ ) and diabetic
mothers with placental weight > 90 centile( B ). The bars 
represent mean +_ SE.
Birth weight 
(kg)
GO
t= 3 * l
p<-01
Figure 8 vii Birth weight of babies born to non-diabetic 
mothers with placental weight < 90 centile, ( O ) and non- 
diabetic mothers with placental weight > 90 centile ( © ).
bars represent mean + SE.
all patients being insulin dependent during pregnancy* All 
were under the care of a single consultant obstetrician and 
received normal clinical care associated with this condition* 
Patients were routinely admitted to hospital for stabilization 
of their diabetes, and most were delivered prior to term either 
by syntocinon induction or by Caesarian Section (LUSCS).
8*2*3 Analytical Methods
hPL, SP^ and PAPP-A concentrations were assayed as described 
previously* The birth weight and placental weight were recorded 
at delivery.
8.2*^ Numerical Analysis of Data
After delivery, patients were allocated into one of two groups 
on the basis of their placental weight being greater than or 
less than the 90 centile for their gestation. Each individual - 
was matched as closely as possible for placental weight to a 
non diabetic control subject. For each group of diabetic 
patients therefore there was a corresponding control group.
The characteristics of these groups are shown in Table 8 III 
and 8 IV. All birth weights were corrected for maternal 
weight and height (Thomson et al 1968). The corrected birth 
weights of all babies born to the control group were all ^ 1 0  
centile for weight.
The presence of significant differences between the groups was 
tested by students t test, a significant finding being taken 
as P$0.05*
8.2.5 Results •
There was no difference in the placental weights of the diabetic 
patients compared with their respective control groups, so the 
groups were well matched. Figures 8 iv - 8 vii show the birth
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hPL (mu/1)
15
H B
1 0
O Q
5
t ~ 2-9 
p o O l
Figure 8 viii Peak hPL concentrations in diabetic mothers
with placental weight > 90 centile ( ■ n ' ) and their non­
diabetic controls ( © )• The bars represent mean + SE.
h P L f m u / l )
15
10 □□
o° 
o □5
t - 5  1 
p<01
Figure 8 ix Peak hPL, concentrations in diabetic,mothers with
placental weight < 90 centile ( □ ) and > 90 centile
( B ). The bars represent mean +_ SE.
h PL(mu/l)
15
10 t =. 0 *2  
p > 0 1
Fig 8 x Peak 
placental weight 
diabetic controls (
hPL concentrations in diabetic mothers with 
< 9 0  centile ( □ ) and their non-
3 ). The bars represent mean + SE.
S Pi (mg/I)
7 0 0
6 0 0
5 0 0
4 0 0
3 0 0
200
100
o© © 
°©
t ^ 2 - 2
p < 0 5
Fig 8 xi Peak SP^ cngcentrations in diabetic mothers with
placental weight> 90 centile ( ■ ) and their non­
diabetic controls ( • ). The bars represent mean + SE-
SP± (mg/I) 
7 0 0  r
6 0 0
5 0 0
4 0 0
3 0 0
200
100
Fig 8 xii Peak SP^ concentrations in diabetic mothers with
placental weights < 90 centile ( □ ) and their non-diabetic
controls ( O ). The bars represent mean +_ SE.
S Pi(mg/I)
7 0 0
6 0 0
5 0 0
4 0 0
3 0 0
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100
□
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p > 0 #l
Figure 8 xiii Peak SP concentrations in diabetic mothers 
with placental weights <90 centile ( □ ) and diabetic
mothers with placental weight >90 centile ( o ). The 
bars represent mean + SE.
2 5 0
200
■ E
150
1 0 0
50
Figure 8 xiv Peak PAPP-A concentrations in diabetic mothers
with placental weights 90 centile ( n ) and their non-
diabetic controls ( • )» The bars represent mean + SE.
PAPP-A ( iu / l )
2 0 0
150
100
50
t = 0-7 
P>0*1
Figure 8 xv Peak PAPP-A concentrations in diabetic mothers
with placental weights < SO centile ( □ ) and their
non-diabetic controls ( O ). The bars represent mean + SE.
weights for diabetics and controls with placental weight 90xn
centile, diabetics and controls with placental weight < 90^
th
centile, diabetics with placental weight < 90 centile and
thdiabetics with placental weight > 90 centile, and non diabetic
controls with placental weights < 90^  centile compared with
thcontrols with placental weights > 90 centile. Only in these 
latter groups was a significant difference in birth weights 
observed.
Figure 8 viii shows hPL levels in diabetics and controls with
thplacental weights > 90 centile. HPL was significantly higher 
in this group of diabetics compared with their non diabetic 
controls (p <0 .01).
Figure 8 ix shows hPL levels in the two diabetic groups (plac- 
ental v/eights <90 centile and >90 centile). HPL con­
centrations were higher in the diabetics with the larger
placentas (p<0.01). However there was no difference in hPL
1.1.
concentrations between diabetics with placental weights < 9 0  
centile and their non diabetic controls (Fig 8 x).
Figures 8 xi and 8 xii show SP^ levels in diabetics with plac-
thental weights ^ 90 centile compared with those in their non
' th 'diabetic controls and in diabetics with placental weights < 90
_ centile compared with those in their non diabetic control's.
No difference in SP^ concentrations existed when diabetics
thwith placental weights > 90 centile were compared with diabetics
s thwith placental weights <90 centile (Fig 8 xiii)•
No difference in PAPP-A concentrations existed between diabetics
thwith placental weights > 90 centile and their controls (Fig
th8 xiv), diabetics with placental weights■< 90 centile and
their controls (Fig 8 xv) or between diabetics with placental
th -
weight ^ 90 centile and diabetics with placental weight \ 90th centile.
116
8.2.6 Discussion
A considerable literature now exists on the use of serum hPL 
measurements in the investigation of pregnant diabetic patients. 
Letchworth in a review (1976) reported that some workers found 
that hPL was higher than in normal pregnancy whereas others 
have found normal concentrations. The value of hPL measure­
ment in assessing placental function in the diabetic patient 
remains uncertain. The results obtained here show no signifi­
cant differences in serum hPL concentration between diabetic
thand non diabetic women with placental weights K. 90 centile.
In this type of diabetic subject, low hPL concentrations such 
as those reported by Ursell et al (1973) may indeed be indic­
ative of poor placental function.
■ ■ th
When placental weights were ^  90 centile a difference between
diabetics and non diabetic subjects became apparent, the diabetics
as a group having higher serum hPL concentrations. However
the birth weights of babies born to diabetic patients were
similar in the two groups irrespective of placental size. This
is in contrast to the findings in non diabetic women where the
thwomen with placental weights ^  90 centile gave birth to babies 
whose birth weights were significantly larger than those in 
women with smaller placentae. This is to be expected from the 
correlation previously found between placental and birth weight.
It seems therefore that there are fundamental functional differ­
ences between the hypertrophied placenta of the diabetic patient 
and the placenta of equivalent weight in the non diabetic subject.
Although clinical control of the patients as judged by blood 
glucose and haemoglobin A.1(; was satisfactory and the outcome 
ofx‘pregnancy was satisfactory, it may be that the elevated
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the elevated serum hPL levels reflect poorer control as evidenced 
by the hyper-placentation, rather than good placental function*
In contrast, serum SP^ concentrations in both groups of dia­
betics were significantly higher than those in their respective 
control groups* However no significant difference was found 
between the serum SP^ concentrations in the two groups of • 
diabetics* These findings suggest that the higher SP^ concen­
trations in the diabetic are associated with the diabetic 
process rather than placental mass*
The metabolism and function of these proteins are not under­
stood* Both are released from the syncytiotrophoblasts 
but hPL has a half life of 15 minutes whereas the half life 
of SP^ is about 30 hours. It is known that hPL has diabeto­
genic properties (Felig 1977) • This and the short half life 
argues in favour of participation in the immediate control of 
carbohydrate metabolism.
The relationship between SP^ levels and carbohydrate is 
equally unclear* Tatra (1976) found elevated SP^ levels 
after insulin induced hypoglycaemia and Singh (1979) found ~ 
SP^ concentrations above the mean in a number of patients 
showing abnormal glucose tolerance tests. Grudzinskas (1979) 
however found SP^ concentrations lying between the 80$ 
confidence limits* Gemmell (1982) found a wide scatter of 
SP^ concentrations 7k% of results falling within the normal 
range.
All these studies however plotted SP^ concentrations against 
the normal range* No attempt was made to match patients for 
placental weights against non diabetic controls. This may 
account for the findings in this study. It is interesting
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were clinically well controlled. Further investigation 
of SP-j and hPL measurements in relation to carbohydrate meta­
bolism are necessary.
Sutcliffe e t a l ( 1982) and Lin et al (1977) showed PAPP-A 
levels to be slightly decreased compared with non diabetic 
levels, although in the latter study the difference was not 
significant. This study does not confirm these findings.
There was no significant difference in PAPP-A concentrations 
between either diabetic group and their non diabetic controls. 
Similarly there was no difference in PAPP-A levels in diabetics 
compared with the overall population. PAPP-A estimation is 
unlikely to be of use in monitoring diabetic pregnancies.
Whilst the findings relating to SP^ levels in pregnant dia­
betics are of interest, a wider study is required before a 
use for this protein in monitoring pregnancies complicated by 
diabetes can be recommended. With the improvement in diabetic 
care it may be argued that intensive care of the pregnant 
diabetic is now less important. Nonetheless most obstetricians 
still monitor placental function closely in this condition. 
Providing the constraints mentioned are borne in mind, hPL is 
likely to remain in favour as a monitor of placental function.
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CHAPTER 9
USE OF THE ONCODEVELOPMENTAL PROTEINS AS INDICATORS OF TUMOUR 
ACTIVITY
9.1 Introduction
The abnormal cellular function seen in neoplastic cells is 
often reflected in.the elaboration of the oneo-developmental 
proteins by cells which do not normally produce them (ectopic 
production) or in excess quantities by cells normally producing 
them (eutopic production)•
Use has been made of a number of these proteins in diagnosis 
and monitoring of a variety of tumours for many years, in 
particular hCG for choriocarcinoma and teratoma, AFP for liver 
tumours and CEA for colonic tumours.
It is possible that the more recently discovered oncofoetal 
antigens may offer an advantage over existing markers in terms 
of earlier prediction of relapse. Alternatively these antigens 
may be effective as markers of tumours which are conventionally 
regarded as marker negative.
These approaches will be studied by consideration of testicular 
teratomas, for which conventional markers and recognized therapies 
exist, testicular seminomas for which no conventional markers 
exist but therapy is effective, and ovarian cancer for which 
no conventional markers exist and therapy is often ineffective.
9*2 Methods of Assay
The oncodevelopmental proteins AFP and hCG were assayed using 
the methods detailed in Chapter 2. CPAP, SP^ and PAPP-A were 
assayed by ELISA as detailed in Chapter 3* The ELISA for SP^ 
was sensitized as described and the assay for PAPP-A was sen­
sitized in a similar manner*ie by prolonging the incubation 
times, and omitting pre-dilution of serum samples.
Details of the assay performances over the period of this study 
are shown in Table 9 I.
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Table 9 1
The Oncodevelopmental Proteins as Tumour Markers: Details of Assay
Performance
AFP hCG CPAP SP1 PAPP-A
Number of Assays 30 27 22 22 12
Mean QC Con­
centrations
50.0
iu/ml
48.1
miu/ml
1.05
iu/1
55.8 71 .6
iu/ 1
Overall Standard 
Deviation 4.5 2.4 0 .16 3.26 8.5
Coefficient of 
Variation % % 15.5^ 5 M 11.9#
Mean Detection 
Limit
3.^
iu/ml
2.1
miu/ml
0 .1 2
iu/ 1
5-6
jig/1
3.6
iu/ 1
Normal Range 0-15 
' iu/ml
0-5
miu/ml
0-2.0
iu/1
-
9*3 Investigation of Oncodevelopmental Protein Concentrations
in the Normal Population
For certain of the analytes measured, knowledge of the reference 
range already existed either from previous work (eg for AFP) 
or from this study (eg for hCG, CPAP) (Table 9 1)• However, 
when SP^ and PAPP-A levels were assayed in sera from a group 
of laboratory staff, many were found to have concentrations 
below the limit of detection of the assays. Assignment of 
a reference range could therefore not be made in the usual way 
and discussion of concentrations of these proteins will be 
made by reference to the detection limits (Table 9 I)•
9*4 Patients Studied
9*4.1 Specimens from Patients
As the intention was to investigate the occurence of certain 
oncodevelopmental proteins 'in neoplasia only patients on whom 
pre-operative specimens were available were included in this 
study. On some patients, serial post-operative specimens 
were also obtained. In some instances, insufficient sample 
existed for the assay of all proteins.
9*4.2 Patients with Testicular Teratoma
25 patients were investigated of which 7 were classified as
stage I, 6 as stage II,3 as stage III and 9 stage IV on histo­
logical grounds•
9*4.3 Patients with Testicular Seminoma
13 patients were investigated. All diagnoses were confirmed
by histology.
9*4.4 Patients with Ovarian Carcinoma
Pre-operative specimens were obtained from 29 patients. All
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Figure 9 i Pre-operative onco-developmental protein 
concentrations in Patients with Testicular Teratoma.
represents the upper limit of normal 
represents the mean detection limit
Table 9 II
Occurence of Pre-operative Markers in Patients with Testicular 
Teratoma
Patients AFP hCG spi PAPP-A CPAP Stage
PB + + + ' ' + ■ IV
FMcC + III (Died)
IS + + IV
JSc + .. + + + II
BL + + + + ■ + IV
JSt + + IV (Died)
GM I
AW + + + . + TV (Died)
LM + I
MH + + + II
AS + + + IV
AK I
TMcN II
DH + + I
JB + + I
CS + + III
JD + + ' + II
AA + + II
TP + + IV
DM + + IV
DN . + , + I
SM + + IV
RC + ■ +' . I
DC . + II
NG + III
tumours were examined by the same pathologist in order to 
ensure consistency of diagnosis. 11 patients were suffering 
from poorly differentiated adenocarcinoma, 9 had papillary 
cystadenocarcinoma, 3 had adenocarcinomata of endometrioid 
type and 2 were borderline. There were also 3 individual 
casesj1 of malignant teratoma, 1 of granulosa cell tumour and 
1 mucinous cystadenocarcinoma. In the final patient a full 
pathology report was not available.
9*5 Results
9*5*1 Normal Subjects
3/25 (12#) of normal male sera and 5/33 (15$) of normal female 
sera were found to contain SP^ concentrations above the mean 
detection limit (5*6 pg/1)•
For PAPP-A concentrations in normal sera, the figures were 11/2^ 
(k6%) and 13/ 2k (56$) respectively.
9.5.2 Patients with Testicular Teratoma
The concentrations of the various oncodevelopmental proteins 
found in this group of patients pre-operatively are shown in 
Figure 9 i and Table 9 II* One patient had an elevated CPAP 
concentration. 72# of patients had elevated AFP and 68# 
elevated hCG (Table 9 • On combining these conventional
markers of teratoma, 60# of patients showed elevation of both 
AFP and hCG. The worst detection limit achieved during SP^ 
assay for this group of patients was 7 .8 pg/1; ^0# of patients
had SP^ concentrations in excess of this. Similarly, for 
PAPP-A, 30# of patients had' concentrations exceeding the worst 
detection limit which in the present context is taken as the 
decision threshold. The use of serial marker assays in the
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Figure 9 ii Patient PB was a 21 year old with 
teratoma of the® testis. Following orchidectomy 
he commenced chemotherapy. He was found to have 
retroperitoneal metastases and underwent lymph node 
dissection. He is now in clinical remission and 
remains marker free.
( B ) AFP .(*.□ ) HCG ( a ) PAPP-A ( O ) SP^
Broken lines indicate results remaining within normal 
range to present.
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Figure 9 iii Patient SM was a 27 year old with teratoma 
of the(S) testis. Following orchidectomy he received two 
courses of chemotherapy. However he developed a differentiated 
adenocarcinoma (with no evidence of yolk sac elements) and 
received interferon. He remains alive.
( ■ ) AFP ( □ ) HCG Broken lines indicate results 
remaining within normal range to present
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Figure 9 iv Patient JS was a 32 year old with teratoma of 
the(R) testis and lymphatic spread* Post orchidectomy he 
underwent chemotherapy and XRT* followed by a further course 
of chemotherapy* Clinical remission was achieved and the 
patient remains alive and.well.
( e ) AFP ( n ) HCG ( A ) PAPP-A ( O  ) SP
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Figure 9 v Patient FMcC was a 19 year old with teratoma of 
the (5)testis. Following a course of chemotherapy, there was
evidence of recurrence and a second course of chemotherapy was 
commenced. However the patient's condition deteriorated and 
he died weeks post orchidectomy. At post-mortem examination 
evidence of pneumococcal meningitis was found together with lung, 
liver, and para-aortic node metastases.
( □ ) HCG ( O ) SP1
2 5
20
15
10
miu/ml iu/l pg/l
- 5 25 50 -
•
•
- • 4 - 20 40 -
•
■ •
3 15 - 30 -
•
•.,j ■ 
•
2 ----- 10 - 20
• ■
.
•
•
•• A
• .
• •
• 5- - M  1 0 .
• • • o«®
•
•
e 
• • —4
------ 1 —  i . . .—.• i
* iu/l
H CG C PAP SP PAPP-A
Figure 9 vi Pre-operative Oncodevelopmental Protein Con- 
.centrations in Patients with seminoma.
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Table 9 H I
Occurence of Pre-operative Tumour Markers in Patients 
with Testicular Seminoma
Patient AFP hCG CPAP spr PAPP-A
AW ■ +  .
SC
DP
AG +
AS +
GW + +
JC + ' ■ +
GB ■ + + + . +
JL +
HP +
TMcG + +
JMcG + ■ +  .. . . +
RMcD + +
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Table 9 IV
Occurence of Pre-operative Markers in Patients with Ovarian Cancer
Patient AFP hCG CPAP f SP1 PAPP-A Diagnosis
JMcC + Cystadeno Carcinoma
MC -+ : ■ + + Papillary cystadenocarcinoma
ABi + + Papillary cystadenocarcinoma
AM + + ■+ Endometrioid
GMcF + + + Papillary Cystadenocarcinoma
MG + + . ■ ■ Borderline
AMcC + Adenocarcinoma
MMcD + Adenocarcinoma
EB Endometrioid
AF Papillary cystadenocarcinoma
CC Adenocarcinoma
MSn Mucinous cystadenocarcinoma
MSi Papillary cystadenocarcinoma
MB + Borderline
MP + + Papillary cystadenocarcinoma
JH Poorly differentiated adenocarcinoma
BB + Poorly differentiated adenocarcinoma
ABr ■.+ ' + Granulosa Cell Tumour
EM + + Endometrioid
IJ + + Papillary cystadenocarcinoma
MM + Adenocarcinoma
EB + + + Adenocarcinoma
IC Malignant Teratoma
MF Papillary cystadenocarcinoma
VS Papillary cystadenocarcinoma
EHi + Adenocarcinoma
EHu Adenocarcinoma
MD Papillary cystadenocarcinoma
MG Adenocarcinoma
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monitoring of patients during and after therapy are shown for 
A patients in Fig 9 ii - 9 v.
9-5*3 Patients with'Seminoma:-
No patients exhibited elevated AFP concentrations prior to 
therapy. Concentrations of other oncodevelopmental proteins 
pre-operatively are shown in Fig 9 vi and Table 9 III. 23% 
of patients had elevated hCG concentrations, J>d>% had elevated 
CPAP concentrations, whilst &9% and 3&% respectively had 
elevated SP^ or PAPP-A. Few patients had elevated markers 
in combination (Table 9 II)« Serial results from k patients 
are shown in Fig 9 vii-9 x.
9.5.A Patients with Ovarian Carcinoma
The results obtained in this group of patients are shown in 
Fig 9 xi and Table 9 IV. No patients showed elevated hCG 
concentrations and in only 2 patients were there mild eleva­
tions of both SP^ and PAPP-A and 2“\% elevation of both CPAP 
and PAPP-A. Only 1*4% had a raised CPAP in conjunction with 
a raised SP^ concentration.
Serial results from 3 patients are shown in Fig 9 xii -9 xiv. 
9*6 Discussion 
•9*6.1 The Normal Population
The detection of oncodevelopmental proteins in the sera of 
normal subjects is largely due to improved assay sensitivity. 
Whilst the presence of AFP, hCG and CPAP in the. sera of normal 
subjects is generally accepted (Ruoslahti and Seppala 1971* 
Borkov/ski and Muquardt, Haije et al 1979) * the situation is 
less clear regarding SP^ and PAPP-A.
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Detection of SP^ in the non pregnant subject has been reported 
(Anthony et al 1 9 8 0 b, Tatarinov 1 9 8 2 )* The proportion of 
subjects depends upon the sensitivity of the assay. In the 
present study SP^ concentrations above the mean limit of 
detection are found in approximately 12% of males and 1 5% of 
females.
Figures have been reported for PAPP-A in a non pregnant pop­
ulation. Bischof et al (1981 b) detected PAPP-A in 100% 
of non pregnant women. The detection rates presented here 
whilst not as high as those of Bischof, could be consistent 
with a later postulate of extra-placental production (Bischof 
et al 1 9 8 2 , Duberg et al 1 9 8 2 ).
The fact that PAPP-A was detected in male serum suggests that 
a source other than decidua or endometrium is responsible for 
at least a proportion of the protein. It may be that PAPP-A 
has been fortuitously designated as pregnancy associated 
rather than pregnancy specific.
9*6.2 . Patients with Testicular Teratoma
A teratoma is a tumour composed of various tissues chaotically 
arranged and usually of the most diverse types, with no relation 
to the site of origin (Muir 1 9 8 0 ). Malignant teratoma of the 
testis accounts for 1% of all malignant tumours in males. The 
incidence appears to be increasing and until recently they 
ranked as the most common fatal cancer in men aged 25-3^ (New- 
lands at al 1 9 8 3 )« However new chemotherapeutic regimes have 
greatly improved the outlook for the patient with testicular 
teratoma (Hainsworth and Greco 1 9 8 3 )*
The availability of tumour marker assays is regarded as an 
essential component of staging workup and follow up of these
patients CHainsworth and Greco 1983)* Furthermore multi­
variate analysis has shown that the strongest predictor of 
survival is not the clinical and radiological extent of the 
disease, but the initial serum concentration of hCG and AFP 
(Newlands et al 1983)•
The occurence of elevated hCG concentrations in 68& of patients 
and elevated AFP concentrations in 72$ of patients with teratoma 
found in this study are in accordance with previously published 
data (Braunstein et al 1973* Blacker et al 1981, Waldman and 
Mclntire 197^)• Differing positivity rates quoted by various 
groups are related to different patient populations and assay 
procedures.
Successful eradication of the disease results in decline of these 
markers to within the normal range (Patient PB Fig 9 ii)-, and 
they remain normal unless there is recurrence of the disease - 
as with patients JS and FMcC (Figs 9 iv and v) . On the grounds 
of rising hCG concentrations (there was no clinical evidence 
of tumour recurrence), JS received further chemotherapy and 
eventually went into remission, remaining alive and well. In 
this case hCG estimation allowed early recommencement of treat­
ment which would have been delayed had the clinician waited 
until symptoms were apparent. These conventional marker levels 
must however be interpreted with caution. The decline in AFP 
and hCG observed in patient SM (Fig 9 iii) indicated that the 
tumour had been successfully eradicated. However in this case 
the teratoma had differentiated to form an adenocarcinoma with 
no evidence of yolk sac elements and this later tumour was marker 
negative for AFP and hCG.
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It is apparent'that for patients with teratoma, hCG and AFP 
are useful markers. The question remaining is whether alter­
native markers will be more useful. The results show that 
there is a lower positivity rate for either SP^ or PAPP-A than 
for hCG or AFP. Thus neither SP^ or PAPP-A are likely to 
replace conventional markers for initial disease workup. In
vJ
only 2 cases (patients 9 and 15) were SP^ or PAPP-A elevated 
above the detection limit without concomitant rise in hCG or 
AFP.
Concordant elevation of hCG and SP^ in patients with testicular 
teratoma has been reported previously (Blacker et al 1981, Lange 
et al 1980). It is further reported that SP^ is elevated only 
in a small percentage of patients who do not have elevation of 
conventional markers (Lange et al 1980). This finding is in 
accordance with the results obtained in the present study.
In the patients under study who showed elevated SP^ or PAPP-A 
levels prior to surgery, the possibility of improved lead-in 
times using these markers remains open to question. In most 
cases neither SP^ or PAPP-A concentrations rose significantly 
in advance of conventional markers.
Occasionally, however, rising*SP^ nor" PAPP-A would have allow'ed 
earlier clinical intervention (patient JS). Even with later 
intervention* clinical remission was still achieved and it is 
therefore arguable whether estimation of these alternative markers 
offers therapeutic advantage.
Opinions on this subject vary. Lange et al (1980) in a small 
number of patients found SP^ levels provided useful clinical 
information not given by hCG or AFP. Blacker (1981) also
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suggested use bf SP^ assays in this situation but stated that 
elevated SP^ levels were generally accompanied by elevated hCG, 
which would tend to negate the use of SP^. It seems unlikely 
that the use of hCG and AFP in monitoring therapy of patients 
with testicular teratoma will be replaced, by assay of SP^ or 
PAPP-A.
9»6»3 Patients with Seminoma >
Seminoma is the commonest malignant tumour of the testis (Muir 
1 9 8 0 ) comprising about kO%> of testicular germ cell tumours.
As these tumours are remarkably radiosensitive, radiotherapy 
is the treatment of choice. No patient with seminoma should 
exhibit raised AFP concentrations because there are no yolk 
sac elements,- and only 5-10^ of patients have raised hCG con­
centrations (Hainsworth and Greco 1 9 8 3 )* There is a need for 
a reliable marker in patients with seminoma.
Recent evidence suggests that an alkaline phosphatase having 
properties of the placental isoenzyme exists in normal testicular 
tissue and may be useful as a marker for seminoma (Paiva et al 
1983)« .
3 8$ of patients in this study showed elevated CPAP pre-operatively. 
•This occurence is lower than that reported by other groups (Jepp- 
sson et al 1 9 8 3 * Javadpour 1983i Paiva et al 1 9 8 3 , Lange et al 
1982). Strict comparison with these results is not possible 
as other groups have measured protein concentration rather than 
enzyme activity.
Two of the 5 patients in whom CPAP was raised before operation 
demonstrated an abrupt fall in CPAP activity after treatment 
to within normal limits; these patients remain alive and well
12?
at 50 and weeks after operation. No further samples have 
been assayed on these patients (JMcG and JC Fig 9 vii and viii).
In the third patient patient GW (Fig 9 ix) there was a slight 
increase in CPAP after operation. Eight specimens were analysed 
over the following 60 weeks and all remained elevated or at the 
upper limit of the reference range. These findings may represent 
a combination of biological and analytical variability in a sub­
ject whose CPAP is normally at the upper extreme .of the reference 
range. This patient also remains alive and well at 90 weeks 
post-operatively. CPAP activity in the fourth patient (GB 
Fig 9 x) remained elevated for many weeks after operation and 
radiotherapy. Although eventually CPAP activity fell to within 
normal limits, subsequently an increase was detected and the 
patient died. Secondary deposits were detected at autopsy.
No further specimens have been received on the fifth patient 
with pre-operatively raised CPAP.
The 8 patients with normal CPAP activity before operation remain 
alive and well.
Only 3 out of 7 patients had raised serum hCG concentrations 
2 of which also had a raised CPAP activity. Similar results 
have been reported by Lange et al (1982). The significance 
of the raised hCG is the subject of some debate but may indicate 
that these patients have a mixed tumour rather than a pure sem­
inoma (Cochran 1976, Kuber et al 1983)* There is insufficient 
data to decide whether or not serum hCG (when present) reflects 
the clinical course of the disease more accurately than CPAP. 
Lange et al (1982) were also unable to decide upon this point.
PAPP-A concentrations were above the assay detection limit in 
V13 patients, of which 3 also had raised CPAP. In patient
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JC (Figure 9 viii), PAPP-A concentrations mirrored CPAP- In 
patient GB, PAPP-A declined to below the detection limit and 
remained there despite clinical evidence of progression of dis­
ease* •
Conversely, in patient JMcG (Figure 9 viii), PAPP-A levels declined 
initially but became elevated again. Despite this finding, 
the patient showed no sign of progression of disease.
In a fourth patient PAPP-A declined to below the assay detection 
limit post operatively; the patient showed no signs of progression.
69/6 (9/^3) of patients had SP^ concentrations above the mean 
limit of detection. However, of these, 6 were close to the 
mean assay limit of detection and must be interpreted with caution 
due to analytical noise. Only 3/^3 patients showed signific­
antly elevated SP^ concentrations, 2 of whom also had elevated 
CPAP.' ■
In patient JMcG, SP^ levels show a similar trend to PAPP-A and . 
do not correspond with the patients clinical condition.
No further specimens were received on the second patient with 
elevated SP^ and CPAP.
SP^ concentrations in the patient with no concomitant rise in 
CPAP, declined to normal post operatively and remained thus.
The patient remained well with no sign of residual disease.
Lange et al (1980) in a study of patients with seminoma found 
elevated SP^ in some cases usually with a corresponding elevation 
in hCG. Szymendera (1983) showed similar results, but neither 
of these authors clarified the usefulness of the test.
From the data presented here it seems that SP^ is unlikely to 
be of value in monitoring patients with seminoma, as it is
129
elevated in only a small proportion of patients and usually 
*
in combination with CPAP. From initial investigations CPAP 
appears to be the preferable marker now that a simple, sen­
sitive and specific assay is available*
9 * 6 . Patients with Ovarian Carcinoma
Because^ of its histologic complexity, the ovary gives rise 
to benign and malignant tumours of epithelial, stromal and 
germ cell origin (Young et al 1 9 8 2 ). In the post-menopausal 
woman, germ cell tumours account for only about 10% of cases.
The major problems in diagnosis and treatment of the epithelial 
group have been the early spread of the disease coupled with 
the lack of early signs and symptoms accounts for the fact 
that most patients already have spread throughout the perit­
oneal cavity when diagnosis is made (lewis 1 9 8 3 ) •
Furthermore until recent years there has been a lack of tumour 
markers reported for most cases of ovarian cancer other than 
hCG and AFP. for ovarian teratomas.
In common with other groups, (Koh and Cauchi 1 9 8 3 , Cauchi et. 
al 1 9 8 1 , Haije et al 1979), the results obtained here show 
that AFP or hCG estimations are of little value in diagnosis 
and monitoring of ovarian cancer.
'However, the other antigens investigated appear initially to 
offer more hope for following therapy. Elevated levels of 
SP^, PAPP-A and CPAP were found in about 1/3 of cases, although 
not necessarily in combination.
As in previous cases, the positivity rate is too low to assist 
in diagnosis. This leaves the possibility of using these 
markers as indices of treatment and progression of disease.
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Even this may not be feasible for PAPP-A because of the wide 
scatter of concentrations found in normal female subjects (Fig­
ure 9 v)• Thus in patient AB (Figure 9 xii) rising PAPP-A 
concentrations might suggest recurrence of disease* All clini­
cal evidence is against this. Similarly although the SP^ 
level declined post-operation, SP^ still remains detectable 
in this patient*s serum.
Patient EM (Figure 9 xiv) has evidence of recurrent disease. 
Unfortunately no further blood specimens were received from 
this patient. It is possible that the elevation of SP^ at 
20 weeks post operation might have been the first evidence 
of recurrence. However PAPP-A and SP^ were both elevated 
prior to operation, but show divergence at 20 weeks. It is 
equally likely that the SP^ elevation is entirely spurious.
Similar patterns are evident in other patients not discussed 
in detail. It seems unlikely therefore that either PAPP-A 
or SP,j reflect tumour mass or recurrence. Bischof (1982 c) 
reached the same conclusion regarding the use of PAPP-A in 
nontrophoblastic tumours.
The use of CPAP in patients with non germ cell ovarian cancer 
has been suggested by Kellen et al (1978). Although their 
data may be criticized in that the blood specimens taken were 
post operation, the incidence of positive sera (35%) accorded 
well with the indidence for pre-operative specimens presented 
here.
However as with SP^ and PAPP-A, CPAP levels do not seem to 
correlate with the course of disease for most patients in this 
study eg patient MB (Figure 9 xiii).
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From the results obtained so far it seems unlikely that any 
of these proteins will be of value in following disease in 
patients with ovarian cancer.
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CHAPTER 10
GENERAL DISCUSSION
The discovery of an increasing number of onco-developmental 
proteins (Klopper 1982) poses problems for both clinician and 
biochemist.
Clinical interest in these proteins is diverse. Firstly 
the obstetrician wishes to know whether the measurement of 
•placental' proteins will aid his management of the pregnant 
patient. Secondly the oncologist requires a marker of tumour 
activity both to aid in diagnosis or prognosis of disease and 
to act as an index of tumour regression during therapy.
None of these functions can be fulfilled until the biochemist 
has devised a satisfactory assay for the protein in question.
The assays of choice have been based on immunological techni­
ques. Whilst serum concentrations of some placental proteins 
can be measured by relatively insensitive techniques such as 
immunoelectrophoresis, radial immunodiffusion or nephelometry 
(Schultz-Larsen et al 1979), • there may be a necessity for 
greater • sensitivity (Pledger et al 1981) and.many groups have 
devised radioimmunoassays for these proteins. Whilst widely 
used, radioimmunoassay is not a perfect tool and the problems 
associated with it led to alternative systems being developed, 
such as the use of enzyme labels as described by Van Weemen 
and Schuurs (1971) and Engvall and Perlmann (1972).
ELISA made rapid inroads in certain areas of laboratory med­
icine notably bacteriology and virology where it was ideally 
suited to detection (if not quantification) of antibodies.
Clinical chemists however have been more reticent about its 
use and RIA still plays a major part in specific protein assay. 
Part of this reticence may be explained by the fact that 
ELISA has certain problems associated with it. As RIA was
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already in use it was felt that changing assay systems (with 
capital expenditure involved) was not justifiable*
However, investigation of the factors involved in ELISA 
should make possible the more rapid development of improved 
assays.
Some RIA was already in use in this department. V/here suit­
able assays existed, the associated parameters were investi­
gated to ensure their continued suitability for use in this 
study (Chapter 2)*
V/here it was necessary to design assays for proteins not prev­
iously measured in the department, ELISA was used (Chapter 3)•
An assay for SP^ was used based on that originally described 
by Macdonald e.t al (1979) - This was further investigated 
to allow a more sensitive assay for use in monitoring SP^ 
as a tumour marker. At this stage problems with the SP^ 
content of normal serum became apparent, necessitating experi­
ments to ensure removal of endogenous SP^ from standard pre­
parations (3®5)» Close investigation of Macdonalds assay 
and the sensitized assay showed them to be suitable for clinical 
use.
Based on similar principles, an ELISA, f©r PAPP-A was developed. 
Again investigation of this showed it to be suitable for measur­
ing PAPP-A concentrations in patients® sera* In the course 
of assaying patient samples for PAPP-A it was noted that haem­
olysis caused interference. Investigation of this effect 
showed it to be specific to PAPP-A and it was concluded that 
only non-haemolyzed specimens should be measured. This was 
in addition to observations made previously by other groups 
for the collection of specimens for pregnancy associated protein
13A
assay (Toop and„Klopper 1983, Sutcliffe 1982).
Elevated PAPP-A concentrations were found in a proportion of 
samples from non pregnant patients as had already been noted 
for SP^. The source of these proteins in non pregnant normal 
subjects remains uncertain, but a number of possibilities have 
been suggested (Bischof et al 1982 a/b, Bischof et al 1983»
Duberg et al 1982). The recognition of detectable levels 
in normal subjects is probably a function of assay sensitivity. 
Whilst this is unlikely to be of importance in the application 
of the assays to the monitoring of placental function, where 
concentrations are considerably elevated, it may cause problems 
where they are used as tumour markers. The ELISA methods 
for SP^ and PAPP-A and the immunoenzyme technique for CPAP 
have been shown to be suitable assays for the measurement of 
these proteins; all of the assays may be adjusted to tailor 
the detection limits and assay range to the clinical requirement
Whilst problems specific to assays for these proteins were 
investigated in this thesis there are however also disadvantages 
common to all sandwich ELISA. The glowing description given 
by Hoskings (1982) would at first sight seem to imply perfection
Are these problems sufficiently great to significantly disad­
vantage ELISA in favour of RIA?
The effect of differing protein matrices on performance has 
already been alluded to (3«5 *^ ) but this is also common to 
many RIA's (Hunter 1972, Hunter and Bennie 1979)*
Microtitre plates form an ideal method of dealing with a large 
number of specimens in a single batch and have proved to be 
superior to various plastic beads in terms of antibody coating
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qualities. However, some variation between different types 
of plate has been noted. Each of these observations has 
implications for the sensitivity and precision of the final 
assay. '
In common with previous observations (Engvall and Perlmann 
1972, Lehtonen and Viljanen 1980) a leakage of bound antibody 
from the microtitre plates was found. This effect seemed 
to depend partially on the protein concentration in the test , 
matrix. However, a reasonably high protein concentration 
was found to be advisable in order to reduce non specific 
binding. When designing ELISA systems investigation of the 
time course of reaction is essential.
The importance was emphasized by the occurence of an excess 
antigen effect (^.9) possibly akin to the *hook* reported 
by Engvall and Perlmann (1972) and since recognized in immuno- 
radiometric assays. The effect seen in ELISA seemed to depend 
only on antigen concentration. Once such problems have been 
observed assay design may be modified in order to circumvent 
them. All of the problems encountered in this study were 
overcome by such modifications. It therefore seems possible 
that ELISA can be a viable alternative to RIA for the deter­
mination of oncodevelopmental proteins. However, it is essential 
that some form of data reduction is available for the routine 
application to patient care. Investigation of several assay 
systems (Chapter 5) showed that methods already in use for 
RIA could be applied with only minor alteration to ELISA.
The use of these in conjunction with the microtitre plate 
format of tests allows the processing of large numbers of 
specimens.
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It is suggested^that as laboratory equipment associated with 
RIA becomes due for renewal, biochemists should seriously 
consider the use of ELISA for certain analytes.
However the clinical chemistry laboratory does not exist for 
its own edification. Whilst ELISA and RIA have been shown 
to be viable test procedures, the provision of any test should 
be dependent on clinical need. The question must be asked 
as to whether analysis of the onco-developmental proteins can 
provide useful adjunct in diagnosis and management of patients.
What criteria must be applied in order to assess this usefulness? 
All too often, little thought is applied to this concept.
For many years the concept of a *normal range* has been applied 
although this has many limitations. Perhaps the time has 
come to adopt Galen and Gambino*s phrase (1975) and to progress 
*beyond normality*. This approach makes no prior assumptions 
about the distribution of data, is applicable to any type of 
test and more importantly provides a common baseline for mean­
ingful comparison. However under this critical examination, 
test performances may not seem as perfect as we often think.
The use of multiparametric tests in the field of diagnostic 
oncology has been proposed by a number of authors (Schwartz 
1973» Sussman et al 19751 Cooper et al 1975)• Problems with 
the assessment of normality in this situation have been 
alluded to (Weldon and Mackay 1972). Applying Galen and 
Gambino's approach (1975) the fallacy of multiparametric 
diagnostic testing becomes apparent; the predictive value 
of a positive result in these circumstances can be so low 
as to be useless.
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The battery test approach may be of use in order to find a 
positive tumour marker for following response to therapy in 
an individual patient. Test selection must be made carefully 
in this instance if the procedure is to be cost effective.
A number of biochemical tests of placental function have been 
proposed (Wilde and Oakey 1975)* Interpretation of the results 
of these must be made against the background of a population 
similar to the one under investigation. For this reason a 
study of normal pregnancies was undertaken. Rather than eval­
uate the usefulness of the tests against a broad spectrum of 
problems, specific aspects only were investigated.
Application of the techniques of Galen and Gambino (1975) was 
used in this thesis to assess the usefulness of hPL estimation 
in detection of IUGR and the continued use of hPL estimation 
for detection of IUGR and conversely for reassurance in patients 
thought to have IUGR can be recommended (Chapter 7)• SP^ 
and PAPP-A appeared to be of little use in these situations. 
Whilst there is increasing use of ultrasound and CTG,as non- 
invasive methods of measuring placental function, it is inter­
esting that a recent document reported "no consensus that
routine ultrasound /Te screening improved perinatal
outcome or decreased morbidity and mortality" (Leader, Lancet 
198*0. The continued measurement of hPL concentrations to 
diagnose and assist the management of LFD pregnancies seems 
worthwhile.
Whilst eclampsia is seldom encountered in modern obstetric 
practice, pregnancy induced hypertension (pre-eclampsia) is 
still relatively common. As there are implications for both 
mother and foetus^early detection and continued monitoring 
are vital. The report by Hughes et al (1980) that PAPP-A
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levels were elevated in women who went on to develop PIH 
suggested that this estimation may provide a suitable screening 
test. The findings in this thesis however do not support 
this claim. Possible reasons for this are discussed in 
Chapter 8, but the use of PAPP-A in this context must be 
regarded critically.
Again, only hPL gave levels which differed from patients with 
normal pregnancies and this finding may be related to the 
lower placental weight found in the hypertensive mothers and 
it is questionable whether comparison with the reference range 
is strictly correct.
A similar problem exists in interpretation of hPL results in 
diabetic pregnancies (Chapter 8).
From the data presented in this thesis a tentative link between 
SP^ and carbohydrate metabolism was drawn. Since most preg­
nant diabetics are now well stabilized, gross abnormalities 
of placental function are rare and studies to further test 
these theories would be time consuming.
Despite the deficiencies, it seems that measurement of hPL 
concentrations will continue for the forseeable future. Use 
of other placental proteins for the monitoring of pregnancy 
remains uncertain.
If a biological function exists for these proteins it is un­
known. Whilst hormonal effects have been proposed for hPL, 
involvement in the immune system for PAPP-A, definite proof 
has yet to be presented. The reason for the occurence of 
these proteins in many non pregnant subjects as well as in 
greater concentrations during pregnancy remains a mystery.
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Are the recently discovered oncodevelopmental proteins likely 
to be of.use in oncology? Despite the enthusiasm of some 
authors (Bohn 1980c), this study does not hold out any great 
hope for their use. The existence of detectable levels of 
most oncodevelopmental proteins in at least some of the pop­
ulation decries their use in diagnosis. Other than the use 
of CPAP (Chapter 9) little extra information would be gained 
in assaying serial samples for various oncodevelopmental pro­
teins. There is little to warrant their routine application 
in oncology.
Although the proteins studied in this thesis seem to be of 
less value than conventional markers in the monitoring of 
placental function or tumour activity, it is possible that 
other newly discovered 'placental* proteins are worthy of 
study as possible monitors of placental function.
Does the ideal tumour marker exist? If it does, it has not 
been found among the proteins investigated here. However, 
the introduction of antibodies raised against tissue specific 
antigens (Bhattacharya and Barlow 19751 Bast et al 1983) may 
hold hope for the future.
The search for tumour markers will continue and time alone will 
reveal the usefulness of newly discovered markers.
1*f0
REFERENCES
REFERENCES ,
Aalberse, R.C., (1973).
Quantitative fluoroimmunoassay•
Clin. Chim. Acta, if8 , 109-111.
Adler, F.L. and Liu, C.T., (1971).
Detection of Morphine by Hemagglutination-Inhibition.
J• Immunol•, 106, 168^-1685•
Afonso, J.F. and Farnham, N.G., (1962).
Studies of a new electrophoretic zone in labor and the 
puerperium and in newborn infants.
Am. J. Obstet. Gynecol., 8 f^, 199-205*
Aherne, W., (1966)•
A Weight Relationship between the Human Foetus and Placenta. 
Biol. Neonate, 10, 113-118.
Ahmed, A.G. and Klopper, A., (1980)•
Separation of Two Pregnancy Associated Proteins with SP^
Determinants and the Conversion of SP ' 3 to SP„ oC .
1 1
Arch. Gynecol., 230, 95-108.
Ahmed, A.G., Toop, K.M. and Klopper, A., (1981).
The Demonstration of Two Pregnancy associated proteins with 
SPn Determinants in Placental Extracts.
Placenta, j?, ^5-52.
Ahmed, A.G., Bremner, R., Nisbet, A., Horne, CJI.W. and Klopper, A., 
(1982a).
Measurement of SP^ in samples with varying SP^ oC : SP^ /3
ratios. ,
Clin. Chim. Acta, 121, 217-22^.
Ahmed, A.G. and Klopper, A., (1982b).
Separation of SP^<C and SP^ p on Hydroxyl-apatite. 
Placenta, 3, 211-216.
Ahmed, A.G. and Klopper, A., (1983a).
Studies on the half life of Schwangerschafts protein 1 
(SPn).
Brit. J. Obstet. Gynaecol., 90* 90*f-907*
Ahmed, A.G. and Klopper, A., (1983b).
Assay of Schwangerschafts protein 1 (SP^) as a test for 
pregnancy.
B.M.J., 286, 1179-1180.
Aickin, D.R., Duff, G.B., Evans, J.J. and Legge, M., (1983)*
Antenatal biochemical screening to predict low birthweight 
infants.
Brit. J. Obstet. Gynaecol., 90, 129-133*
Alpert, E. and Perencevich, R.C., (1975)*
Human AFP, immunochemical analysis of isoproteins.
Proc. Nat. Acad. Sci. U.S.A., 259, 131-135*
Anthony, F., Spencer,.K., Mason, P., Masson, G.M., Price, C.P.
and Wood, P.J., (1980a).
The Variable Influence of an oC Component in Pregnancy 
Plasma on Four Different Assay Systems for the Measurement 
of Pregnancy Specific p  ^Glycoprotein.
Clin. Chim. Acta., 105, 287-295.
Anthony, F., Masson, G.M. and Wood, P.J., (1980b).
The Radioimmunoassay of a pregnancy, specific ^ glyco­
protein in plasma as a pregnancy test for subfertile women. 
Brit. J. Obstet. Gynaecol., jB7, **96-500*
1**2
Avrameas, S., (1969a).
Coupling of enzymes to proteins with glutaraldehyde.
Imraunochem., j6, ^3-52.
Avrameas, S. and Ternynck, T., (1969b).
The Cross Linking of Proteins with glutaraldehyde and 
its use for the preparation of immunoadsorbents•
Immunochemistry, 6», 53-66.
Avrameas, S. and Ternynck, T., (197*0-
Enzyme-Conjugated Antibody Methods. In: ’'Immuno chemistry”
(edited Steinberger, L.A.) Prentice Hall Inc, Englewood 
Cliffs, New Jersey. , p.122-123*
Baird, D. and Walker, J •, (1959)•
‘ In: •‘British Obstetric and Gynaecological Practice; Obstetrics”, 
2nd ed., (edited Holland, E.) Pub. Heinemann Medical Books, 
London, p.91^*
Bast, R.C. and 11 others., (1983)•
A Radioimmunoassay using a monoclonal antibody to monitor- 
the course of epithelial ovarian cancer.
N. Engl. J. Med., 309, 883-887.
Belfield, A. and MacDonald, D.J., (1979)•
Possible interference in ELISA systems by serum complement.
In: Abstr. 3rd European Congress of Clinical Chemistry
(BMA) Brighton, p.73*
Bersinger, N.A., (198^).
Two-site enzyme immunoassay for pregnancy associated plasma 
protein A (PAPP-A)•
Clin. Chim. Acta., 13^, 297-306.
1^ 3
Bergstrand, C.G. and Czar, B., (1957)•
Paper electrophoretic study of human fetal serum proteins 
with demonstration of a new protein fraction.
Scand. J, Clin. Lab. Invest., 9., 227-286.
Bhattacharya, M. and Barlow, J.J., (1978).
Ovarian Tumor Antigens.
Cancer, 42, 1616-1620.
Birken, S. and Canfield, R.E. (1977).
Isolation and amino acid sequence of COOH-terminal fragments 
from the beta subunit of human choriogonadotrophin.
J. Biol. Chem., 252, 5386-5392.
Bischof, P., (1979a).
- . . Purification and Characterization of Pregnancy Associated 
Plasma Protein A (PAPP-A).
Arch. Gynecol., 227, 315-326.
Bischof, P., Bruce, D., Cunningham, P. and Klopper, A., (1979b). 
Measurement of Pregnancy Associated Plasma Protein A 
(PAPP-A).
Clin. Chim. Acta 95, 243-247.
Bischof, P., Hughes, G. and Klopper, A., (1980).
Relationship of obstetric parameters to the concentration 
of pregnancy associated plasma protein-A.
Am. J. Obstet. Gynecol., 138, 494-499*
Bischof, P., Haenggeli, L., Sizonenko, T., Herrmann, W. and 
Sizonenko, P.C., (1981a).
Radioimmunoassay for the Measurement of Pregnancy Associated 
Plasma Protein A (PAPP-A) in Humans.
Biol. Reprod., '24,’1078-1081.
■/ 144
Bischof, P., Duberg, S., Herrmann, W. and Sizonenko, P.C., (1981b). 
Pregnancy Associated Plasma Protein-A (PAPP-A) and hCG in 
Early Pregnancy.
Brit. J. Obstet. Gynaecol., 88, 973-975•
Bischof, P., Duberg, S., Schindler, A.M., Obradovic, D., Weil, A., 
Faigaux, R., Sizonenko, P.O. and Herrmann, W., (1982a). 
Endometrial and plasma concentrations of pregnancy associated 
plasma protein-A (PAPP-A)•
Brit. J. Obstet. Gynaecol., 89, 701-703*
Bischof, P., Duberg, S., Herrmann, W. and Sizonenko, P., (1982b). 
Amniotic Fluid and Plasma concentrations of pregnancy 
associated plasma protein A (PAPP-A) throughout pregnancy: 
Comparison with other fetoplacental products.
Brit. J. Obstet. Gynaecol., 89, 358-363*
Bischof, P., Rapin,C.H., Weil, A., Herrmann, W., (1982c).
Is pregnancy-associated plasma protein A a tumor marker?
Am. J. Obstet. Gynecol., J43, 379-381.
Bischof, P., Martin-Du-Pan, R., Lauber, K., Girard, J.P., Herrmann, W.L. 
and Sizonenko, P.C., (1983)•
Human Seminal Plasma Contains a Protein that Shares Physico­
chemical, Immunochemical and Immunosuppressive Properties with 
Pregnancy Associated Plasma Protein A.
J. Clin. Endocrinol. Metabolism, 56, 359-362.
Blacker, C., Feinstein, M.C., Rodger, M.qnd Scholler, R., (1981). 
Evaluation of PS and other Tumor Markers in Germ Cell 
Tumors of the Testis.
Andrologia 13 . ^58-^67*
1^5
conn, n • , v. \yy \j •
Detection and characterization of pregnancy proteins in the 
human placenta and their quantitative immunochemical deter­
mination in sera from pregnant women.
Arch Gynaekol., 210, 440-457* •
Bohn, H., (1972).
Isolierung und Charakterisierung des schwangerschfts-spezifischen 
£  ^Glykoproteins.
Blut, 24, 292-302.
Bohn, H.,(1974).
Studies on the pregnancy Specific (2^  Glycoprotein (SP^)
Arch. Gynaekol, 216, 347-351*
Bohn, H., Schmidtberger, R. and Zilg, H., (1976).
Isolierung des schwangerschaftsspezifischen  ^glykoproteins 
(SP^) und antigenverwandter Proteine durch Immunoadsorption. 
Blut., 32, 103-113.
Bohn, H. and Kraus, W., (1977)
Isolation and Characterisation of Pregnancy Specific f>  ^
Glycoprotein from urine of Pregnant Women.
Arch. Gynaekol., 223, 33*
Bohn, H., (1980a).
Protein Antigens of the Human Placenta. In: "The Human
Placenta: Proteins and Hormones", (edited Klopper, A.,
Genazzani, A., and Crosignani, P.G.) Academic Press, London.
Bohn, H., Grudzinskas, J.G., Rosen, S., Seppala, M., Tatarinov, Y.S., 
Chard, T., Klopper, A.-, Schultz-Larsen, P., Sizaret, P. and 
Teisner,B.,(1980b).
Reference Preparation for Assay of some Pregnancy and Cancer 
Associated Proteins.
Lancet, Oct. 11th, 796.
‘ ' 146
Bohn, H., U9&0c; .
New Placental and Pregnancy Proteins as Possible Markers 
in Oncology.
Klinische Wochenschrift, 58, **89-^ 92.
Borkowski and Muquardt, (1979)•
Human chorionic gonadotrophin in the plasma of normal non­
pregnant subjects.
N. Engl. J. Med*, 301, 298-302.
Braunstein, G.D., Vaitukaitis, J.L., Carbowe, P.P. and Ross, G.T., 
(1973).
Ectopic production of human chorionic gonadotrophin by 
neoplasms.
Ann. Intern. Med., 78, 39-^5•
Braunstein, G.D., Rasor, J. and Wade, M.E., C1975)
Presence in normal testes of a chorionic-gonadotrophin-like 
substance distinct from human luteinizing hormone.
N. Engl. J. Med., 293, 1339-13^3.
Braunstein, G.D., Rasor, Joan L., Engvall, Eva and Wade, M.E., (1980). 
Interrelationship of human chorionic gonadotrophin, human 
placental lactogen, and pregnancy specific £ glycoprotein 
throughout normal human gestation.
Am. J. Obstet. Gynecol., 138, 1205-1213.
Brock, Barron, L., Watt, M., Scrimgeour, J.B. and Keay, A.J.,
(1982).
Maternal plasma fetoprotein and low birthweight: a
prospective study throughout pregnancy.
Brit. J. Obstet. .
ik?
Brook, C.G.D., 0983).
Consequences of intrauterine growth retardation.
286, 164-165.
Browne, J.C., .(.1973) •
Development of the Placenta and Membranes. In: "Post-
thgraduate Obstetrics and Gynaecology”,4 Edition.
Butterworth, London, 449-496.
Bullock, S.L. and Walls, K.W., 0977).
Evaluation of Some of the Parameters of the Enzyme-Linked 
Immunospecific Assay.
J. Infect. Disease, 136, 5279-5285-
Burgos, M.H. and Rodriguez, E.M., (1966).
- Specialised Zones in the trophoblast of the human term 
placenta.
Am. J. Obstet. Gynecol., 9 6, 342-356.
Burt, Susannah M., Carter, Timothy J.N. and Kricka, Larry J., (1979). 
Thermal Characteristics of Microtitre Plates used in Immuno­
logical Methods.
J. Immunol. Methods, 31/ 231-236.
Cantarero, L.A., Butler, J.E. and Osborne, J.W., (1980).
The Adsorptive Characteristics of Proteins for Polystyrene 
and Their Significance in Solid Phase Immunoassays.
Analytical Biochemistry, 105< 375-382.
Challand, G.S., Spencer, C.A. and Ratcliffe, J.G., (1976).
Observations on the Automated Calculation of Radioimmunoassay 
Results. *
Ann. Clin. Biochem., 131 354-360.
148
Chapman, M.G., 0 iShea, R.T., Jones, W.R. and Hillier, Robyn, (1981) 
Pregnancy-Specific £ ^  Glycoprotein as a Screening Test for 
at risk pregnancies.
Am. J. Obstet. and Gynecol., 141, 499-502.
Chard, T. and Grudzinsaks, J.G., (1980).
New Placental Proteins - Biology and Clinical Applications. 
In: "The Human Placenta: Proteins and Hormones", (edited
Klopper, A., Genazzani, A., Crosignani, P.G.) Academic Press 
London.
Chard, T., (1982a).
Proteins of the Human Placenta. Some General concepts.
In: "Pregnancy Proteins, Biology, Chemistry and Clinical
Applications", (edited Grudzinskas, J.G., Teisner, B. and 
Seppala, M.), Academic Press, London.
Chard, T., (1982b).
Placental Lactogen: Biology and Clinical Applications.
In: "Pregnancy Proteins, Biology, Chemistry and Clinical
Applications", (edited Grudzinskas, J.G., Teisner, B. and 
Seppala, M.), Academic Press, London.
Chard, T. and Klopper, A., (1982).
Placental Function Tests.
Springer Verlag, Berlin, Heidelberg, New York.
Chow, B.F., (1947).
The Determination of plasma or serum albumin by means of 
a precipitin reaction.
J. Biol. Chem. 167, 757-763*
Cochran, J.S., (1976).
The Seminoma Decoy: Measurement of serum Human Chorionic
Gonadotrophin in Patients with Seminoma.
uomraittee on enzymes ol tne bcanainavian Society Tor Clinical 
Chemistry and Clinical Physiology. (197*0 •
Recommended methods for the determination of four enzymes 
in blood (2nd report)•
Scand. J. Clin. Lab. Invest., 33, 291-306.
Cooper, D.W., (1963)•
A serum protein present in pregnant women.
Nature 200 , 898.
Cooper, E.H., Turner, R., Steele, L., Neville, A.M., and Mackay, A.M., 
0975).
The contribution of serum enzymes and carcinoembryonic antigen 
to the early diagnosis of metastatic colorectal cancer.
Brit. J. Cancer, 31, 111-117.
Coryn, G., (1931*).
Les phosphatases du sang dans le diagnostic des affections 
osseuses.
J. Chir., 33, 213-22^.
Cotes, P.M., Bas-Gaines, R.E., (1978).
An International Collaborative study of the Assay of Human 
Placental Lactogen: Establishment of WHO International
Reference Preparation of Human Placental Lactogen.
Brit. J. Obstet. Gynaecol., 85, *t51-*+59«
Curzen, P., (1979).
Prognostic value of fetoplacental function tests: a review.
J. Roy. Soc. Med., 72, 118-122.
Dati, F., Kapmeyer, W., Grenner, G., Sieber, A., Bellmann, 0.,
Luben, G. and Bohn, H., (1982).
Comparison of Enzyme Immunoassay for Pregnancy-Specific ft ^
150
Glycoprotein (SP^) and cC Fetoprotein (AFP) with Other 
Immunochemical Methods#
Ric. Clin. Lab., 12, 265-287.
Dawes, G.S., (1968)•
The Placenta and. Foetal Growth. Ini "Foetal and Neonatal 
Physiology", Year Book Medical Publishers, Chicago.
Dean, H.R., Webb, R.A., (1926).
The Influence of Optimal Proportions of Antigen and Antibody 
in the Serum Precipitation Reaction.
J. Path. Bact., 29, 473-^92.
Duberg, S., Bischof, P., Schindler, A.M., Beguin, F., Herrmann, W. 
and Sizonenko, P.C., (1982).
Tissue and plasma concentrations of pregnancy associated 
plasma protein-A (PAPP-A): comparison with other feto­
placental products.
Brit. J. Obstet. Gynaecol., 89, 352-357*
Engvall, E. and Perlmann, P., (1972).
Enzyme-Linked Immunosorbent Assay, ELISA.
J. Immunol., 109, 129-135*
Engvall, E. and Yonemoto, R.H., (1979)•
Is SP^ (pregnancy specific beta 1 glycoprotein) elevated 
in cancer patients?
Int. J. Cancer, _15, 759-761.
Engvall, E., (1980).
Pregnancy Specific /^Glycoprotein (SP^) Purification and 
Partial Characterization.
Oncodevelopmental Biology and Medicine _1, 113-122.
151
Feinberg, J.G., (,“1957) •
Identification, Discrimination and Quantification in 
Ouchterlony Gel Plates.
Int. Arch. Allergy and Applied Immunology, T1, 12^-152.
Felig, P., (1977).
Body Fuel Metabolism and Diabetes Mellitus in Pregnancy.
Med. Clinics of North America, Vol 61/1, kj-6 6 .
Fishman, W.H., Inglis, N.R., Green, S., Anstiss, C.L., Ghosh, N.H., 
Reif, A.E., Rustigan, R., Krant, M.J. and Stolbach, L.L., 
(1968).
Immunology and Biochemistry of Regan Isoenzyme of Alkaline 
Phosphatase in Human Cancer.
Nature, _219, 697-699.
Fishman, V/.H. and Singer, R.M., (1976).
Placental Alkaline Phosphatase: regulation of expression
in cancer cells.
Ann. N.Y. Acad. Sci., R59, 261-272.
Fox, H., (1979).
The correlation betv/een placental structure and transfer 
function. In: “Placental Transfer” , (edited Chamberlain,
G.V.P. and Wilkinson, A.W..) Pitman Medical, Bath,
Frazier, G.R. and Rodbard, D., (1973).
Radioimmunoassay data processing. .
2nd edition NIH-RIA 72-1 and NIII 72-2. National Information 
Service, Springfield.
Gaede, P., Trolle, D. and Pedersen, H., (1978).
Extremely low placental lactogen hormone (hPL) values in 
an otherwise uneventful pregnancy preceding delivery of a 
normal baby. ,
—  Acta "Obstet. Gynecol. Scand. 5 7 , 203-209.
152
Galen, R.S. and Gambino, S.R., (1975)•
Beyond Normality: the predictive value and efficiency
of medical diagnoses*
John Wiley and Sons, New York, London, Sidney, Toronto,
Gamberini, G., Grosso, A., Morelli, M., Morgagni, D., Galletta, E. 
and Fabbri, I*, (1980)•
HPL, ^SP^ and LAP in the Normal and Pathological Pregnancy.
RIG, Clin. Lab., 10, 233-237.
Garrow, J.S.,and Hawes, S.F., (1971)•
The relationship of the size and composition of the human 
placenta to its functional capacity.
J. Obstet. Gynaecol. Brit. Cmwlth., 78, 22-28.
Gau, G. and Chard, T., (1976).
Location of the protein hormones of the placenta by the 
immunoperoxidase technique.
Brit. J. Obstet. Gynaecol., 83, 976-8.78.
Gemmell, R.S., (1982).
Pregnancy specific glycoprotein in normal and complicated
pregnancies.
Med. Lab. Sci., 39, 245-256*
Gordon, Y.B., Grudzinskas, J.G., Lewis, J.D., Jeffrey, Diana and 
Letchworth, A.T., (1977a)•
Circulating Levels of Pregnancy Specific  ^Glycoprotein and 
Human Placental Lactogen in the Third Trimester of Pregnancy: 
Their Relationship to Parity, Birth*Weight, and, Placental Weight. 
Brit. J. Obstet. Gynaecol., 84, 642-64?.
153
Gordon, Y.B./Grudzinskas, J.G., Jeffrey, Diana, Chard, T.and 
Letchworth, A.T., (1977b).
Concentrations of Pregnancy Specific ft  ^Glycoprotein in 
Maternal Blood in Normal Pregnancy and in Intrauterine 
Growth Retardation.
Lancet, Feb 12, 331-333*
Gordon, Y.B., Lewis, J.D., Pendlebury, D.J., Leighton, M. and 
Gold, J., (1978).
Is measurement of placental function and maternal weight 
worthwhile?
Lancet May 13, 1001-1003*
Gordon, Y.B. and Chard, T., (1979).
; The specific Proteins of the Human Placenta. Some New 
Hypotheses. In: "Placental Proteins", (edited
► Klopper, A. and Chard, T.), Springer Verlag, Berlin.
Grabar, P. and Williams, C.A., (1953)-
Methode Permettant L1etude Conjugee des Proprietes Electro-
phoretiques et Immunochimiques D’un Melange de Proteines.
*
Application au Serum Sanguin.
Biochim. Biophys. Acta., 10, 193-194.
Griffiths, B.W. and Godard, A., (1981).
Heterogeneity of Pregnancy Specific  ^Glycoprotein following 
purification from maternal serum and partial characterization 
of a high molecular weight component.
J. Reprod. Immunol., _3, 117-129*
Grudzinskas, J.G., Gordon, Y.B., Davies Humphreys, J., Brundell, M. 
and Chard, T., (1979)•
Circulating Levels of Pregnancy Specific p  ^Glycoprotein 
in Pregnancies Complicated by Diabetes Mellitus.
Brit. J. Obstet. Gynaecol., 86, 978-980.
. '154"
Grudzinskas, J.G., Coombes, R.C., Ratcliffe, J. and Chard, T., 
(1980a).
Circulating levels of pregnancy specific beta 1 glycoprotein 
in patients with testicular bronchogenic and breast carcinoma. 
Cancer, 45, 102-103.
Grudzinskas, J.G., Lee, J.N., Teisner, B., Chard, T., (1980b). 
Synthesis and Secretion of Placental Proteins. In:
”The Human Placenta. Proteins and Hormones”, (edited 
Klopper, A.), Academic Press, London.
Grudzinskas, J.G., Gordon, Y.B., Wadsworth, J., Menabawey, M. 
and Chard, T., (I98D.
Is placental function testing worthwhile? - An update on 
placental lactogen.
Aust. N.Z. J. Obstet. Gynecol., 21, 103-105.
Grumbach, M.M., Kaplan, S.L., Sciarra, J.J. and Burr, I.M., (1968). 
Chorionic Growth hormone-prolactin: secretion, disposition,
biologic activity in man and postulated function as the 
"growth hormone" of the second half of pregnancy.
Annals N.Y. Acad. Sci., 148, 501-331.
Guibal, J . ,  Donati, R., Oudghiri, T., Viala, J . L .  and Bastide, J . M . ,  
(1980).
A Comparison between Human Placental Lactogen (hPL) and
Pregnancy Specific fZ  ^Globulin (SP^). im '«The 
Human Placenta: Proteins and Hormones”, (edited Klopper,A.
Genassani, A. and Crosignani, G.P.), Academic Press, London.
Haije, W.G., Meerwaldt, J.H., Talerman, A., Kuipers, *j., Baggerman, L. 
Teeuw, A.H.', Van der Pompe, W.B. and van Driel, Jolie, (1979).
The value of a Sensitive Assay of Carcino-placental Alkaline 
Phosphatase (CPAP) in the Follow-up of Gynecological Cancers.
155
Int. J. Cancer, 24, 288-293*
Haimovich, J., Hurwitz, E., Novik, N. and Sela, M., (1970).
Use of Protein-Bacteriophage Conjugates for Detection 
and Quantitation of Proteins.
Chim. et Biophys. Acta, 207, 125-129.
Hainsworth, J.D., Greco, F.A., (1983).
Testicular Germ Cell Neoplasms.
Am. J. Med., 78, 817-832.
Heikinheimo, M., Wahlstrom, T., Aula, P., Virtanen, I. and 
Seppala, M., (1980).
Pregnancy Specific ^  ^glycoprotein (SP^) in cultured 
amniotic fluid cells.
J. Clin. Endocrinol., Me tab ol.,'5>1_, 1432-1436.
Hendry, H., Herrmann, H. and Collins, M.F., (1979).
Factors involved in Enzyme Linked Immunoassay of Viruses 
and Evaluation of the Method for Identification of Entero­
viruses.
J. Clin. Microbiol., 10, 210-217*
Hendry, R.M. and Herrmann, J.E., (1980).
Immobilization of Antibodies on Nylon for use in Enzyme- 
Linked Immunoassay.
J. Immunol. Methods, 35, 285-296.
Hevey, R., Bonacker, L.H. and Sparacio, R., (1976).
An Enzyme Immunoassay for the Determination of Human 
Alpha-Fetoprotein. From: First International Symposium
on Immunoenzymatic Techniques, Symposium No.2, (edited 
Feldman et al) , North Holland Publishing Company , Amsterdam
Hindersson, P., Teisner, B., Folkersen, J., Grudzinskas, J.G. and 
V/estergaard, J.G., (1981) • ~  ~
Investigation into the Molecular Heterogeneity of Pregnancy
specific £ ^-Glycoprotein (SP^).
Placenta, 228, 233-2^ +0.
Ho, P.C. and Jones, W.R., (I980).
A Comparison of Assay Methods for Pregnancy Specific ^ ^
Glycoprotein (SP^).
Aust. N.Z. J. Obstet. Gynaecol., 20,.109-112.
Horne, C.H.W., Towler, C.M. and Milne, G.D., (1977)•
Detection of pregnancy specific £  ^Glycoprotein in 
formalin fixed tissues.
J. Clin. Pathol., 32 ,19-23.
Horne, C.H.W. and Nisbet, A.D., (1979).
Pregnancy Proteins: A Review.
; Invest. Cell Pathol., 2, 217-231.
Hosking, C.S. (1982).
The ELISA technique in laboratory medicine (Editorial 
Comment)•
Aust. Paediatr. J., 18, 165-166.
Hughes, G., Bischof, P., Wilson, G. and Klopper, A., (1980). 
Assay of a Placental Protein to determine fetal risk,
B.M.J., 671-673.
Hunter, W.M., (1972).
thThe Radioimmunoassay of Hormones. Proceedings of 126 
Meeting of the Society for Endocrinology.
J. Endocrinol., 5jf, i-ii.
Hunter, V/.M., Bennie, J.G., (1979) •
Reduction of non-specific responses in human pituitary 
gonadotrophins.
J. Endocrinol., 80, 59-68.
157
I to, Y. and Higashi, K., (1961).
Studies on the prolactin-like substances in human placenta* 
Endocrinologia Japonica, 279-287*
Janisch, H. and Spona, J*, (1980)*
Placental Perfusion and Placental Hormones as an Index 
of Placental Function in EPH Gestosis and Placental Insuf­
ficiency. In: fThe Human Placenta: Proteins and Hormones",
(edited Klopper, A., Genazzani, A* and Crosignani, P.G.), 
Academic Press, London.
Javadpour, N., (1983)*
Multiple Biochemical Tumour Markers in Seminoma.
Cancer, 52, 887-889.
Jeppsson, A., Wahren, B., Stigbrand, T*, Edsmyr, F. and Andersson. L.,
(1983).
A Clinical evaluation of Serum Placental Alkaline Phosphatase 
in Seminoma Patients.
Brit. J. Urol., 55, 73-78.
Josomovich, J.M., McLaren, J.A., (1962).
Presence in the human placenta and term serum of a highly 
lactogenic substance immunologically related to pituitary 
growth hormone.
Endocrinol*, 71, 209-220i’
Karg, N.J., Csaba, I.F., Than, G.N., Arany, A.A. and Szabo. D.G.,
(1981).
The Prognosis of the Possible Foetal and Placental Comp­
lications During Delivery by Measuring Maternal Serum Levels 
of Pregnancy-specific Beta 1 glycoprotein (SP^).
Arch. Gynecol., 231, 69-73*
158
Karonen, S.L., Morsky, P., Siren, M. and Senderling, U., (1975)*
An enzymatic solid-phase method for Trace iodination of
125
Proteins and Peptides with I iodine.
Analyt, Biochem., 67, 1-10.
Kato, K., Hamaguchi, Y., Fukui, H. and Ishikava, E., (1975)
Enzyme linked immunoassay I Novel method for the synthesis 
of the insulin galactosidase conjugate and its applic­
ability for insulin assay.
J. Biochem., 78, 235-237* ’ •
Kellen J.A., Buch, R.S., Malkin, A., (1976).
Placenta-like alkaline phosphatase in gynaecological 
cancers.
Cancer Res., 56, 269-271.
Kenney and Keeping, (1951)*
Matrix Algebra and the Method of Least Squares. In: 
"Mathematics of Statistics", 2nd Edition, Van, Nostrand & 
Co., New York, Chapter X.
Klopper, A. and Hughes, G«, (1978)*
Placental secretion of oestrogens and protein hormones. 
Arch. Gynaecol.,225, 171-177*
Klopper, A. and Hughes, G., (1980)..
The New Placental Proteins: Some Clinical Applications •
of their Measurement. In: ,lThe Human Placenta: Proteins
and Hormones", (edited Klopper, A., Genazzani, A. and 
Crosignani,.P.G.), Academic Press, London.
Klopper, A., (1 9 8 2 ).
Newly Discovered Pregnancy Associated plasma proteins.
Brit. J. Obstet. Gynaecol., £>9, 687-688.
159
Koh, S.H., Cauchi, M.N., (1983)./
Prognostic Significance of Oncofetal Antigens in Patients 
with Ovarian Cancer.
Aust. N.Z. J. Obstet. Gynaecol., 23, 69-72.
Kraus, R., (1897).
Ueber specifische Reactionen in Keimfreien Filtraten aus 
Cholera, Typhus und Pestbouillon-culturen, erzeugt durch 
homologes Serum.
Wiener klinische Wochenschrift, 32, 736-738.
Kuber, W., Kratzik, C.H., Schwartz, H.P., Susani, M. and Spona, J.,
(1983).
Experience with Beta-hCG-Positive Seminoma.
Brit. J. Urol., 55, 555-559-
Lange, P.H., McIntyre, K.R., Waldmann, T.A., Hakala, T.R. and 
Fraley, E.E., (1976).
Serum alpha fetoprotein and human chorionic gonadotrophin 
in the diagnosis and management of non seminomatous germ 
cell testicular cancer.
New Engl. J. Med. 295, 1237-12*f0.
Lange, P.H., Bremner, R.D., Horne, C.H.W., Vessella, R.L. and 
Fraley, E.E., (1980).
Is SP^ a Marker for Testicular Cancer?
Urology, 15/ 251-255*
Lange, P.H., Millan, J.L., Stigbrand, T., Vessella, R.L.,
Ruislahti, E. and Fishman, W.H., (1982).
Placental Alkaline Phosphatase as a Tumor Marker for 
Seminoma.
Cancer Res., ^,32^-32^7-
160
Laurell, C.B., (1966)•
Quantitative Estimation of Proteins by Electrophoresis 
in Agarose Gel.
Analyt. Biochem., 1j?, 45-52.
Leader, (1984).
Diagnostic Ultrasound in Pregnancy 
Lancet, July 28^.
Lee, J.N., Salem, H.T., Al-Ani, A.T.M., Chard, T., Huang, S.C., 
Ouyang, P.G., Wei, P.Y. and Seppala, M., (1981)•
Circulating concentrations of specific placental proteins 
(human chorionic gonadotrophin, pregnancy specific Beta 1
glycoprotein and placental protein 5) in untreated gestational
trophoblastic tumours.
Am. J. Obstet. Gynecol., 139* 702-704.
Lee, J.N., Salem, H.T., Chard, T., Huang, S.C. and Ouyang, P.C.,
(1982).
Circulating placental proteins (hCG, SP^ and PP5) in tropho­
blastic disease.
Brit. J. Obstet. Gynaecol., 89, 69-72.
Lee, R.G., Adamson, C. and Kin, S.W., (1974).
Competitive Adsorption of Plasma Proteins onto Polymer 
Surfaces.
Thromb. Res., 4, 485-490.
“  &
Lehtonen, O.P. and Viljanen, M.K., (1980).
Antigen Attachment in ELISA.
J. Immunol. Methods, 34, 61-70.
Letchworth, A.T., Boardman, R., Bristow, C., Landon, J., and 
Chard, T., (1971a).
A Rapid Radioimmunoassay for human chorionic somatomammotrophin. 
J • Obstet. Gynaecol. Brit. Cmwlth., 78-, 535-541.
Letchworth, A.T., Boardman, R.J., Bristow, C., Landon, J., and 
Chard, T.,(1971b).
Rapid semi-automated method for the measurement of HCS.
The normal range in the third trimester and its relation 
to fetal weight.
J. Obstet. Gynaecol., Brit. Cmwlth., 78, 542-548.
Letchworth, A.T., (1976).
Human Placental Lactogen Assay as a Guide to Fetal Wellbeing.
In: ’’Plasma Hormone Assays as a Guide to Fetal Wellbeing”,
(edited Klopper, A.), Churchill Livingstone, Edinburgh.
Leute, R., Ullman, E.F. and Goldstein, A., (1972).
Spin Immunoassay of Opiate Narcotics in Urine and Saliva.
J. Am. Med. Assoc., 221, 1231-1234.
Lewis, J.L., (1983).
A radioimmunoassay for ovarian cancer.
N. Engl. J. Med., 309, 919-921.
Li, C.H., Dixon, J.S. and Chung, D., (1973)*
Amino acid sequence of human chorionic somatomammotropin.
Arch. Biochem. Biophys., 155, 95-110.
Lin, T.M., Halbert, S.P., Kiefer, D., Spellacy, W.N. and Gall, S., 
(1974).
Characterization of Four Human Pregnancy Associated Plasma 
Proteins.
Am. J. Obstet, Gynecol., 118, 223-236. ___________
162
Lin, T.M., Halbert, S.P., Spellacy, W.N. and Bern, E.B.H., (1977)* 
Plasma Concentrations of four pregnancy proteins in com­
plications of pregnancy,
Am. J. Obstet. Gynecol., 128, 808-810.
Linpisarn, S., Kricka, L.J., Kennedy, J.H. and Whitehead, T.P., 
Sensitive sandwich enzyme immunoassay for serum ferritin 
on microtitre plates.
Ann. Clin. Biochem., 18, 48-53*
Louvet, J.P., Ross, G.T., Birken, S. and Canfield., R.E.,
(1974).
Absence of neutralizing effect of antisera to the unique 
structural region of human chorionic gonadotrophin.
J. Clin. Endocrinol. Metabol•, 39, 1155-1158.
MacDonald, D.J., Belfield, A., Steele, C.J., Mack, D.S., and 
Shah, M.M., (1979)*
The Quantitation of Pregnancy Specific p ^Glycoprotein 
by Enzyme Linked Immunoassay.
Clin. Chim. eta, 94, 41-49*
McWilliams, D. and Boime, I., (198$>).
Cytological localization of placental lactogen messenger 
ribonucleic acid in syncytiotrophoblast layers of human 
placenta.
Endocrinol., 107,76l-765*
163
Mabon, J., Pledger, D.R. and Belfield, A., (198*+).
Immunoenzymatic assay of carcinoplacental alkaline phos­
phatase*
Med. Lab. Sci., k±, 29 -3k .
Maiolini, R. and Masseyeff, R., (1975)•
Sandwich Method of Enzyme Immunoassay Application to rat 
and human alpha-fetoprotein.
J. Immunol. Methods, J3, 223-23** •
Mancini,G., Cabonara, A.O. and Heremans, J.F., (1965)'»
Immunochemical Quantitation of Antigens by Single Radial 
Immunodiffusion.
Immunochem., 2, 235-25^*
Mandruzzato, G.P., Serilli, S., Radillo, L., (1980).
Clinical significance of SP^ in Pathological Pregnancies. 
In: ”The Human Placenta: Proteins and Hormones”, (edited
Klopper, A., Genazzani, A. and Crosignani, P.G.), Academic 
Press, London•
Marrack, J.R., Hoch, H. and Johns, R.G.S., (1951)•
The Valency of Antibodies.
Brit. J. Exp. Path., 32, 212-230.
Mattiasson, B., Svenson, K., Barrabaeck, C., Jonssen, S. and 
Kronvall., (1978).
Non-equilibrium enzyme immunoassay of gentamycin.
. .'■■Clin. Chem., 2*+, 1770-1773-
l6*f
Messer, K.n., \ \yofj •
Heat Stable alkaline phosphatase as an index of placental 
function*
Am* J. Obstet* Gynecol*, 98, *f59-^ 65*
Millan, J.L., Stigbrand, T., (1981)•
Sandwich Enzyme immunoassay for placental alkaline phosphatase. 
Clin. Chem., 27, 2014-2018.
Morgan, F.J., Canfield, R.E., Vaitukaitis, <J.L. and Ross, G.T., (197*0 
Properties of the Subunits of Human Chorionic Gonadotrophin. 
Endocrinol., 9^, 1601-1606.
Morgan, F.J., Birken, S. and Canfield, R.E., (1975)•
The amino acid sequence of human chorionic gonadotrophin.
The alpha subunit and beta subunit.
J. Biol. Chem., 250, 52*f7-5258.
Morita, Y., Aibara, S., Kobayashi, T., (1980).
Basic Isoenzymes of Horseradish peroxidase. In: '*0xidases
and Related Redox Systems”, (edited King, T.E., Mason, H.S., 
Morrison, M.), Pergamon Press, Oxford.
Muirs Textbook of Pathology 11^ ed11. (1980). Chapter 13*
Tumours, (edited Anderson, J.R.), Edward Arnold, London.
Nakane, P.K., Kawaoi, A., (197*0•
Peroxidase labelled antibody. A new method of conjugation.
J. Histochem. Cytochem., 22, 108^-1091.
Nakayama, T., Yoshida, M. and Kitamura, M., (1970).
L-Leucine sensitive, heat stable alkaline phosphatase 
isoenzyme detected in'a patient with pleuritis carcinomatosa. 
Clin. Chim. Acta, 30, 5*^ -5**8.
165
Neligan, G.A, Kolvin, I., Scott, D. and Garside, R., (1976).
Born too Soon or Born too Small?
Clinics in Developmental Medicine No. 61, p.101, Heinemanp, 
London.
Newlands, E.S., Rustin, G.J.S., Begent, R.H.J., Parker, D. and 
Bagshawe, K.D., (19&3)•
Further Advances in the management of Malignant Teratomas 
of the Testis and Other Sites.
Lancet, April 30 , p.948-951.
0*Beirne, A.J. and Cooper, H.R., (1979)
Heterogeneous Enzyme Immunoassay.
J. Histochem. Cytochem., 27, 1148-1162.
O'Sullivan, M.J,, Bridges, J.W. and Marks, V., (1979)*
Enzyme Immunoassay: A Review.
Ann. Clin. Biochem., 16, 221-240.
Ouchterlony, 0., (1948).
Antigen-Antibody Reactions in Gels.
Arkiv For Kerai, Mineralogi och Geologi., 14, 1-9*
Oudin, J., (1949)* ’
\
La diffusion d'un antigene dans une colonne de gel 
contenant les anticorps precipitants homologues. Etude 
quantitative des trois principales variables.
C.R. Hebd. Seanc. Acad. Sci., Paris, 228, 1890-1892.
Paiva, J., Damjanov, I., Lange, P.H., Hsirris, H., (1983)* 
Imraunohistochemical Localization of Placental-Like 
Alkaline Phosphatases in Testes and Germ Cell Tumours 
Using Monoclonal Antibodies.
Am. J. Pathol., 111, 156-165.
166
Pavlou, C., Chard, T. and Letchworth, A.T.,(1972).
Circulating levels of human chorionic sommatomammotrophin 
in late pregnancy: disappearance from the circulation
after delivery, variation during labour and circadian 
variation.
J. Obstet. Gynaecol. Brit. Cmwlth., 79, 629-634.
N/frgard-Peder sen, B. and 31 others., (1978).
Clinical use of AFP and HCG in Testicular Tumours of 
Germ Cell Origin.
Lancet, _2, 1042.
Pesce, A.J., Ford, D.J., Gaizutis, M. and Polla, V.E., (1977)•
Binding of Protein to Polystyrene in solid phase immunoassay. 
Biochim. Biophys, Acta, 492, 399-407*
Pinon, J.M. and Dropsy, G., (1977)*
ELIEDA (Enzyme Linked Immuno-electro-diffusion-Assay):
. Application of a combined immunoelectrodiffusion and immuno- 
enzyme method to the study of immune response in parasitic 
infections.
J. Immunol• Methods, 16, 15-22.
Pledger, D.R., Belfield, A. and Stromberg, P., (1981).
Pregnancy Specific ft  ^Glycoprotein: A Comparison of
Analysis by Radioimmunoassay and Enzyme Linked ImmunoSorbent 
assay. Observations on patients with Malignant Teratoma 
of Testis.
J. Clin. Chem. Clin. Biochem., _19, 9^3-9^6.
Pledger, D.R. Lunan, C.B. and Belfield, A., (1982).
Human placental lactogen and pregnancy specific ^
glycoprotein in pregnant diabetic women.
Brit^ "J^ ~0bs te t. Gynaecolr^897"827-830^ T-'
167
Pledger, D.R., §teele, C.J., Belfield, A., Hutchison, R.S. and 
McLelland, A.S., (1982).
A routine method for alkaline phosphatase assay in pregnancy 
serum.
Clin. Chim. Acta, 122, 71-7**«
Pledger, D.R., Belfield, A., (1983)*
An ELISA for pregnancy associated plasma protein A.
Ann. Clin. Chem., 20 , 236-2*f0.
Pluta, M., Hardt, W., Schmidt-Gollwitzer, K. and Schmidt- 
Gollwitzer, M. , (1979) •
Radioimmunoassay of Serum SP^ and HPL in Normal and Abnormal 
Pregnancies.
Arch. Gynecol., 227, 327-336.
Pluta, M., Hardt, W. and Schmidt-Gollwitzer, M., (1980).
Radimmunological measurements of SP^ in Comparison to hPL 
and Oestriol in Normal and Pathological Pregnancies. In:
"The Human Placenta: Proteins and Hormones", (edited Klopper, A.
Genazzani, A., Crosignani, P.G.), Academic Press, London.
Ranta, T., Siiteri,. J.E., Koistinen, R. , Salem, H.T., Bohn, H., 
Koskimies, A.I., Seppala, A., (1981).
Human seminal plasma contains a protein that shares physico­
chemical and immunochemical properties with placental protein —
5 from the human placenta.
J. Clin. Endocrinol. Metabol., 33, IO87-IO89.
Ratcliffe, J.G., (197*0.
Separation techniques-in saturation analysis.
Brit. Med. Bull., 30, 32-38.
168
Robertson, W.B.> Brosens, I., Dixon, H.G., (1967).
The pathological response of the vessels of the placental 
bed to hypertensive pregnancy.
J. Path. Bact., 93, 581-592.
Rodbard, D. and Lewald, J.E, (1970).
Computer analysis of radiological data and radioimmunoassay 
. -data. '■
Acta Endocrinol. (Suppl.)., W?, 79*
Rosen, S.W., Weintraub, B.D., Vaitukaitis, J.L., Sussmann, Hu., 
Hershman, J.M., Muggia, F.M., (1975)*
Placental Proteins and Their Subunits as Tumor Markers.
Ann. Int. Med., 82, 71-83.
Rosen, S.W.,(1982).
In vitro Production of SP^ by Human Fibroblasts and other 
non Trophoblastic Human Cells. In: "Pregnancy Proteins:
Biology, Chemistry and Clinical Applications”, (edited 
Grudzinskas, J.G., Teisner, B. and Seppala, M.), Academic 
Press, London.
Rubenstein, K.E., Schneider, R.S. and Ullman, E.F., (1972).
"Homogeneous” enzyme immunoassay. A new immunological 
technique.
Biochim. Biophys. Research Communications., ^7, 8^6-851.
Ruoslahti, E. and Seppala, M., (1971)•
Studies on carcino-fetal proteins*III Development of a 
radioimmunoassay for AFP. Demonstration of AFP in serum 
of healthy human adults.
Int. J. Cancer, 8^, 37^-383.
169
Samake, H., Rajkowski, K.M. and Cittanova, N., (1983)*
The choice of buffer protein in steroid (enzyme .) 
immunoassay.
Clin. Chim. Acta, 130* 120-135*
Saunders, G.C., Clinard, E.H., Bartlett, Mary L. and Saunders, W.M., 
(1977)*
Application of the Indirect Enzyme Labelled Antibody Micro­
test to the Detection and Surveillance of Animal Diseases.
J. Infect. Dis., 1^36 , 5258-5266.
Saxena, B.B., Hasan, S.H., Haour, F. and Jollwitzer, M.S., (197*0-* 
Radioreceptor assay of human chorionic gonadotrophin: 
detection of early pregnancy.
; Science, l8*t, 795-795*
Schultz-Larsen, P., Sizaret, P., Martel, N. and Hindersson, P.,
(1979).
Differences in the Slopes of Dose-Response Curves Measuring 
Pregnancy Specific p   ^Glycoprotein (SP^) by means of 
Radioimmunoassay.
Clin. Chim. Acta, 95, 3^7*
Schultz-Larsen, P., Lyngbye, J., Westergaard, J.G. and Teisner, B.,
(1979)*
Pregnancy Specific Glycoprotein (SP^) Determined by Means 
of Electroimmunoassay, Radial Immunodiffusion and Nephelometry. 
Clin. Chim. Acta, 99, 59-69.
Schwartz, M.K., (1973)*
Enzymes in Cancer.
Clin. Chem., 19, 10-22.
170
Sciarra, J.J., Kaplan, S.L. and Grumbach, M.M.,' (1.963)
Localisation of the anti-human growth hormone serum within 
the human placental evidence for a human chorionic ’’growth 
hormone - prolactin”.
Nature, 199, 1005-1006.
Sciarra, J.J., Sherwood, L.M., Varma, A.A. and Lundberg, W.B.,
Human placental lactogen and placental Weight.
Am. J. Obstet. Gynecol., 101, 413-**16.
Searle, F., Leake, B.A., Bagshawe, K.D. and-Dent, J., (1978).
- Lancet, 1_, 579-581.
Selenkow, H.A, Varma, K., Younger, D., White, P. and Emerson, K.,
Patterns of serum immunoreactive HPL and HCG in diabetic 
pregnancy.
Diabetes, 20, 696-706.
Sherwood, L.M., Handwerger, S., McLaurin, W.D., Pang, E.C., (1971)• 
Comparison of the structure function of HPL and Human GH 
In: ’’Second International Symposium on Growth Hormone”, 
(edited Pecile, A., Muller, E.E.), Excepta Medica, Amsterdam
Singh, M.M., Anthony, F. and Wood, P.J., (1979)•
The Relation between Pregnancy Specific f t   ^Glycoprotein 
(SP^) Levels and Abnormal Glucose Tolerance in Pregnancy. 
Brit. J. Obstet. Gynaecol. , 86, 5^8-*+62.
Sinosich, M.J., Teisner, B., Folkersen, J., Saunders, D.M. and 
Grudzinskas, J.G., (1982).
Radioimmunoassay of Pregnancy Associated Plasma Protein A.
(1968)
Serum SP^ Pregnancy Specific P  ^Glycoprotein in Chorio 
carcinoma and other Neoplastic Disease.
(1971)
Clin. Chem., 28, 50-53
171
Smith, R., Klopper, A., Hughes, G. and Wilson, G., (1979)*
The compartmental distribution of oestrogens and preg­
nancy specific beta 1 glycoprotein.
Brit. J. Obstet. Gynaecol., 86, 119-12A.
Smith, R., Cooper, W. arid Thomson, M.A.R., (1980).
Pregnancy Associated Plasma Protein A. A Measure 
of Placental Ageing. In: "The Human Placenta: Proteins
and Hormones1’, (edited Klopper, A., Genazzani, A, and 
Crosignani, P.G.) Academic Press, London and New York.
Smithies, 0., (1959)•
Zone electrophoresis in starch gels and its application to 
studies of serum proteins.
- Adv. Protein Chem., 1A, 65-113*
Spellacy, W.N., Teoh, E.S., Buhi, W.C., Birk, S.A. and McCreary, S.A.,
(1971).
Value of human chorionic somatomammotropin in managing 
high-risk pregnancies.
Am. J. Obstet. Gynecol., 1091 588-598.
Stigbrand, T., Millan, J.L., von Schoultz, B., (1982).
Placental Alkaline Phosphatase: Clinical Significance.
In: "Pregnancy Proteins: Biology, Chemistry and Clinical
Application", (edited Grudzinskas, J.G., Teisner, B.,
Seppala. M.), Academic Press, London.
Sussman, H.H., Weintraub, B.D., Rosen, S.W., (197^)*
Relationship of Ectopic Placental alkaline phosphatase to 
ectopic chorionic gonadotrophin and placental lactogen. 
Discordance of three "markers" for cancer.
Cancer, 3£, 820-823.
172
Sutcliffe, R.G.Kukulska-Langlands, B.M., Horne, C.H.W., .
MacLean, A.B., Jandial, V., Sutherland, H.W., Gibb, S. 
and Bowman, A.W., (1982)•
Studies on the Concentration of Pregnancy associated 
Plasma Protein A during Normal and Complicated Pregnancy. 
Placenta, 3, 71-BO.
Szymendera, J.J., Zborzil, J., Sikorowa, L., Lenko, J., Kam- 
inska, J.A., Cadek, A., (1983)-
Evaluation of Five Tumor Markers (AFP, CEA, hCG, hPL and 
SP^) in Monitoring Therapy and Follow-up of Patients with 
Testicular Germ Cell Tumors.
Oncology, 40, 1-10.
Tatarinov, Y.Sf and Masyukevich, V.N., (1970).
Immunochemical identification of a new ? ^ -globulin 
in the blood serum of pregnant women.
Bull Exp. Biol. Med. U.S.S.R., 69, 66-68.
Tatarinov, Y.S., (1982)•
Pregnancy Specific Beta 1 Glycoprotein, Placental Specific 
Alpha 1 and Alpha 2 Microglobulins. In: ’’Pregnancy Proteins:
Biology, Chemistry and Clinical Application”, (edited 
Grudzinskas, J.G., Teisner, B., Seppala, M.), Academic Press, 
Sydney.
Tatra, G., Tempfer, H. and Placheta, P., (1976).
Influence of blood glucose levels on serum concentrations 
of pregnancy-specific protein SP-1 and HPL during the last 
trimester of pregnancy.
Europ. J. Obstet. Gynecol., Reprod. Biol., _6 , 53-57«
173
Teisner, B., Westergaard, J.G., Folkersen, J., Husby, S. and 
Svehag, S.E., (1978).
Two Pregnancy Associated Serum Proteins with PS Glyco*- 
protein Determinants.
Am. J. Obstet. Gynecol., 1311 262-266*
Teisner, B., Folkersen, J., Hindersson, P., Jensenius, J.C. and 
Westergaard, J.G., (1979)•
Quantification of the Pregnancy Specific /^Glycoprotein 
(SP^) by Immunoprecipitation Techniques: the Influence
of a Cross-reacting High Molecular Weight ^ Protein. 
Scand. J• Immunol., j), *+09-*+17*
Teisner, B. and Grudzinskas, J.G., (1982).
Pregnancy Specific  ^Glycoprotein (SP^) Conversion of 
spi > to SP^ oC by Acidification: An Artefact.
Arch Gynecol., 2311 1 *+1-1^ 7.
Thomson, A.M., Billewicz, W.Z. and Hytten, F.E., (1968).
The Assessment of Fetal Growth.
J. Obstet. Gynaecol. Brit. Cmwlth., 75, 903-916.
Thomson, A.M., Billewicz, W.Z. and Hytten, F.E., (19&9)*
The Weight of the Placenta in Relation to Birthweight.
J. Obstet. Gynaecol., Brit. Cmwlth., 7 6 , 86^ -872,
Thornes, D.R.,(1958).
“Proteins of Pregnancy11.
M.D. Thesis, University of Dublin.
Toop, K.M. and Klopper, A., (1983)*
Effect of anticoagulants on the measurement of pregnancy 
associated plasma protein A.
Brit. J. Obstet. Gynaecol., 90, 150-155*
17*+
Towler, C.M., Glover, R.G. and Horne, C.H.W., (1978).*
Problems encountered in the measurement of Pregnancy- 
Specific j?  ^ Glycoprotein.
Clin. Chim. Acta, $7, 289-296.
Tsuji, A., Maeda, M., Arakawa, H., Matsuoka, K . , Kato, M.,
Naruse, H., Irie, M . , (1978).
Enzyme immunoassay of hormones and drugs by using 
fluorescence and chemiluminescence reactions. In:
"Enzyme linked Immunoassay of hormones and drugs” ,
(edited Pal, S.B.), Walter de Gruyer, Berlin/New York.
U.K. Collaborative study on AFP in relation to NTD, amniotic
fluid AFP measurement in antenatal diagnosis of anencephaly 
and open spina bifida in early pregnancy.
Lancet, 2:, 6 5 1. .
Ursell, W., Brudenell, M. and Chard, T., (1973)•
Placental lactogen levels in diabetic pregnancy.
B.M.J., ii, 80-82.
Vaitukaitis, J.L., Robbins, J.B., Nieschlag, E. and Ross, G.T., 
(1971)*
A method for producing specific antisera with small doses 
of immunogen.
J. Clin. Endocrinol. Metabol., 33, 988-991*
Vaitukaitis, J.L., Ross, G.T., Braunstein, G.D., Rayford, P.L., 
(1976).
Gonadotrophins and their subunits: basic and clinical
studies.
Recent Progress in Hormone Research, 32* 289-331*
173
Vaitukaitis, J.L., (1977)*
Human Chorionic Gonadotrophin. In: "Endocrinology of
Pregnancy", 2nd Ed, (edited Fuchs, F. and Klopper, A.), 
Harper and Row, New York.
Van Der Waart, M., Schuurs, H.W.M., (1975)*
Towards the Development of a radioimmunoassay (RIA). 
Zeitschrift fur Analitische Chemie, 279* 1*t2-1 k7•
Van Leusden, H.A., (1976).
Chorionic gonadotrophin in pathological pregnancy, 
ins "Plasma Hormone Assays in Evaluation of Fetal 
Wellbeing", (edited Klopper, A.), Churchill Livingstone, 
Edinburgh, London and New York.
Van Oss,C.J. and Singer, J.M., (1966).
The Binding of Immune Globulins and Other Proteins by 
Polystyrene Latex Particles.
Reticuloendoth., Soc., 3>, 29-^0*
Van Weemen, B.K. and Schuurs, A.H.W.M., (197*1) •
Immunoassay using Antigen-Enzyme Conjugates.
F.E.B.S. Letters, 15, 252-236.
Velan, B., Halmann, M., (1978).
Chemiluminescence immunoassay, a new sensitive method 
for determination of antigens.
Immunochem., J15, 331-338.
Vermeulen, R.C.W., Kurver, P.H.J., Artsnft, Van Kessel, H., 
V/ilson, G.R. and Klopper, A., (1982).
The Relationship between the Surface Area of the Tropho- 
blast and Some Placental Products.
Placenta, 359-366.
176
Wald, N.J., Cuckle, H.S., Borehara, Jillian, Turnbull, A.C.,
(1980).
Maternal Serum Alpha Fetoprotein and Birth Weight,
Brit* J. Obstet. Gynaecol., 87, 860-863.
Waldman, T.A. and Mclntire, K.R., (197*0•
The use of a radioimmunoassay for alpha foetoprotein 
in the diagnosis of malignancy.
Cancer Suppl., 3^ , 1510-1517*
Warnock, M.L., Reisman, R., (1989)*
Variant Alkaline Phosphatase in Human Hepatocellular 
Cancers.
Clin. Chim. Acta, 2*f, 5-12.
Weldon, K.L., Mackay, J.S., (1972).
On improving the diagnostic value of Quantitative Medical 
Laboratory Tests in Health Screening.
J. Chron. Dis., 25 < 697-709*
Westergaard, J.G. and Teisner, B., (1982)•
In: "Pregnancy Proteins - Biology, Chemistry and Clinical
Application”,'(edited Grudzinskas, J.G., Teisner, B. and 
Seppala, M.) , Academic Press, Sidney, p.3^ +5*
Wharton, C.W. and Eisenthal, R., (1981).
Complex Kinetics and Cooperativity. In: ’’Molecular
Enzymology", Blackie and Son Ltd., Glasgow and London*
p. 187-191.
Wilde, C.E. and Oakey, R.E., (1975).
Biochemical Tests for the Assessment of Feto-Placental 
Function.
Ann. Clin. Biochem., 12, 83-118. _____
177
Wisdom, G.B., (i976).
Enzyme Immunoassay.
Clin. Chem., 22, 12^3-1255.
Yalow, R.S., Berson, S.A., (i960.)
Quantitative aspects of the reaction between insulin 
and insulin binding antibody.
J. Clin. Invest., 39, 1157-H75.
Yorde, D.E., Sasse, E.A., Wang, T.Y., Hussa, R.O. and Gargancis,
J.C., (1976).
Competitive Enzyme-Linked Immunoassay with Use of Soluble 
Enzyme/Antibody Immune Complexes for Labelling .1. Measure­
ment of Human Choriogonadotrophin. 
j Clin. Chem., 22, 1372-1377-
Young, R.C., Knapp, R.C. Perez, C.A., (1982).
Cancer of the ovary. In: "Cancer: Principles and practice
of oncology”, (edited De Vita, V.T., Heilman, S., Rosen­
berg, S.A.), J.B. Lippincott, Philadelphia.
Younoszai, M.K., Haworth, J.C.,'(1969)•
Placental dimensions and relations in preterm, term and 
growth retarded infants.
Am. J. Obstet. Gynecol., 103< 265-271•
Zollinger, W.D., Dalrymple, J.M. and Artenstein, M.S., (1976). 
Analysis of parameters affecting the solid phase radio­
immunoassay quantitation of antibody to meningococcal 
antigens.
J. Immunol. Methods, 117< 1788-179,8.
Zondek, B., Ascheim, S., (1927)-
Ei und Hormon.___________________________ ____ _______
Klinische Wochenschrift, _2, 1321-1322.
' ■' 7^8
APPENDIX I REAGENTS
1. General Reagents
i) Phosphate Buffered Saline Tablets were obtained from 
Oxoid, Basingstoke, Hants and reconstituted according 
to the manufacturers instructions.
ii) Sephadex G25 and G150, cyanogen-bromide-activated sepha- 
rose and Sephacryl S200 were obtained from Sigma UK,
Poole, Dorset.
iii) Ultragel ACAjk was obtained from LKB, Croydon, Surrey.
iv) Hydroxyl-apatite (spheroidal) was obtained from BDH,
Poole, Dorset.
v) Protein calibration kits for gel filtration were obtained 
from Pharmacia (GB) Ltd, Hounslow, Middlesex.
vi) M partigen immunodiffusion plates for SP^ assay (Behring- 
werke) were obtained from Hoechst (UK) Ltd, Hounslow, 
Middlesex.
vii) All other general reagents were of analytical reagent 
quality.
2. Reagents used in ELISA Systems
Carbonate/bicarbonate (coating) buffer pH 9*6 containing 
0.015 mol/l sodium carbonate and 0.035 mol/ 1  sodium bi­
carbonate pH 9*6.
Sodium citrate (molar) solution adjusted to pH 7*^ with 
molar HCL.
Sample diluting solution.99 ml PBS and 1 ml sodium citrate 
Wash Buffer.10jul Tween 20 in 100 ml PBS.
Diluent for antibody-enzyme.PBS containing 25$ chicken
i)
ii)
iii) 
i v y
v)
citrate.
vi) Horse radish peroxidase Type VI*Sigma London Ltd, Poole, 
Dorset.
vii) OPD (phosphate-citrate) buffer. 0.13 molar Na^HPO^.
2H^0 and 0.027 molar citric acid, pH 6.0.
viii) Chromogen.Orthophenylene Diamine (OPD) was obtained from 
Sigma, Poole, Dorset. 20 mg of OPD was dissolved in
50 ml OPD buffer and 10 jil of fl 0^ (30^ w/v) added 
before use.
ix) Sulphuric acid k molar prepared by adding 100 ml concen­
trated sulphuric acid to 350 ml water.
3. Sera, Antisera and Antiserum conjugates used in ELISA systems
i) Chicken serum was obtained from Flow Laboratories, Irvine, 
Scotland.
ii) Antiserum to SP^ manufactured by Dako Immunoglobulins, 
Copenhagen was obtained from Mercia Brocades, West Byfleet, 
Surrey.
Antiserum to PAPP-A and hCG were also obtained from this 
source•
iii) Anti SP^ - horse radish peroxidase conjugate (Dako, Cop­
enhagen) was obtained from Mercia Brocades, as was anti- 
serum-peroxidase conjugate for hCG. Dilutions were 
made in antibody enzyme diluent as described in text.
iv) Antiserum to TSH was obtained from the Scottish Antibody 
Production Unit, Law Hospital, Carluke, Scotland.
v) SP,j standard serum was obtained from Hoechst Pharma­
ceuticals, Hounslow, Middlesex.    ^ - ------ — - :—
vaj International Reference Preparation (IRP 78/610) was
obtained from International Agency for Cancer Research, 
Lyon, France.
4. Solid Phases used in ELISA Systems
i)
ii)
iii)
iv)
v)
5. Reagents used in hPL Assay
i) Barbitone buffer pH 8 .6 was prepared by mixing 1720 ml
of sodium barbitone (12-37 g/l) with 270 ml of 0 .06 M
hydrochloric acid and adjusting the pH as necessary 
(hPL).
ii) hPL Assay diluent.250 mg of human albumin (Hoechst
Pharmaceuticals, Hounslow, Middlesex) were dissolved 
in 300 ml pH 8 .6 barbitone buffer.
iii) hPL Precipitant*Analar propan-2-ol .(isopropanol) was 
obtained from BDH.
Cooke Flexible Microtitre Plates (M29A) were obtained 
from Dynatech Laboratories, Billingshurst, Sussex.
Immulon Micro-Elisa Plates (M129A) were obtained from 
Dynatech Laboratories, Billingshurst, Sussex.
Nunc Micro Elisa Plates (Grade I) were obtained from 
Gibco Europe, Paisley, Scotland.
Polystyrene Beads (Matt finish) diameters 3»2, *t.8 and 
k mm were obtained from Euromatic Ltd, Brentford, 
Middlesex.
Nylon beads with diameters 3*2 and 6.4 mm were obtained 
from Northumbria Biologicals, Cramlington, Northumber­
land.
78 g sodium dihydrogen phosphate (Na H^PO^H^O) in 
1 litre of distilled water (A), 90 g of disodium hydro­
gen phosphate (Na^HPO^.21^0) in 1 litre of water (B), 
and mixing 19*7 ml of (A) with 80.3 ml (B) adjusting 
the pH if necessary.
v) Anti—hPL was Obtained from RAST Allergy Unit, Benenden 
Chest Hospital, Kent.
Horse Serum III was obtained from Wellcome Diagnostics, 
Dartford, Kent.
vi) Iodination grade hPL (Code 71/166) was obtained from 
NIBSC. 7.33 jig in 10 pi of pH 7*4 phosphate buffer 
were used for iodination.
vii) hPL Standard - International Reference Preparation 
IRP (73/545) was obtained from the National Institute
of Biological Standards and Control, Holly Hill, London. 
A range of standards 0-11.3 mu/1 were prepared in horse 
serum (Wellcome III).
viii) Solid phase lactoperoxidase - gift from Dr R Chapman, 
Department of Biochemistry, Glasgow Royal Infirmary.
10 jil aliquots in 200 jul of 0.05 M pH 7*4 phosphate 
buffer containing no protein or azide were used for 
iodination.
6. Reagents used in AFP Assay
i) Bovine gamma globulin was obtained from Armour Phar­
maceuticals, Eastbourne, England). Antiserum to AFP
was obtained from SAPU, Law Hospital, Lanarkshire and 
used at a FD of 1:140,000.
and Gynaecology, Ninewells Hospital, Dundee. For use 
20 jil were diluted in 15 ml diluent.
iii) Diluent buffer for AFP assay 0.05 M barbitone buffer 
pH 8.6 prepared by dissolving 36.84 g sodium barbitone
in 1 L distilled water and adjusting the pH if necessary.
Before use 25 mg of bovine gamma-globulin were dissolved
in 50 nil of buffer.
iv) AFP Standards. British Standard (72/227) was obtained 
from NIBSC. Dilutions were prepared in a pooled male 
serum (known to be free of endogenous AFP) to cover a 
concentration range 0-147 u/ml.
v) PEG.5 .6 g PEG 6000 were dissolved in 50 ml barbitone
buffer without protein.
7. Reagents used in CPAP Assay
i) Tris Buffered Saline (TBS) was prepared from saline tab­
lets obtained from Oxoid Ltd and buffered to pH 7.4 with 
10 mmol/l Tris (hydroxymethyl/methylamine and hydrochloric 
acid).
ii) Diluent was prepared from TBS to which had been added 
75 g/l of human albumin (obtained from Hoechst UK Ltd, 
Hounslow).
iii) Chromogen reagents were obtained as a kit (Cat No 415286)
for alkaline phosphatase analysis from Boehringer Corpor­
ation Ltd, Lewes, England. This comprised 10 mmol/l 
p-nitrophenyl phosphate in 1 mol/1 diethanoiamine pH 9*8 
containing 0.5 mmol/l magnesium ions.
iv) Placental alkaline phosphatase was obtained from Miles
Laboratories Ltd, UK, Cat No 36-495-2.
APPENDIX II COMPUTER PROGRAMS
p ( 2 - o fr&cL &/J p f" L=^2-Y^tiT KtA)t-TT\ c p/9-m- C C h  ~ $ 0
ERDV.
5 PR I NT11SOST 
10 PR I NT "
20 PRI‘NT1 MSI3RLCULRTES KM .,VM ,-RND STD ERRORS FOR HVPERBOLIC CURVES QBEVIMG TH"
21 PR I NT "E SI IC HR EL. IS MENTEN EQN"
25 PRINT,!;@MlFRESS j$::® TO CONTINUE"
SO GETOfcsIF C$<>"C" THEN30
50 0 1 MS '• 20 > ,r V < 20 >
100 PR I NT "103"
101 N = 0
110 PRINT";g;|INPUT NUMBER OF POINTS" s INPUTN
ISO PRINT"23IHPUT DRTR IN THE FORMRT. . . SUBSTRRTE.,VELOCITV
13 5 X ~ 0 : V=0 ; R = 0 ; B 0 : G=0 : 0 ™ 0 E! ==O ; 0 E=0 ; K M - 0 s V M=0 : V 0 = 0
140 FOR 1=1TON
15© IS-!PUTSV : S C I > =S : V < I > =V
ISO X=VT2
170 V=X/S
180 R=R-i-V&X
190 B=B+Xt2
200 G=G+V#V
21© D=D+X$V
220 E=E+VT2
230 NEXT
240 DE = < R&E > -•• < Gi’lC! >
258 KM=<B$G-R#D>/DE
260 VM='::B^E <DT2>>/DE
278 VO=VM
450 R 1 =0 £ G 1 =0 “ 0 1 =0 1 =0 I! I:. 1 =0
508 FOR 1=1TON
510 F=<VM#S<I>>/<S<I>+KM>
530 F 1=-< VM*S <I> >/<<S < I> +KM > T2 >
558 Rl=Rl+<Ft2>
560 G1 =G 1 F&F 1 ’>
570 D1=D1+VCI>SHF 
580 Bl=Bl+<Flt2>
598 E1=E1+V<I>$F1 
600 NEXT
610 DE1=R1^B1-<G1T2>
620 B8= < B 1 *D 1 ~G 1 *E 1 ■' /DE1 
630 B9=<R1#E1-G1$D1>/DE1 
640 VM=VM#BS 
650 KM=KM+<B9/B8>
668 C=C+1sIFCCl© THEN458
700 FOR I = 1 TON : V 1 = V 1 + < V < I > T2 > NEXT
710 32= V 1 -• < 88*0 1 > < B9*E 1 > > / < N-2 >
720 S=SQR<S2>
730 !<E = < S/138 •’ *SQR < < R 1 /OE1 > >
740 VE= < VCRS*SQR '■ >• B 1 /DE1 > >
750 OPEN4 .r 4 ,•! CMD4 
768 PRINT SPRINT 
770 PR I NT1 !<M= "KM 
780 PRINT"VM= "VM 
790 PRINT"STD ERROR KM= "KE 
80O PRINT"STD ERROR VM= "VE 
810 FOR !<= 1 TO 10 PR I NT : NEXT 
828 PRINT#4:CL0SE4 
860 STOP ViWER^TYj
K.J j. i^ i n ■-. .i ==n
2©2© fl < 1 n 3 /-1 s=fl < 1 3 y -.i-!:-:!T4
203© R < 1,4>=fl<1,4 y+XT3
204© Fi < 2 , 1 > =fl < 2 ,1>+XT5
205© Fi < 2 ,2>=fl<2 , 2 y “i-7T4
2©6© fl < 2 3 '■> ~~ ! "i < 2 , 3 y -I-7T3
2070 Fi < 2 .r 4 > =fl < 2 , 4 !:■ +XT2
2©80 fl < 3 ,1>=fl<3,1>+NT4
283© fl < 3 , 2 > =Fi < 3,2>+Xt3
2188 fl < 3 3 > — Fi < 3 ,3>-i-7T2
2110 Fi < 3,4>=FK3 ,4 > +y.
2120 fl < 4 , 1 > =fl < 4 , 1 >-hXT3
2138 fl<4 , 2 > =fl < 4 , 2 > H-KT2
2148 Fi < 4 3 =Fi 4-, 3 > -i-7
2150 G < 1>=G<1>+ <7T3::-*V
216© G < 2 j =G < 2 -i-< :4T2 y #v
2178 G<3 y =g < 3 y
218© 0 < 4 > =G < 4 i1 -i-V
2130 
3000 
3010 
3020 
30:30 
3040 
3030 
306© 
3070 
3©30 
3030 
4© 10 
4©20 
403© 
4340 
4650 
4060 
41370 
■4030 
4030 
4100
RETURN
S<l,l>=SQR<FKl,i:0
S(l,2)^fl<l,2)/SCL,1>
S < 1,-3 > =fl < 1 3  > 73 < 1 ,• 1 >
S 4 1 4  > =fl < 1 ,• 4 > 73 < 1, 1 >
2 "" Gl-lFi< H 2 1 : ••• 3 1 .r 2 4'2 
3 > = < Fi < 2 ,3 > -• .< 3 < 1 ,2 > #3 < 1, 3 > > 73 
„ 4 fl < 2 4  > -3 <1,2 > *3 < 1 4  > > 73 < 2 
3 > = SQR < Fi (3,3 > - < S < 1 3  > t2 > - < 3 < 2
r *4 > = < Fl<34- > --S<1 ,3 > #3<1 ,• 4 y  S < 2 ,
. 4 > =SQR < Fi < 4 , 4 > --3 < 1 4  > 42--3 < 2 ,• 4 > 
> = G < 1 > 73 < :i. , 1 >
K < 2 > = < G < 2 > --S j.2 &!< < 1 > y 73 < 2 ,2 >
K < 3/•’:: < G < 3 > --S <1,3 > < 1 > -3 < 2 , 3 > $!< < 2
K < 4 > = < G < 4 > -- 3 < 1 , 4 > *.K < 1 > - 3 < 2 , 4 > m <  < 2 
U < 4 > ==!< < 4 > ,••' 3 < 4 , 4 y 
U < 3 > =: < K < 3 > - 3 < 3 , 4 > $U < 4 > > 73 < 3 , 3 >
U < 2 > <  K < 2 > --S < 2 ,• F: y $U < 3 -S < 2 , 4 $U < 4
U < 1 > = < K < 1 > -3 < 1 , 2 > 3U < 2 > 3 < 1 , 3 > 7U < 3
PRIMTU<1>,U <2 >,U <3>,U <4>
RETURN
•«'* *• i*1
i* ■!>
3 < 2 
3 <3 
3 < 3 
3 < 4 
!•< < 1
p p *!•
2 y
3 > T2 > 
> W-S < 2 
2-3 < 3
*i ,*■ ! r |
' ~S £ 3 .
,1 tS |~t I. r*‘
• S<1,
,4 > >73<3,3> 
,4>T2>
4 > =i4< < 3 > 73 < 4 , 4- >
4 > 44.J < 4 > > ,•■•‘3 < 1 .. 1 >
O p  C(s /  Cqa) ^ t2MTa#TiOfJ
EftDV,.
j.0 PR I NT "JOS"
20 PRINTnja CUBIC SOLUTIONS"
30 PRINT""
40 PRINT"FOR SOLVING EQNS OF THE TYPE-- V=flXt3+BXt2+CX+D 
5© PRINT"PRESS C TO CONTINUE"
50 GET A$:IF A$0"C" THEN60
10G DIM Fi < 4 ,• 4 > : DIMS C 4 4  > sDI MU < 4 > s DIMG < 4 > sDI MK< 4 >
1 © 1 FOR I = 1T04 s FOR J= 1T04 : fl < I,J) =0 S < I J  > =0 s G < I > =© U C I > =0 : K < I > =©
102 NEXT:NEXT
20© PRINT" iSOir
21© PRINT"ENTER DUPLICATE BLANKS"
22G INPUT Bl.,82
2 3 © B = B 1 16 2 /1=:!
24© PRINT""
25© PRINT"ENTER NUMBER OF STDS IN STD CURVE"
26© INPUT!-!
261 A 4 4  > =N 
27© FOR 1=1TON
28© PRINT" SOig"
29© PR I NT " IPO I NT " I " ENTER CONC " PR I NT " "
295 INPUT V
296 V<I>=Y
30© PRINT"ENTER DUPLICATE CDS"
31© INPUT 01.,02
3 2 © X = < <■. 01 0 2 > 2 > ~ B 
33© Z<I>=X
34© GOSUI62000 
35© NEXT 
36© GOSUB 3©80 
37© PEI NT "mg"
388 PRINT"EQN SOLUTION IS"
390 PRINTU<1>"Xt3+"U < 2>"NT2+"U <3 >"X+"U < 4 >
4©0 0PEN4..-4 :CMD4
41 © PR I NTCHE# CUB IC F IT"
42© PRINT"EQN SOLUTION IS...
430 P R I N T "V = "U < 1 > "X t 3 + "U <2>"X T 2 + "U <3>"X + "U <4>:P R I N T ""
44© PRINT"STD CURVE DATA"
45© PRINT#4 : CLOSE 4- 
460 FOR 1=1TON
4 7 © C == © : X=© s V=©
48© 0PEN4 ..-4 :iCl'‘1D4
49© PR I NT " ACTUAL VALUE:=" V(I)
495 X~Z<i;:*
50© PR I NT " CALCULATED VALUE= " U < 1 ■' #Xt3+U < 2 > $Xt2+U < 3 > $X-!-U C 4 >
510 PR I NT#4 l* CL.0SE4
51 1 C=U < 1 > CXT3+U < 2 > H«XT2+U < 3 > CX-UJ < 4 >
526 R9=R9+ < V < I •’ -C > T2
53© R7=R7 + < V < I > -C > 12X V '• I >
540 NEXT
55© 0PEN4 .r 4 : CMD4
568 PRINT"RESIDUAL SQUARES="R9
57© PRINT"MEAN RESIDUAL="R9/N fcLA^SoW
58© PRINT"CHI SQUARED^"R7 
5 9 © P RI ! •! T # 4 s C L 0 S E 4 
608 STOP
VNIVER^ITYi
LIBRARY:
g f\T\C F \T of_____ ^ S o  Cfc j  Co & r_fc>J > (Mr? 0/0
10 REM PROGRAM FOR CURVE FITTING USING A TRIANGULAR MATRIX 
15 REM UNKNOWNS STORED IN MATRIX U
i s pr i nt " ana"
17 PRINT"CURVE FITTING PROG SUITABLE FOR PARABOLIC CURVES SOLVED BV QUADRATIC"
18 PRINT"EQUATION"
IS' PRINT" IN THIS FORMAT THE PROG IS SET UP FOR ""JIELISA"
26 PRINT "E.G., PAPP--A AND CEA CURVES"
21 PRINT""
23 PR I NT" jSjMOTE THAT STD CURVE DATA IS IN AU/LjS"
24 PRINT".$TEST CONCS ARE PRINTED IN IUXL BASED ON IRP 78/610.1$" 
50 DIM A<3,3> sDIM S<3,3!>
60 DIM G<3> :DIMK<3> :DIMIK3>
70 FOR 1=1T03
8 0 F 0 R J = 1T 0 3
90 A<I,J>=8
108 S<I,J>=0
110 NEXT:NEXT
120 FOR 1=1 T03
130 G <I>=0:K<I>=0:U<I>=0
140 NEXT
141 PRINT""
142 PRINT""
150 PR I NT " INPUT BLANK ODS. - BL1 , BL.2 "
160 INPUT B1,B2
170 B=<Bl+B2>/2
171 PRINT""
208 PRINT "HOW MANV STDS IN STD CURVE EXCLUDING BLANK?"
210 INPUT N 
220 A <3, 3 >=!-•!
230 FOR M=1TON 
240 PR I NT" 103"
25© PRINT " F‘01 NT " M " ENTER DUPLICATE ODS IN THE FORMAT..0D1,0D2" 
268 INPUT 01,02 
2 61 X = < 01 0 2 / 2 — B 
262 X<M>=X:Z<M>=X
27© PRINT"ENTER STD CONC IN AU/L"
28© INPUT V 
281 V<M>=V :
298 A < 1 , 1 > = A < 1 , 1 > -I-XT4 
30© A < 1,2 > =A <1,2 >+XT3 
310 A < 1 , 3 =A < 1 , 3 > +Xt2 
320 A < 2 , 1 > =A <! 2 1 y -1-XT3 
330 FK2,2>=p<2,2;>+XT2 
348 FK 2 , 3 > =A £2,3 +X 
35© A 3 , 1 > =A £ 3 , 1 > -J-XT2 
36© A£3,2>=A£3,2>+X 
378 G£1>=G£1> + £XT2>#V 
380 G<2>=G<2>+X*V 
390 G£3>=G£3>+V 
108 NEXT
11© PRINT "DATA LOADED"
160 S£l,l>=SQR£A£l,i::0 
17© S£ 1 ,2>=A£1 ,2>/S£ 1 , 1 i- 
lS© s <: i, 3 > = a < i, 3 > xs < i, i :>
19© S £2,2 >=SQR£A £ 2,2 >~ £S £ 1,2 >T2 >>
50© S £ 2 , 3 > = £ A £ 2 , 3 > •-• £ S £ 1, 2 >iftS£ 1 , 3 > >/S£2,2>
22 PRINT""
56© U<2> = <K<2>-<S<2,3>3feU<3>:>>/S<2,2>
57© IK 1 > = <!<< 1 >-<S<1 ,2>3fcU<2> >-<S<1 ,3>&U<3> > >/S< 1 1 }
53© PRINT 11P 1
530 PRINT " jgUNKNOWN VFlLUES R E E j $ "
6©0 PRINT
61© PRINT TRB2©., "Ui="U<l>
620 PRINT TAB20,"U2="U<2>
63© PRINT TAB2© r " U3 = "U <3>
631 PRINT"ENTER RSSRV NANE"sINPUTA$
632 PRINT"ENTER DATE"xINPUTV*
64© 0PEN4 4 s CMD4
641 PRINT CHE3K 1 > ,,fi$
642 PRINT CHR-4>< 1 > V’T
65© PRINT "EQN SOLUTION IS - - . "U< 1 > "Xt2+"U<:2> "X+"U<3>
66© PR I NT#4 CL0SE4 
661 GOTO1©00
67© PRINT" TEST DRTR INPUT"
6S0 PRINT"PRESS C TO CONTINUE"
6S5 INPUTC& IF C $ O nC" THEN6S5 
630 PEI NT "MIS"
73© PRINT"ENTER DUPLICATE ODS IN THE F O R M A T . G D I ,002"
735 PR I NT " TERN I NATOE= 1 8 © 0  "
740 INPUT T1,T2
741 IF T 1>33 THEN STOP 
745 V=V+ :L
75© T=<Tl+T2>/2
770 V= < U < 1 >*TT2-i-U 2> #T+U < 3 >
30© Q P E N 4 4 : CMD4
320 PRINT"TEST "V "CONC="V$3"IU/L"
33© PRINT# 4 SCL0SE4 
36© G0T073©
100© 0PEN4,4xCMD4
101© PRINT C H R $ O V S T D  CURVE DRTR"
1011 PRINT#4x CL0SE4
102© FOR 11=1 TON
1025 OPEN4 4  x CMD4
1030 PRINT"RCTUAL VRLUE"Vai>
1©40 PRINT "CALCULRTED VALUE="<U <1>*2<M >T2+U<2 > < M >+IK3 > >
1 ©41 C= < LK 1 > $Z < M > T2-I-U < 2 !:> < N > +U < 3 > .•*
1 ©42 R1 =R 1 •:! C~V < N > > T2 
1 ©43 R2=R 1 /N x R3= < C-V < N > T2/V < N >
1©45 PRINT# 4 x CL0SE4
1050 NENT
1051 OPEN4 r 4 x CMD4
1052 PRINT"SUN OF RESIDURL SQURRES="R1
1053 PRINT"MEAN RESIDURL="R2
1054 PRINT"CHI SQURRED ="R3
1055 PRINT#4 x CLOSE4
106© PRINT"DO VOU WISH TO RLTEE DRTR <V OR ID"
107© INPUT
188© IF V$0"V" GOTO670 
103© IF V$="V" THEN G0T07©
L O &  -LD&\< ~ r j
ERDV -
10 REM LOG LOGIT TRANSFORM FITTED ON LINEAR REGRESSION EQN 
20 PR I NT " lOiii"
SO PR I NT " .;i_.OG-LOG IT TRANSFORMS"
40 PRINT""
50 PR I NT "ACCEPTS +VE AND --VE LOGIT POINTS"
60 PRINT"FITS CURVE BV LINEAR REGRESSION AND PROVIDES HARD COPV OUTPUT" 
70 PRINT"TEST DATA ENTRV PROVIDED AFTER CALCULATION ROUTINE"
80 PRINT"PRESS C TO CONTINUE"
38 GET AS x IF ASO"C" THEN SO:: 
loo PRiNT"j;i;;ii"
110 PRINT "STD CURVE DATA INPUT"
128 PRINT 
121 PRINT""
ISO X-0 sX2—X xXV—N :;V2-X ::DI—X ::D2—X xEl—X :;Fi—X :;D—X ::E—X xF™:X sG=X ;:PI—X xUl—X ::U3—X 
14© N—X s M~4:4 x C—X x R—X : 3U—X x P=X x Q—X x SI —X x f—X 
158 PRINT"ENTER DUPLICATE BLANKS"
168 INPUT BI.,B2 
171:3 B 3 = B 1 B 2 / 2
ISO PRINT"INPUT NUMBER OF DATA POINTS"
ISO INPUT K 
200 FOR 1=1TUK 
210 PRINT"j03"
220 PRINT"POINT "I
230 PRINT"ENTER DUPLICATE OD VALUES"
24© INPUT VS., VS
258 V3~<V3-iVS>/2-B3
260 VI =LOG '• V3X < 1 •-V3 > >
27© V<I>=VI 
28© PRINT""
2S0 PRINT"ENTER CONC"
30© INPUTXK
381 XI-LOG<XK>72.30259
31© X <I> =XI
40© N=H+1
410 X-X-i-XI
42© V=V+VI
4 3 G X 2= H  2 ■+• X111!1': X I
44© V2=V2+VI$VI
450 XSVsXV+XisfcVI
460 D1=D1 + <XI--VI>
47© D2-D2-!- < y. I -VI > t2 
48© NEXT 
490 A=XV--X$V/H 
580 B=X2•--Xi’KX/N 
51© M=A/B 
520 D=V2-V#V/N 
53© C=<V~MjHX>/N 
54© E=B$D 
55© F=SQR<E>
560 R-fl/F 
57© G=D/B
58© H=<l~Rt2>/<N~2>
591:3 3U 3 !.:•! R \ G H 
600 P-XXN 
610 Q—V.■•■'!■•!
62© U 1—D 1XN
VJWER5ITY
> XM > $230259 > > ?2 
XM > $2 , 30259 > > ?2X < EXP < Z*2. 30
650 0PEM4 .r 4 ::CMD4
660 PRINT CHRilK 1 "STD CURVE DRTR"
67© PR I NT1 NUMBER OF PAIRS = " jN !
6S0 PR I NT "HERN OF LOGIT ODS ="j:P 
690 PR I NT" MEAN OF LOG CONG = " ;Q 
70© PR I NT "GRADIENT = ” HI
710 PRINT"STD ERROR OF GRADIENT^";SG 
72© PR I NT "V AN IS INTERCEPT = ".sC 
73© PRINT"STD ERROR OF INTERCEPT^"?SI 
740 PRINT"CORRELATION COEFF. =";R 
75© PR I NT" STUDENT-"S T VALUE = ".XT'
76© PRINT#4sCL0SE4 
77© PR I NT "JillS"
780 FOR I 11 Uk 
79© Z=X<I>
800 V=V<I>
810 0PEN4.,4 CMD4
82© PRINT"ACTUAL CONC="EXP<2*2„30259>
831 PR I NT " CALC CONC= " EXP < < < V--C > XN > H«2 » 38259 >
832 E 1 :=E 1 + < EXP 2*2. 38259 > -EXP '• < < V~(
833 R9=R9+ *• EXP < Z&2 - 38259 > -EXP < < V-C 
848 PR I NT #4 ; CL OS EE 4-
848 PRINT"RESIDUAL SUN OF SQUARES-"El
849 PRINT"NEAN RESIDUAL SUN OF SQUARES:.." E INK 
85© NEXT
851 0PEN4 ,-4 ::CND4
852 PR I NT "RES I DUAL SUN OF SQUARES::.:" E1
853 PR I ITT'"NEAN RESIDUAL SUN OF SQUARES..:11E 1 XK PR I NT "CHI SQUARED^
854 PRINT#4sCL0SE4
86© PRINT"TEST DATA?<V OR N>"
87© GET R$:IF A$<>"V"ANDA$0,,N" THEN87©
88© IF A:J:="N " THEN STOP
881 PRINT" g m "
882 Z9=©
89© PR I NT "ENTER TEST ODS< 999,-0 TO STOP>"
89 1 Z 9:~: Z 9 + 1
900 INPUTV8,.V9
901 IF V8:..-999 THEN STOP 
91© V3~ <; V8-f-V9 > X2--B3
928 VI =-LOG < V3X < 1-V3 > >
93© 0PEN4 .r 4 CMD4 
939 PRINT "TEST "Z9
94© PR I NT " CONCENTRAT I ON= " EXP < < < VI -C > XN > #2.. 38259 >
968 PRINT#4sCL08E4 
978 G0T0898
T>Ata cft-pnuiE UBfrvy pvf
Of DftTA —  $\ATOwA7&& pofc UsiT OaJ
5 PR I NT " JOS"
58 PR I NT " " s PR I NT " "
51 PRINT"l!lRUTO--HERLS-' PROGRRMME"
57 PR I NT1 " s PR I NT " "
78 PRINT"ENTER VOUR NfiNE"
71 INPUT Nil?
73 PRINT"INPUT RSSRV NAME"sINPUTZT 
75 PRINT"INPUT DRTE" sINPUTDT 
80 0PEN4.,4 :CMD4 
SI PRINT CHRT>•'. 1 > ., "RSSRV,, . . "Z$
82 PR I NT CURT < 1;»*• GPERfiTOR. - - " NT
83 PR I NT CHRT < 1 !:• " DRTE. - „ " DT
84 PR I NT#4-: CLOSE4
90 DIMR<4,-4> sDIII8<4,4>
91 DIM O < 4 > DIM K < 4 > : DIM U < 4 >
108 GOTO210
110 CLOSE ! : OPEN 1., 7 : FOR 1 = 1 TO 10 : GET# 1 , RT s NEXT 
128 F'R I NT " EMEERD PLRTE ON MULTISKRN."sL=l 
130 GET#C 1 RT s I FRT= " " THEN 130 
140 T=TI
150 GET#01 .r CHT < L >
160 I FT I >T+04G0T0190 
170 I FONT ■: L !:■ = " " GOTO 150 
180 L=L+C1 i; GOTO 140 
190 PRINT"SII!RTR RERD IN,, a"
200 G 0T0250
210 C1 = 1 x 02=2 s 03™ 10 ;! 04=30 :05=680 
280 DIMO FIT < 615 .,• OD < 8 .. 12 >
230 MOT=" "
240 G0T0118 
258 FORI=1TO9
260 I FONT < I > = " „ " THEN:•■■:= I -2 s FI =VRL < CHT < I -4 > +CHT < I --3 > >
270 NEXT 
280 1=8
290 N= I NT < L--5 > 751 > +FI 
3©8 F'ORK=F I TON 
310 FQRJ=1TG3 
328 RT=""
33© F0RM=1T05
348 RT=RT+GHT<X+1+M>
350 NEXT 
368 R=VRL<RT>
378 IFfi>8THENR=<INT <<R-18 > #1888+8„5 > >/18©0
380 UlJJ r K = H
39© I=1+6
488 NEXT
418 1=1+3
428 NEXT
430 RT= " RBCDEFGH " s FOR I = 1T08 s ALT < I > =M IDT < R T I  , 1 : NEXT
44© LT="“""
458 I FIYIT= " 14" THENPRI NT " 01 MO NODE ".RIOT;" .iCOLUNNl" sGOTO470
468 PRINT"3 Ml
478 PT<2::' = "HiR0Wir 
48© PT <: 3 > = " I
ULT ISKRN 3C0LUMN!I:
.ill .11211 .331 3411
yti'xms-Yi
51© K=i
528 FOR J=0TO I NT < < IT-1 > 76 >
538 I FJ'= 1THEHPRI NT " I!" s PR INTPT < 4 >
548 F0RL=1T08 
558 F0RM=1T06
56© IFH=1THENPRINT" 3";ALT<L)j"|| ";
578 IF < M+6T J >NOR < M+6$ J > <F I THENPR I NT " - " ; : GOTO608
58© fiB=0D<L,.M+6$J::'
59© G0SUB688 
68© NEXT 
61© NEXT 
62© NEXT
621 PRI NT " MiSHIFiRDCOPV? "
622 GETATsIFAT=""THEN622
623 IFAT="H "THENGOSUB1888
624 PRINT'RFILE ON JT1APE OR I-iDlISK OR .$N|fO FILE?"
625 GETAT a IFAT=""THEN625
626 IF AT="T"THENGOSUB1448 sG0T0624
627 IF AT="D"THENGOSUB1548 sG0T0624
628 PRINT"CALCULATE RESULTS <Y OR N>"
629 INPUT VTsIF VT="V" G0T02888 
638 PRINT"SHORE PLATES?"
648 GETAT
658 IF AT="N "THENSTOP
66© IF AT="V "ORAT=" "THEH80©
67 0 G 0 T O 6 -4 0 
68© P=8
698 IFAB<0THENflB=ABi'!>:--! :P=1 
700 A= I NT < ABT 1808+©. 5 > +2000 
718 b t =s t r t o t >
72© F0RR=2'1 Ub
7:38 AT < R > =N I DT < BT., R 1 >
740 NEXT
750 A=VAL<AT<2>>~2 
768 RT<2>=STRT<A>
778 I FP= :l. THEN AT < 2 > = "
788 F:'R I NT AT < 2 > ; " . " ; AT < 3 > .? AT < 4 •' ; AT < 5 > ;
798 RETURN
808 l=,R I NT " ;;iSPLE ASE WAIT.. "
810 A=FRE<©>
820 F 0 I = 1T0615 : CHT C L s MEX T
840 GOTO!18
1888 RT= " ABCDEFGH " s FOR 1 = 1 TOS s ALT < I > =N I DT < A T 1 1  > : NEXT 
1018 CLOSE4 
1028 0PEN4.. 4
1830 PR I NT#4 CHRT < 1 > " MULT ISK AN " CHRT < 129 >
1848 L.T="'”"
1858 PR I ITT'#-4... TAB < 34 > ; CHRT < 1 > " COLUMN " CHRT < 129
1868 PR I NT# 4 CHRT < 1 > " ROW " CHRT < 129 > ; : FOR I = 1T078 s PR I N T # 4 L T  ; : NEXT PR I NT#4 
1878 PRINT#4,.CHRT-:: 1 >" 1 2 3 4 5 6 7 8 9 18 11 12"HT
1088 F0RL=1T08 
1898 F0RM=1T012
1108 I FM>NTHENPR I N T # 4 " - " ; GOTO 1158
1110 22=00 L M  !:• s 2M= 1 s 2N=3
1120 I FM= 1 THENPR I NT#4 s PR I MT#4 ;;PR I NT#4., CHRT < 1 > " " ALT < L   CHRT < 129 > ; " " ."
1130 G0SUB11.9©
1148 PR I NT#4... 22T ;
1150 NEXT
1168 NEXT-
1170 PRIMT#4
1188 RETURN
119© IF 2MC0THEN2M=8
1 2 8 8  I F 2 M < 0 T H E N 2!••! == 8
1210 SI=SGM<22>
1240 I FZA<>©THENZL= I NT < LOG '• ZA > /LOG < 1 © > +1 > s I FZM<ZLTHENZM=ZL 
1250 ZA=ZA/l©tZM 
126© 81 $= " " s IFSI =- 1TI-IENSI $= " - "
1270 NU$="" sDI=0
12S0 IFZM=8THENNU$=" " sGOTO136©
129© FORZI =1T0ZM
130© ZA=ZA# 1 © s ZB= I NT < ZR !:* s ZA=ZA-ZB 
131 © IFDIO0THEN1348
1328 I FZB=©ANDZ I OZMTHENNU$=NU$+,! " s GOTO 135©
1338 01=1sNU$=NU$+SI$
1348 NUT=NUT+CHRT<ZB+48>
135© NEXT
136© IFZN=©THEN1428 
1378 NU$=HU$+"."
1 '330 F0RZI = 1T0ZN
139© ZA=ZA# 18 i: ZB= I NT < ZR > s ZA=ZA-ZE 
1488 NUT=NUT+CHRT<ZB+48 >
1418 NEXT 
142© ZZ$=NUT 
1430 RETURN
144© PR I NT " SPRE:PARE TAPES"
1458 INPUT"SFILE NAME";AT 
1468 CLOSE2 ; 0PEN2 ,• 1 ,• 1 RT 
1470 FORX=ITOH 
1488 FORJ=1T08 
1498 PR I NT#2 0 0  < J . I >
1508 NEXT 
151© NEXT 
1528 CL0SE2 
1538 RETURN
1540 I NPUT " SDR IVE NUMBER <381 OR .ii !I> iJlIiiillll" ;BT 
155© INPUT"W ILE NAME";AT 
1560 RT=BT+ M ; " +RT+ " SEQ " + " 14 "
1578 CLOSES : O P E N S 8 3  , AT 
1588 FORI=1TON 
1598 F0RJ=1T03
1688 PR I NT# 8 0 0  J I  > ; CHRT (13) ;
1610 NEXT 
162© NEXT
1638 IFDSO0THENPRI NT " SO ISK ERROR! : PR INTDST s GOTO 1548 
1648 CLOSES:
1658 RETURN 
2888 PR I NT" JOS"
2018 PRINT"CALCULATION ROUTINE COMMENCES"
2108 FOR 1 = 1T04 uFOR J=1T04 
2138 A I J ):• =8 s S < I r J > =©
2148 U < I > =8 si<< I > =© ::G < 11'-' =©
2158 NEXT ; NEXT
216 0 X .1. 0 ii X 2= 8 ii X 3= 0 ;i X 4 =-• 0
217© REM CONSTANT VALUES ARE...
2188 A=8„ 0-1223 
2198 B=©.74635 
2288 C=• - 5» 75063 
2210 D=-~l„ 88382
2220 PRINT TABS©"ENTER NUMBER OF STDS IN STD CURVE EXCLUDING BLANK 
2230 INPUT N 
224© PR I NT " JOlJ"
2268 FOR M=1TON 
2278 X<M>=8 
2280 NEXT 
2298 PRINT"J03"
2388 FOR M=1TON
2381 PR I NT " .gpO I NT "M "ENTER CONC"
2310 INPUT X<M>
2350 PRINT"STD VALUES ENTERED ARE..."
2368 FOR 1 TON
2378 PRINT ‘'POINT”!''!" "NOD
2338 NEXT
2381 PRINT""
2382 PRINT"DO YOU WISH TO ALTER THESE VALUES?<A=ALTER OR N=NOT ALTER>
2383 I NPUT V4? ;: IF V7="N" THEN2428
2390 IF V$="A "THEN PRINT"INPUT POINT TO BE CHANGED<1T0"N">"
2391 INPUTC1 X < C 1 > =© s PR I NT " I NPUT CORRECTVALUE " : INPUTX < C 1 > s G0T02350 
2420 03= k < OD C 2 3 > +00 < 2 ,4 > > 72 >
2430 PR I NT " BLANK 1 = " OD < 2 3  > " BLANK2= " OD 2 4  > " MEAN="03
244-0 IF 0 D 2 3 > 0 D '! 2: 4 3’ 8 „ 31*!': 0 D 2 4 1  H L N U U S U B 6 8 8 8
2458 IF OD £23> COD >:! 2 4 > -8 „ 3:#0D< 2 4  > THEN GOSUB6808
2468 FOR K9=5T015 STEP2sK3=INT<K972>~l
2478 IF K9<=11 THEN K6=2:K7=K9
2488 IF K9>11 THEN K6=3 :K7=K9~12
2498 'r''% K 8 =  >:! <! 0 D 4 K 6 K 7 3 ~\- 0 El K K 6 K 7 1 '? 7 2 — 0 3
2495 PRINT"OD VALUE -BLANK P0INT"!<8 :PRINT V<K8>
2580 IF OD < K 6 K 7  > >0D < K6. K7+1 > +8 2 * 0 0  ■:! K 6 K 7 + 1 > THE!-! G0SUB6288
2518 IF OD < !<6K7 > COD < K 6 K 7 + 1 > -0.. 2TOD •:! K 6 K 7 + 1 > THEN GOSUB 6288
2528 NEXT K9
2598 PRINT"CHECK THAT ALL STD NEAN ODS ARE POSITIVE"
2688 PRINT" DO YOU WISH TO ALTER OD DATA AT ANY POINT INCLUDING BLANK 
2618 INPUTY$:IF Y$="Y" THEN G0SUB6588 
2638 PRINT" ;;Oi"
2648 PRINT"CALCULATION SUBROUTINE ...PAUSE OF 88 SECONDS"
2641 FORTH-1 TON X=N < M > : Y=Y < H >
2642 GOSUB7088
2643 MEXTM
2644 GOSUB7270 
2658 FOR T=1T018
2660 Fl == A -i- U < 1 > B == E3+L! «! 2 > s C=C +• U <. 3 > s 10 -- D U < 4 >
2678 FOR I = 1 TO4- :FORJ=1T04 :;A < I J > =8 ::S <! I J =© sU< I > =© sK< I > =©:G <I> ==8 
2688 NEXT::NEXT 
2698 FOR H=1TON 
2718 N=X<M>
2715 Y=Y<M>
2716 GOSUB7080 
2728 NEXT 
2725 G0SUB727©
2738 NEXT T 
2770 PR I NT " jOi"
2788 PRINT "CONSTANT A XDIFF=” <A2-A::'*10©
2798 PRINT "CONSTANT B XDIFF="<B2~B>*1©0
2888 PRINT "CONSTANT C XDIFF="<C2-C>*1©8
2818 PRINT "CONSTANT D XDIFF="<02-0>*188
282© PRINT""
2830 PRINT"IF XDIFF IS OF THE ORDER E-85 PRESS C TO CONTINUE"
2848 GET A# : I FA-HO-" C " THEN2848 
382© X=© “ Y ©
3829 CLOSE!4 
3838 OPEN4 r 4 s CND4- 
3031 PRINT""
3848 PRINT CHR$<1>"STD CURVE DATA"
3841 PRINT#4 sCL0SE4 
3858 FOR 11=1 TON 
3851 OPEN4 4  s CMD4 
306© Z=N<!VD 
387© Y=Y<M>
3838 X=EXP < < C7D > - < 17D > SLOG C < Y-A > / < A+B-Y > > >
3 ©I 9 © F? 9=R 9 + Z—X 4' 2 “ R 3=R 8 '■! 2!!—X > T 2 ) N 
3©91 R7=R7+ < < Z--X > 42 !:■ 7Z 
3118 PRINT"ACTUAL VALUE"Z 
3128 PRINT"CALCULATED VALUE"X
3168 OPEN4 4  ; CM 04 
3178 PRIHT"A="A2 
3188 PR I NT " 8 = " B2 
3138 PRIMT"C="C2 
3288 PRINT"D="02
3218 PRINT"MEAN RESIDUAL SQUARE="R8sPRINT"CHI SQUARED = "R7 
3228 PR I NT#4 : CLGSE4
3238 PRINT"MANUAL OR AUTO INPUT OF TEST DATA?CM OR A>"
3231 INPUTATsIF AT-"M "THEN GOSUB 7688
3232 0PEN4.,4;;CMD4
3233 PRINT CHRTCl > "tEST RESULTS"
3234 PR I NT#4 sCLOSE4 
3245 PR I NT "103"
3258 PRINT"ENTER NUMBER OF UNKNOWNS"
3268 INPUT U1 
3278 7=8sY=8 
3271 U2=8
3288 FOR J=5TQ11 STEP2
3238 V= < 00 < 3 , J > +00 < 3 , J+1 > > 72-03
3388 U2=U2+1
3382 IF (V-AX8 THEN 3328
3 318 X=E X P < < C 7 0 > - < < 17 0 > * L 0 G < < V •- A > 7 < A+ B - 'r > > > >
3328 0PEN4.,4 sCMD4
3338 IFV™A<8THEN PRINT"TEST "U2"00 < BLANK " jIFV-A<8THEN3358
3340 pp j j-jy JEST " U2 " = " X " MG7L "
3341 IF 00 < 3 J > >80 < 3 J+1 > +8. 2*00 < 3 J+1 > THEN PR I NTCHRT < 1 > " BAD RE PL I CATES "
3342 IF 00 < 3 J > <80 < 3 ,• J+1 > -8. 2*00 < 3 J+1 > THEN PR I NT CHRT < 1 > " BAD RE PL I CATES "
3358 PRINT#4:CL0SE4 
3368 IF U2=U1 THEN G0T04888 
3378 NEXT J 
3388 FOR I ==4T07 
3388 FOR ,1=1 TO 11 STEP2 
3488 V= < 00 < I J  +0D < I J + 1 > > .•••'2-03 
3485 U2=U2+1 
3487 IFV-RC8THEH 3428
3418 X=EXP<(C7D>-<<170 > *LOG<<V-A>7 <A+B-Y>> >>
3428 OPEN4 4  CMD4
3438 IFV-FK8THEN PR I NT "TEST "U2" 00<BLAHK " : IFV--AC8THEN3458 
3448 PRINT ”TEST"U2"="X"MG7L"
3441 IF 00 < I J  > >00 < I J + 1 > +0. 2*00 < I J + 1 > THEN PR I NT CHRT < 1 > " BAD REPLI CATE
3442 IF 00 < I J  > <00 < I J + 1 > -8. 2*00 < I , J+1 > THEN PR I NT CHRT < 1 > " BAD REPL I CATE
3458 PR I NT#4 s CLOSE4-
3468 IF U2=U1 THEN G0T04888 
3478 NEXTsNEXT 
4888 FOR I = 1 TO2:5
4818 PR I NT " MTEST DATA COMPLETEJS"
4828 NEXT
4838 PR I NT "MORE PLATES?<V OR 1-0'"
4831 INPUTVTsIF VT="N"THEN STOP
4832 IF VT="V" THEN PR I NT " .SNOW TVPE RUN<CR>" sSTOP 
6880 03=8
6818 PR I NT "JOS!"
6828 PR I NT "BAD BLANK REPL I CATES., . . ENTER MANUALLY IN THE FORMAT 001 .,002"
6838 INPUT 01,.02 
6848 03=<01+02>72
6858 PR I NT " BLANK 1 = " 01 " BLANK2= " 0 2 "  OK TO CONTI HUE? < Y OR N >
6868 INPUT VTsIF VT="N" THEN G0T0S888 
6878 RETURN
6288 PRINT" BAD REPLICATES IN STD CURVE...... ENTER 00 DATA MANUALLY? <V OR N>"
6285 INPUTVTsIF VT="N" THEN STOP 
6215 PRINT"jOSi"
6238 PRINT" P0INT"K8"ENTER DUPLICATE 00 VALUES IN THE FORMAT 0017302"
6248 I NPUT V 1 ,• V2
6258 V < M > = < Y 1 +Y2 > 72-03
CO 
CO
6518 IF VT="N" THEH6548:03=©sPRINT"ENTER HEW BLANK ODS"
6511 PRINT"ENTER NEW BLANK ODS"
6528 1 NPUT 01 ,02 : 03= < 01 +02 >72
6538 PRINT"OK TO CONTINUE?<V OR N>" sINPUTYT : IF VT<>"V" THEN6588 
6548 PRINT"DO YOU WISH TO ALTER A STD OD VALUE?<V OR N >"sINPUTVT 
6558 IF VT="N " THEN2638
6568 FOR M=1TONsPRINT"POINT "M" "V<M> :;NE7T
6578 PRINT"INPUT POINT TO BE ALTERED"sINPUT CisY<Cl>=8
6588 PR I NT " I NPUT NEW DUPLI CATE ODS " s I NPUT V 1 Y2 s V < C 1 > = < V 1 + Y2 > 72-03
6598 FOR M=1TON sPRINT"POINT "M ” ”V <N > sNEXT sG0T06548
6658 FOR !T= 1 TON s PR I NT V < M > s NEXT
6660 PRINT "OK TO CONTINUE <V OR N>"
6678 INPUTVTsIF VT="N" THEN G0T06588 
6688 RETURN
7088 V3=F!+E:-* < EXP' < C—Di'HLOG < X > X < 1+EXP < C--D*LOG < X > > > >
7818 REN SUB ROUTINE FOR DATA STORAGE. . RETURNS TO 2728<NEXT XXV > 
7828 Xi=l
7838 X2= < E X P < C -•• D * L 0 G < X > > 7 < 1 E X P < C D * L 0 G < X > > > >
704 8 X3=B* < EXP < C--D*L0G < X 7 < 1 + EXP < C--D*t..0 G < X > > ?2 >
7858 X 4=••••• < B*LOG < X > *EXP < C~-D*LOG < X > > 7 < 1+EXP < C—D*LOG < X > > > t2 >
7868 R=V-V3
7878 A < 1 , 1 > =fl < 1 ,1 > +X1T2 
7888 A < 1 ,2 > = A < 1 2 > +X 1 *X2 
7898 A < 1 , 3 > =A < 1 ,• 3 > +X1 *X3 
7' 188 A < 1 , 4 > =fi < 1 4  > +X17X4 
7118 A < 2 1  > =A < 2 1  > +X1 *X2 
7128 A < 2 , 2 > =A < 2 2  > +X2t2 
713 8 fl < 2 3  > = A < 2 ,• 3 > + X 2 * 3:3 
71 4 8 A < 2 4  > = A < 2 ,• 4 > + 712 * X 
?' 158 A '•! 3 ,• 1 =14 '•! 3 ,• 1 +X !i. :7 X 3 
7168 A(3,2> = A <32> +X2*X3
717 8 A <3.3 > = A < 3 ,• 3 > + X 3 T 2
7 18 8 fl < 3 ,• 4 > = A < 3 .4 > + X 3 * X 4 
719© A < 4.. 1 > =A < 4 ,• 1 I'-1 +X1 *X4 
7288 A < 4 2 =A < 4 2  > +X2*X4 
7 218 Fl < 4 3  •’ = A < 4 3  > X 3 * X 4 
722© fl < 4 ,• 4 > =A < 4 .4 > +X4T2 
r''238 G < 1 L'i 1 + X 1 *R 
7248 G < 2 >=G< 2 >+X2*R
7250 G < 3 j ~~ G < 3 > + X 3 * R 
F260 U < 4 =U < 4 y +X4-*R 
7265 RETURN
7278 S < 1 , 1 > =SQR < A < 1 ,• 1 > >
72818 S < 1 . 2 > = A < 1 2 > 7S <1,1 >
7298 S <1,3 > =A <1,3 >7S<1,1>
7308 S < 1 , 4 > =fl < 1 , 4 > .-‘S < 1 , 1 >
7318 10 < 2 ,• i:! y = SWF% < H < 2 ,• 2 < 1 ,• 2 T2 >
7328 S < 2,3> = < A < 2,3 >-< S <1,2 >*S<1,3 > > >/S< 2,2 >
7338 8 < 2,4 > = < fl < 2,4>- S <1,2 > AS<1,4> >/S< 2,2 >
7348 S < 3 , 3 > = S Q R < A < 3 ,• 3 > - < S < 1 , 3 > T 2 > - < S < 2 , 3 > 12 > >
73158 S < 3 , 4 > = < A < 3 , 4 > --S < 1 , 3 > *S <1,4 > ~S <2,3 > *8 <2,4 > > / S < 3 , 3 >
7368 S < 4 , 4 'y =SQR < A < 4-, 4 > -- < S < 1 , 4 > T2 y — < S < 2 , 4 > 't'2 > -• < S < 3 , 4 > T2 > >
7-3 78 K < 1 y L:i < 1 < 1 , 1
738© K < 2 > = < G < 2 > --S < 1 , 2 > *K < 1 > > XS < 2 , 2 >
7398 K < 3 > = < G < 3 > S < 1 , 3 > *K < 1 > S < 2 , 3 > *K < 2 > > X S < 3 , 3 >
7488 !< < 4 'y -■ < G < 4 > -S < 1 , 4 > M'lK < 1 > ™S < 2 , 4 > *K < 2 > --S < 3 , 4 > *1< < 3 > > XS < 4 , 4 >
7 418 U < 4 y |< < 4 > X S < 4 , 4- >
7428 U < 3 'y ~~ < K < 3 y -S < 3 , 4 !'• *U < 4 > XS < 3 , 3 >
7' 4 3 0 ij 3 ;i =: i; j< < 2 > — S < 2 , 3 > * U < 3 > — S < 2 , 4 > * U < 4 > !> X S < 2 , 2 j
7448 U < 1 > = < K < 1 > -S < 1 , 2 > *U < 2 > --S < 1 , 3 > *U < 3 !:• ~S < 1 , '4 > *U < 4- > > XS < 1 , 1 >
7458 A2=A+U<1>
7468 2=El -!■•!J < 2
7478 C2=C+U< 3 >
7488 D2=D+U< 4 >
7618 PRINT"ENTER HUMBER OF UNKNOWNS"
7628 INPUT U1
7638 PRINT"NON ENTER DUPLICATE OD VALUES IN THE FORMAT 001,002 
7648 FOR I=1T0U1 
7658 U2=U2+1
7668 PRINT"JTEST"U2"INPUT ODS“
7678 INPUT T 1,T2 
7' 6 ?' 5 X ==8 s V=8 
7688 V= < T 1+T2 > X2--03 
l~ij;l0 X^ENP1 CXD 1 XU .■* *L.UG V“" A H-l-t3— V
7788 0PEN4,4sCMD4 
7718 PRINT""
7728 PRINT"TEST"U2"="X "MGXL"
7738 PRINT""
7748 PR I NT*4 s CLOSE4
7758 NEXT I sPRINT"MORE RESULTS?<V OR N>"; INPUT VT 
7751 IF Y$="N" THEN STOP 
7768 RETURN
i^Egsrrv
